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“Ego Petro Yspanus, considerans diuersas egritudinum passiones per 
negligentiam in corporibus homini generati, quedem utilia et experta ad salutem 
humana uite sanitatis conseruandam inueni et probaui ratione ueridica que in artis 
medicine gremio non inueniuntur. Vnde cum sit melis custodire sanitatem quam 
morbum repugnare, tractandum est de sanitate. (...). Vtilius est enim infirmatem 
preuenire quam ipsa concepta forte irrecuperabile auxilium postulare (…).
De nocentibus cerebro
(...) hebrietas crebra multum nocent capiti et toti corpori (...)  sollicitudo, tristitia, 
iracundia et cubare capite inclinato (…).”
Pedro Hispano, Liber de Conservanda Sanitate, XIII century 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A. Abstract
Introduction
Depression and dementia are very common and disabling conditions. Most 
dementia conditions are irreversible, whereby the identification and correction of 
the risk factors seems to be of paramount importance. Among the several risk 
factors identified so far, depression emerges as an important target. Several case-
control and cohort studies yielded heterogeneous results, but the meta-analyzes 
performed found approximately a two fold increase in the risk for dementia in 
depressed patients.
However, the quality of the studies varies widely, and the accuracy of the 
diagnosis of depression is frequently not the ideal. Furthermore, the nature of the 
risk is not clear and the following issues have been repeatedly raised: (a) 
depressive symptoms are quite common in dementia and could be a symptom of 
this disorder, and not a true, and early, risk factor, (b) depression and dementia are 
heterogenous disorders, with distinct biologies, and eventually the risk is different, 
depending on the specific disorder involved, and (c) what is the role of 
antidepressants? That is, does the risk diminish if the depression is cured?
Antidepressants have neuroprotective properties at the molecular level, but the 
evidence is much less consistent in vivo.
To answer these questions, two studies were performed: a clinical 
longitudinal controlled study and a preclinical behavioral study. 
Methods
A cohort of 322 depressed patients (exposed cohort), recruited for a 
taxonomic study of depression between 1977-84, was built. Subjects without 
depression, admitted for surgery at the same time as the exposed subjects, were 
the group not exposed to depression. Subjects were contacted again between 
2009 and 2013, to assess their dementia status. The risk for dementia in the 
depressed cohort was compared to the risk in the surgical cohort using binary 
regression, and the odds ratio were computed (OR). The same analysis was 
performed in subjects younger than 45 years old (considered to have early onset 
depression). To quantify the association between different depression subtypes 
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(namely melancholic, anxious, and psychotic) and dementia, crude and adjusted 
hazard ratios (HR) were obtained with 95% confidence intervals (95% CI) using 
Cox proportional hazards regression.
The preclinical behavioral study assessed the cognitive effect, using the 
Morris Water Maze test (MWM), of escitalopram in rats submitted to a maternal 
separation protocol (MS; MS is a protocol that induces depressive-like behaviors). 
A two-way ANOVA was carried out for analyzing probe trial time (using MS and 
and escitalopram as treatment factors), computing main effects and interactions. 
Two-way ANOVA repeated measures was used for the learning curve of MWM. 
Results
In 133 (41.3%) depressed subjects, followed-up for a mean (standard 
deviation) of 25.7 (7.2) years, the diagnosis of dementia could be established or 
excluded. Among these, 44 (33.1%) developed dementia versus 20 (15.0%) 
among the subjects with no depression at baseline, and this result is significant 
[OR 2.50 (1.14-5.49; 95% CI); p=0.022]. Subjects with early onset depression had 
an increased risk for dementia when compared to the surgical cohort patients [OR 
6.85 (95% C.I. 1.38-34.00); p=0,019]. Patients suffering from depression with 
melancholic features had an increased risk of developing dementia compared to 
those depressed without melancholic features [HR 3.64 (1.78-11.26; 95% CI); 
p=0.025].
In the preclinical study, all groups of animals showed a significant learning 
effect in the MWM over time, but no differences have been found upon treatment. 
However, escitalopram treatment significantly increased the time spent on the 
platform quadrant in the probe trial in the MS group [F(1.23)=10.764; p=0.004], 
thus seeming to have improved the memory.
Discussion
The main results of current study are that depression is a risk factor for 
dementia, with a risk magnitude in line with the longest longitudinal studies with an 
accurate diagnosis of depression. Two limitations were considered: the lack of 
formal cognitive assessment at the baseline, and the number of subjects lost to 
follow. However, the depressed cohort had a low age at baseline, what altogether 
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with the long follow up, makes unlikely the depressed patients were demented at 
baseline. The erosion in this study is high, but in line with previous studies with a 
similar design and follow up time, and the differences between those with and 
those without a known outcome were minimal and were taken into account.
When exploring the nature of this risk, (a) these results support the 
hypothesis that depression is an early risk for dementia, again in line with the 
studies with a stronger design, (b) depression with melancholic features was found 
as the only depression feature or subtype that was associated with an increased 
risk for dementia. Melancholia can have a permanent deleterious effect on 
cognition, but this was the first study showing a higher risk for dementia. 
Melancholia is associated with hypercortisolism, and it is known that high cortisol 
damages the hippocampus, providing a biological rational for these findings. 
However, no biological assessment of HPA activity were made, and this is a 
limitation of this study. The inclusion of biological markers would support a 
biological explanation, but would not interfere with the conclusions of the study, 
and (3) chronic treatment with escitalopram improved hippocampal dependent 
memory, in a model that induces depressive-like behaviors (MS). Our results are 
line with the neuroprotective action of antidepressants, but take a step further by 
showing that escitalopram also improves cognition in vivo. Transposition of results 
from animal studies to humans has limitations, but animal studies allow the use of 
models that are not easily amenable or ethically allowed to humans, and 
permitting a reliable evaluation of a number of internal and external factors, such 
as pharmacological interventions. 
Conclusions
The results presented seem to support a role of depression as a risk factor for 
dementia, and add novel information regarding the nature of this risk. According to 
these results, depression is not merely a prodrome of dementia, but  an early risk 
factor, and melancholia is the only subtype associated with an increased risk. Also, 
they point to a neuroprotective action of escitalopram in depression.
Keywords: depression, dementia, risk factor, melancholia, and 
antidepressants 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Sumário
Introdução
A depressão e a demência são condições patológicas causadoras de 
grande sofrimento. A maior parte das doenças que provocam demência é 
irreversível, e as terapêuticas existentes têm uma eficácia limitada e não têm 
efeito demonstrado na progressão da doença. Assim sendo, a identificação dos 
factores de risco tem uma importância crucial. De entre os vários factores de risco 
identificados, a depressão reveste-se de uma importância particular.
Vários estudos caso-controlo e de cohort têm demonstrado que a 
depressão pode ser um factor de risco para demência. Apesar de não ser um 
achado constante em todos os estudos, as meta-análises realizadas revelam que 
os sujeitos com depressão têm aproximadamente o dobro do risco de desenvolver 
demência, quando comparado com não deprimidos. Todavia, os estudos são 
heterogéneos no que toca à qualidade e, frequentemente, o rigor no diagnóstico 
de depressão não é o ideal. Para além disso, a própria natureza do risco é pouco 
clara e algumas questões têm sido frequentemente levantadas.
(a) Não é claro se a depressão é um factor de risco precoce ou um 
pródromo/manifestação inicial de demência. A depressão é muito comum em 
demências, especialmente nas fases iniciais, e até tem sido sugerido que surge 
das mesmas estruturas anatómicas. Assim, estudos caso-controlo que não 
tenham em conta o tempo entre os dois diagnósticos, ou estudos longitudinais 
com tempo de seguimento curto, não seriam capazes de distinguir entre estes 
dois aspectos.
(b) Qual o papel dos sub-tipos de depressão. A depressão é uma doença 
heterogénea, com diferentes gravidade e sub-tipos, que parecem estar 
associados a diferentes aspectos biológicos. A abordagem ideal para responder a 
esta questão seria um estudo idêntico ao anterior, mas com rigor aumentado no 
diagnóstico de depressão, por forma a permitir distinguir os vários subtipos.
(c) Qual o papel das diferentes demências. Existindo várias causas de 
demoncia, não é claro a qual das demências a depressão poderá estar associada.
(d) Qual o papel dos antidepressivos, i.e., se a depressão for curada, o 
risco de demência diminui? Existem evidências pré-clínicas, especialmente in 
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vitro, para um papel neuroprotector dos antidepressivos, pelo que é tentador 
pensar que o tratamento a longo prazo com antidepressivos pode atenuar o risco 
de demência. O estudo ideal seria um ensaio clínico longo, em que doentes 
deprimidos seriam tratados com antidepressivos, tendo como endpoint a evolução 
para demência. Resultam óbvias as impossibilidades materiais e éticas de um 
trabalho deste tipo. Assim sendo, a evidência terá de ser obtida de outra forma, 
com as devidas limitações, por exemplo mimetizando o ensaio em modelos 
animais. 
Com base nestas questões, foi desenvolvido o presente estudo. As 
hipóteses do presente trabalho são (1) A depressão é um factor de risco precoce 
para demência?, (2) Os diferentes sub-tipos de depressão estão associados a 
riscos para demência de intensidade diferente?, (3) A depressão é um factor de 
risco para alguma demência em particular? (4) Se tratarmos com antidepressivos, 
durante um longo período de tempo, ratos submetidos a um protocolo que induz 
comportamentos depressivos, a deterioração cognitiva é diferente dos ratos não 
tratados?
Métodos
Foi realizado um estudo longitudinal, com duas coortes. Um grupo de 
doentes admitidos no Serviço de Psiquiatria do Hospital de Santa Maria, entre 
1977 e 1984, com o diagnóstico de depressão, para um estudo taxonómico de 
depressão, foi considerada a coorte dos expostos à depressão. Os não expostos 
foram doentes admitidos no mesmo hospital, na mesma altura, para 
apendicectomia ou colecistectomia de rotina, sem depressão na altura do 
internamento. 
À entrada, o coorte de deprimidos tinha sido submetido a uma extensa 
avaliação demográfica, clínica e psiquiátrica, e ainda preenchidos vários 
questionários, com destaque para a escala de depressões da Associação para a 
Documentação e Metodologia em Psiquiatra (AMDP  - Arbeitsgemeinschaft für 
Methodik und Dokumentation in der Psychiatrie). Esta escala avalia a presença e 
a gravidade de todos os sintomas depressivos e foi usada para confirmar o 
diagnóstico e identificar os sub-tipos de depressão, de acordo com o Diagnostic 
and Statistic Manual 5 (DSM-5).
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Entre 2009 e 2013 os sujeitos de ambos os coortes foram contactados, e 
os procedimentos do follow up tiveram por objectivo determinar se os sujeitos 
estavam dementes e a data de início da demência. Incluíram uma avaliação 
demográfica, clínica e psiquiátrica, uma avaliação neuropsicológica extensa, 
outros instrumentos validados para a população portuguesa (aos próprios e aos 
familiares), foram contactados os médicos assistentes, revistos os processos 
hospitalares e eventuais processos em instituições e, caso aplicável, os 
certificados de óbito. O diagnóstico e a idade de início de demência foram 
determinados numa conferência de caso, com psiquiatra, neurologista e 
neuropsicóloga, usando a melhor evidência disponível. Foram usados os critérios 
do DSM-5 para Perturbação Neurocognitiva Major (demência), implicando sempre 
pelo menos duas fontes concordantes de informação. Para a determinação do 
tipo de demência foram usados os critérios habituais em investigação.
O risco de demência no grupo deprimido foi comparado com o risco no 
grupo cirúrgico utilizando regressão binária, e os respectivos odds ratios (OR) 
foram calculados. A mesma análise foi realizada em indivíduos com idade inferior 
a 45 anos de idade (considerados como tendo depressão de início precoce). Para 
quantificar a associação entre os diferentes subtipos de depressão (ou seja, 
melancólico, ansioso e psicótico) e demência foram obtidos os hazard ratios (HR) 
brutos e ajustados, com intervalos de confiança de 95% (IC 95%), utilizando uma 
análise de regressão de Cox. Foi ainda estimada a incidência cumulativa de 
demência tendo em conta o risco competitivo de morte, usando um modelo de 
regressão de riscos competitivos. O estudo foi desenvolvido de acordo com a 
Declaração de Helsínquia e foi aprovado pela Comissão de Ética da Faculdade de 
Medicina de Lisboa e do Centro Hospitalar Lisboa Norte, pela Comissão Nacional 
de Protecção de Dados e pelo Instituto de Registos e Notariados.
O estudo pré-clínico consistiu na submissão de ratos a um protocolo que se 
sabe induzir sintomas depressivos - a separação maternal (MS - Maternal 
Separation). Foi criado um grupo controlo, que não foi submetido a qualquer 
separação. A metade dos animais de cada grupo foi administrado escitalopram na 
comida durante um mês. Todos os animais foram submetidos a um teste de 
comportamento do tipo desespero aprendido (o Forced Swimming Test) e, 
posteriormente, um teste de memória e aprendizagem (MWM - Morris Water 
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Maze). Foi avaliada a curva de aprendizagem no MWM e o tempo passado no 
quadrante onde estava a plataforma (probe trial, indicativo de memória de longo 
termo). O tempo no probe trial do MWM foi calculado através de uma two-way 
ANOVA, usando MS e escitalopram como fatores de tratamento), e foram 
calculados os efeitos principais e as interações. A ANOVA two-way repeated 
measures foi utilizada para a curva de aprendizagem do MWM.
Resultados
Em 133 (41,3%) dos sujeitos deprimidos, que foram acompanhados em 
média (desvio padrão) durante 25,7 (7,2) anos, o diagnóstico de demência pode 
ser estabelecido ou excluído. Destes 133, 44 (33,1%) desenvolveram demência, 
contra 20 (15,0%) nos indivíduos sem depressão no início do estudo, e este 
resultado é significativo [OR 2.50 (1.14-5.49; 95% CI); p=0.022]. Os indivíduos 
com depressão de início precoce tiveram um risco aumentado de demência [OR 
6.85 (95% C.I. 1.38-34.00); p=0,019], quando comparado com os sujeitos da 
coorte cirúrgica. Os sujeitos com depressão melancólica tiveram um risco 
aumentado de desenvolver demência em comparação com aqueles com 
depressão sem características melancólicas [HR 3,64 (1,78-11,26; I.C. 95%); p = 
0,025]. Estes resultados foram confirmados por várias análises de sensibilidade.
No estudo pré-clínico, todos os grupos de animais apresentaram um efeito 
significativo na aprendizagem no MWM ao longo do tempo, mas não foram 
encontradas diferenças entre os grupos. No entanto, o tratamento com 
escitalopram aumentou significativamente o tempo gasto no quadrante onde 
estava a plataforma (probe trial) no grupo MS [F (1,23) = 10,764; p = 0,004], 
parecendo assim que melhorou a memória. 
Discussão
(1) O risco dos sujeitos com depressão desenvolveram demência foi, 
aproximadamente, o dobro dos sujeitos sem depressão, o que está de acordo 
com os estudos com desenho mais forte - longitudinais e com mais rigor no 
diagnóstico de doença depressiva;
(2) os sujeitos com depressão com início antes dos 45 anos têm um risco 
de demência aumentado, quando comparados com sujeitos não deprimidos, com 
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a mesma idade e sexo. Este achado aponta no sentido da depressão ser um 
factor de risco precoce e não apenas um pródromo/manifestação inicial da 
demência. Este achado está em linha com os estudos longitudinais com tempos 
de seguimento mais longos, mas não com estudos caso-controlo, em que o tempo 
que medeia os dois diagnósticos não é tido em conta, ou é determinado de forma 
pouco rigorosa. Eventualmente o desenho destes estudos não permite avaliar de 
forma correcta a existência de depressão, incluindo formas de menor gravidade;
(3) os sujeitos com depressão melancólica têm um risco aumentado de 
demência comparados com não deprimidos, o que não parece acontecer nos 
sujeitos deprimidos sem sintomas melancólicos. Este achado, que nunca tinha 
sido estudado antes desta forma rigorosa, poderá explicar a heterogeneidade dos 
resultados dos vários estudos. A depressão melancólica tem sido associada de 
forma mais consistente com achados biológicos relacionados com a 
hiperactivação do eixo hipófise hipotálamo-suprarrenal. Tem sido demonstrado 
que o cortisol actua nos receptores  dos glicocorticóides (GR) no hipocampo, 
levando à atrofia deste órgão, o que parece fornecer um racional biológico para a 
depressão melancólica estar associada a um risco aumentado de demência. No 
entanto, não foram feitas avaliações biológicas da actividade HPA, e esta é uma 
limitação do presente estudo. A inclusão de marcadores biológicos apoiaria uma 
explicação biológica, mas não iria interferir com as conclusões;
(4) o tratamento crónico com escitalopram melhorou a memória episódica, 
num modelo que induz comportamentos depressivos-like (MS). Os nossos 
resultados estão linha com a ação neuroprotetora de antidepressivos, mas dão 
um passo em frente, mostrando que o escitalopram também pode melhorar a 
cognição in vivo. O estudo ideal para esclarecer o papel de antidepressivos na 
modulação do risco de demência em sujeitos deprimidos seria um ensaio clínico. 
Todavia, um ensaio deste tipo seria muito caro e difícil de justificar eticamente. A 
transposição dos resultados de estudos animais para os humanos tem limitações, 
embora estudos com animais permitam a utilização de modelos que não são 
eticamente permitidos ou facilmente passíveis de serem realizados em seres 
humanos, e também permitem uma avaliação fiável de vários factores, como p.ex. 
intervenções farmacológicas.
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Conclusões
Os resultados aqui apresentados parecem apoiar a ideia de que a 
depressão é um factor de risco para a demência. Parecem também ajudar a 
esclarecer a natureza desse risco, na medida em que a depressão não parece ser 
meramente um pródromo de demência, mas antes um factor de risco precoce, e 
que a melancolia é o único sub-tipo associado a  um risco aumentado. Além 
disso, esses resultados apontam para uma ação neuroprotectora do escitalopram 
nos défices cognitivos crónicos na depressão.
Palavras-chave: depressão, demência, factor de risco, melancolia, 
antidepressivos. 
 19
 20
B. Introduction
The World Health Organization (WHO) proposition “No health without 
mental health” reflects both the increased awareness of the importance of mental 
disorders, and the challenge to prevent and treat these disabling conditions. The 
WHO reports on the burden of mental disorders have been quite impressive, as 
neuropsychiatric disorders are considered the first cause of disability-adjusted life-
years (DALYs; an integrated measure of disease burden ) in high income 1
countries (Prince, Patel et al. 2007). In the high income countries, such as 
Portugal, neuropsychiatric conditions are responsible for around 30% of all DALYs 
of non-communicable diseases. The first and second conditions responsible for 
more DALYs are depression (10%) and dementia (2%). 
Dementia has a syndromic conceptual definition, and can be caused by 
several disorders. Most of these disorders are irreversible and the available 
therapies have limited beneficial effects, highlighting the importance of the 
identification and control of risk factors. This strategy could assume a major 
relevance for dementia prevention (Peters, Beckett et al. 2008, Ritchie, Carriere et 
al. 2010, Fotuhi, Do et al. 2012, Norton, Matthews et al. 2014). Among the several 
risk factors identified so far, depression emerges as potentially important one 
(Reitz, Brayne et al. 2011), although controversial (Byers and Yaffe 2011, da Silva, 
Goncalves-Pereira et al. 2013). Depression is amenable to prevention, has a high 
prevalence, is diagnosed inexpensively, and the disease can be treated effectively 
(Kupfer, Frank et al. 2012). If it was possible to delay the onset of dementia by 1 
year, the prevalence of dementia would be reduced by 12 million cases in 2050 
(Paillard-Borg, Fratiglioni et al. 2009).
However, the way these conditions are related is not clear, and 
disentangling these possible different relations is a crucial step for the design of 
preventing strategies. Depression can be a prodrome of dementia, because 
depressive symptoms are common in dementia, especially at the initial stages. It 
has even been suggested that depression could arise from the anatomical lesions 
of dementia (Boland 2000). On the other hand, or perhaps concomitantly, 
depression can be an early risk factor for dementia.
 The sum of years lived with disability with years of life lost.1
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Other questions have been raised, as both conditions are heterogenous 
disorders, and the different subtypes can have different risk magnitudes, or show 
no relation. We believe that the relative paucity of longitudinal studies, without 
accurate methods to diagnose both conditions, is limiting a deeper understanding 
of the nature of this complex relation.
The role of antidepressants is also unclear. That is, if the depression is 
treated, does the risk wane? The ideal study to answer this question would be a 
very long clinical trial comparing treated with non treated depressed patients. 
Obviously, such a trial is ethically unacceptable. Animal models offer an alternative 
in these circumstances. Depression and other disorders can be induced in animals 
in a manner that is not easily amenable or ethically allowed to humans, and animal 
models also permite a reliable evaluation of a number of internal and external 
factors (e.g. modifications with drug therapy).
In conclusion, depression is probably a risk factor for dementia, but the 
nature of this relation is complex and unclear. Because dementia disorders are 
mainly irreversible conditions, a deeper understanding of the nature of this risk will 
have an important impact in dementia prevention. 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1. Dementia 
1.1. Historial evolution
Etymologically, dementia derives from the latin word dementatus, which 
means to be out of out of one’s mind or to have no mind. It seems that Celsus in 
the I century A.D. was the first to use the word dementia in a medical context. 
Throughout history dementia has been indistinguishable from other psychiatric 
disorders, although at same points the word was used to describe loss of memory 
and judgment (Mahendra 1987).
Until 19th century, two opposite views on the relation of aging and loss of 
capacities were kept. One, called discontinuity, reflected the opinion of Cicero that 
the loss of capacities - senilis stultitia - only occur in those at risk. Another point of 
view, called “continuity” was defended by a  contemporary of Cicero,  Lucretius - 
the decline of intelectual (and physical) abilities are inexorable consequences of 
aging (Huppert, Brayne et al. 1994).
It is not clear whether Pinel or Esquirol used a more contemporary 
approach for the word dementia. Pinel described cognitive impairment as an 
irreversible failure in the association of ideias, with several symptoms, thought to 
occur in the elderly. He also coined the term “senile dementia”. Some authors 
report that Esquirol was the first to classify dementias. As Esquirol changed his 
point of view throughout his life it is not clear who in fact coined the actual concept. 
Esquirol defined “acute dementia” (short lived, reversible, following fever or 
hemorrhage), “chronic dementia” (irreversible, cause by masturbation, 
melancholia, mania, epilepsy, and others) and “senile dementia” (resulted from 
aging and consisted in a loss of the faculties of understanding) (Mahendra 1987). 
Kraepelin distinguished functional psychosis (insanities) from disorders with 
an obvious brain damage (varieties of imbecility). Under the acquired imbecilities 
(dementia), Kraepelin included apoplectic dementia, old age, and epilepsy (Myron, 
2009). Later, putting together the work of Alzheimer, Pick, Kraepelin and others, 
Roth & Morrissey (1952) divided the mental diseases peculiar to old age in senile, 
arteriosclerotic, and presenile (including Alzheimer’s disease and Pick’s disease) 
psychosis. Psychosis was used in the sense of a severe mental disorder.
Due to the acknowledgement of an organic basis for these conditions, the 
diseases causing dementia were classified in DSM I and II in the Chapter “Organic 
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Brain Syndromes” (cited in Kaplan 1st and 2nd Edition), and a closer approach to 
the present concept was published in DSM III.
The several diseases causing dementia have been elucidated throughout 
history. On the XIX century, Griesinger , who belonged to the school of “somatics”, 2
considered that psychic diseases are caused by organic diseases, and was the 
first to describe senile dementia as a result of arteriosclerois in the cerebral blood 
vessels (Mahendra 1987). Although the general paralysis of the insane was 
described in the XVII century, its relation to Treponema pallidum, and 
neurosyphilis were discovered in the first half of the last century (Weiner and 
Lipton 2009).
The most well known advance in the field, however, was achieved by a 
german psychiatrist, Alois Alzheimer. Dr. Alzheimer described a case of a 51-years 
old female patient (August D), who had shown progressive cognitive impairment 
disease, along with focal symptoms, hallucinations, and delusions (Maurer, Volk et 
al. 1997). The neuropathological findings at necropsy (senile plaques and 
neurofibrillary tangles) defined the disease, and are still today considered the 
hallmarks of the disease (American Psychiatric Association 2013). The eponym 
was originally referred to presenile dementia, but actually it referes to the largest 
cause of dementia.
Other causes of dementia has been described, and refined, throughout the 
years, such as Frontotemporal Dementia (FTD) (Kertesz 2007, Rascovsky, 
Hodges et al. 2011) or Dementia with Lewy Bodies (DLB) (Goedert, Spillantini et 
al. 2013). A more detailed description of these subtypes can be found in Section 
2.3..
Before progressing to dementia, patients usually exhibit mild, but 
increasing, cognitive impairments. These deficits reflect the progressive 
neurodegeneration promoted by the several causing diseases. These stages, their 
meaning and definition, have been extensively discussed in the literature 
(reviewed by Gerstenecker and Mast 2014). However, Petersen et al. (1999) 
defined conceptually the condition, called Mild Cognitive Impairment, and 
 His quote “psychical disorders are brain disorders” are frequently cited, in the context of 2
biological psychiatry
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proposed the first operational criteria. In DSM-5 the condition is referred as Minor 
Neurocognitive Disorder, existing on a spectrum with Major Cognitive Disorder.
1.2. Epidemiology
According to the report from the Alzheimer’s Disease International (2009), it 
is estimated that globally dementia affected 35,6 millions of people worldwide in 
2010. These numbers will probably duplicate each 20 years, up to 115,4 millions in 
2050. 
We are aware of only two studies reporting epidemiological data of 
dementia in Portugal. The first, performed by Garcia et al (1994), calculated the 
prevalence of dementia projecting to the Portuguese population the European data 
gathered by the EURODEM study (Hofman, Rocca et al. 1991, Rocca, Hofman et 
al. 1991). The estimated prevalences, for 1991 and for individuals over 60 years, 
were 2.4% for dementia (about 92 000 cases) and 1.3% (about 48 000 cases) for 
AD. 
A more recent epidemiological study, developed in the North of Portugal, 
yielded an overall prevalence of dementia of 2.7% for individuals between 55 and 
79 years-old (Nunes, Silva et al. 2010). The prevalence was higher in rural areas, 
increased in with age, decreased with education years and was also higher in 
individuals with cerebrovascular disease.
1.3. Clinical features, diagnosis and neurobiology
Conceptually, dementia is a clinical condition characterized by a cognitive 
decline. It has been defined operationally by the Diagnostic and Statistical Manual 
of Mental Disorder 5th Edition (DSM-5; American Psychiatric Association 2013) 
and by the World Heath Organization Internacional Classification of Diseases 10th 
Edition (ICD10) (ICD10; World Health Organization 1992). According to DSM-5 
criteria (the most used criteria in research) the core symptom of dementia - called 
“Major Neurocognitive Disorder” (Major NCD) - is a significant decline in one or 
more cognitive functions. This decline must be significant and have an impact in 
the independence to perform the activities of daily living, and must not occur 
exclusively in the course of a delirium. Although neuropsychological testing can 
support the diagnosis, the diagnosis of dementia is clinical (Garcia 1984), 
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according to both ICD10 and DSM-5. DSM criteria are easier to use, are 
considered accurate (Knopman, DeKosky et al. 2001), and are the most used 
criteria in research for dementia diagnosis .3
At least one cognitive domain should be affected, including complex 
attention, executive function, learning and memory, language, perceptual-motor, 
and social cognition according to DSM-5. For ICD10 a memory impairment plus 
several other deficits is mandatory for the diagnosis. Because the core symptoms 
are the cognitive impairments, it is conceptually distinct from other psychiatric 
disorders, such as bipolar disorder or schizophrenia; in these disorders, although a 
cognitive decline can be documented, it is not the core feature.
It is recommended to document the cognitive deficits by neuropsychological 
tests (NT). NT assess brain functions that, with certain restrictions, can be viewed 
as separated and that can be correlated with certain brain areas. Attention, 
executive functions, learning, memory or language are exemples of cognitive 
domains commonly assessed by NT. A NT yields a quantitative record, expressing 
the difference from normality. Normality is a key issue for NT, as a normative 
database for a test is essential to ensure that the deficits seen in a given individual 
are not related to age, years of education, native language or others.
A very important number of NT have normative data and validated versions 
for the Portuguese population. It is noteworthy the efforts of the Grupo de Estudos 
de Envelhecimento Cerebral e Demências, that have already published three 
editions of Escalas e Testes na Demência (GEECD 2015). The last edition intends 
to have detailed psychometric (in what concerns to validity - a test’s ability to 
measure what it proposes to measure - and reliability - the consistency of times 
scores), and normative data for a vast number of tests.
As mentioned above, the cognitive decline should be severe enough to 
interfere with daily activities. However, this is not easy to define operationally. 
 Three important differences exist in the diagnostic criteria for dementia between DSMIV 3
and DSM-5. (1) A single cognitive deficit is required for the diagnosis of dementia, instead 
of two, and a memory impairment is not mandatory for the diagnosis. (2) Also a new 
diagnostic category, for less severe forms of cognitive impairment, was created. (3) The 
etiologies were reformulated and updated with more recent criteria. We believe these 
changes, although not fully evaluated, reflect the more recent research in the field. 
Namely the existence of dementia without or with very mild memory impairment, the 
importance of mild cognitive impairment, and the accumulating knowledge on amyloid 
detection, the classification of FTD, or the new LBD criteria.
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DSM-5 states there must be an interference with the independence in activities of 
daily living (at the minimum, assistance is required for complex activities) and 
performance below 2 standard deviations (s.d.) bellow appropriate norms for the 
diagnosis of Major Neurocognitive Disorder (Major NCD). For Minor NCD (an 
equivalente of Mild Cognitive Impairment), DSM-5 specifies that these complex 
activities must be preserved, but a greater effort, compensatory strategies or 
accommodation are required to be performed. A difference between 1 and 2 s.d. is 
required in neuropsychological evaluation. These criteria are openly arbitrary, 
because DSM-5 assumes the continuity between normality, Minor NCD and Major 
NCD. ICD10 defines a threshold of impairment as an interference in daily activities 
not enough to loose independence.
The guidelines for the evaluation of dementia in Portugal are still under 
discussion (DGS 2011). The proposal recommends the use of screening tests for 
the detection of the cognitive impairment, such as the MMSE (Folstein, Folstein et 
al. 1975, Guerreiro 1998) or the MOCA (Nasreddine, Phillips et al. 2005, Freitas, 
Simoes et al. 2011), both validated for the Portuguese population. 
If a diagnosis of dementia, or NCD, is made, the next step is to explore the 
etiology. It is considered good clinical practice the prescription of laboratory 
analysis (complete blood count, fasting serum glucose, serum creatinine, serum 
electrolytes (including calcium), liver functions tests and enzymes, thyroid 
hormones, B12 vitamin, folic acid and syphilis serology) and brain scan (CT or 
MRI) to exclude reversible conditions and to provide information for the etiological 
diagnosis (DGS, 2011, Sorbi, Hort et al. 2012). These prescriptions are also valid 
for Mild Cognitive Impairment (Pereira, Simoes do Couto et al. 2006).
The etiological diagnosis for each dementia is driven by the clinical picture 
and eventually confirmed by specific exams (Sorbi, Hort et al. 2012). There are 
several standard criteria that can be used such as the NINCDS-ADRDA (National 
Institute of Neurological and Communicative Disorders and Stroke - Alzheimer’s 
disease and Related Disorders Association) criteria (McKhann, Knopman et al. 
2011) for AD, the NINDS-AIREN (National Institute of Neurological Disorders and 
Stroke - Association Internationale pour la Recherche et l’Enseignement en 
Neurosciences) criteria (Roman, Tatemichi et al. 1993) for vascular dementia, the 
criteria proposed by the International Behavioural Variant FTD (fronto-temporal 
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dementia) Criteria Consortium (Rascovsky, Hodges et al. 2011) for the behavioral 
variant of fronto-temporal dementia (FTD), and the criteria proposed by McKeith et 
al (2005) for Lewy Body dementia. 
Several conditions can cause dementia (Table 1), although mixed forms are 
common (Attems, Konig et al. 2005, Santana 2005, Beach, Adler et al. 2015).
Table 1 Causes of dementia
1. Alzheimer’s disease
2. Fronto-temporal dementias
3. Lewy body dementia
4. Parkinson’s disease dementia
5. Cortiocobasal degeneration
6. Progressive supranuclear palsy (PSP)
7. Vascular dementia
8. Chronic subdural haematoma
9. Hypoxia related to hypoperfusion
10. Mixed dementia (AD and VD)
11. Normal pressure hydrocephalus
12. Wilson´s disease
13. Huntington’s disease
14. Vitamins deficitis
Vitamina B1, vitamina B12, niacine, folate.
15. CNS infections
Syphilis, borreliosis, tuberculosis, brucellosis, viral encephalitis, VIH infection, 
prion diseases.
16. Endocrine diseases
Thyroid, parathyroid, and adrenal.
Chronic metabolic disturbances (e.g. uremia)
17. Intoxicationsa
Aluminum, copper, mercury, plumb, zinc, arsenic, alcohol.
Other (pesticides, flame retardants, solvents, etc).
18. Neoplasia
Primary and metastatic CNS tumors.
Paraneoplasic syndroms.
19. Trauma
20. Immune diorders
Systemic lupus erythematosus, temporal arteritis.
21. Hepatic or renal failures
22.  Metabolic conditions
23. Radiation
24. Electric shock
25. Other neurological conditions
Epilepsy, multiple sclerosis.
26. Other
Idiopathic cerebral ferrocalcinosis, metachromatic leukodystrophy, 
neuroacanthocytosis
Adapted from Santana (2005) and Neurgoschl (2004). Notes: a(Genuis and Kelln 2015).
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There are important variations in the frequency of these different disorders, 
depending on the sample characteristics (age, dead or alive, country of origin, how 
the recruitment took place, etc), on the diagnostic criteria, and others. In clinical 
series this discrepancies are noteworthy. E.g., the frequency of LBD range from 0 
to 30 % (reviewed by Zaccai, McCracken et al. 2005).
A notable serie of a community sample, non demented at study entry, was 
published very recently involving 1173 autopsies (Beach, Adler et al. 2015) . It was 
found that the most common cause of dementia at the autopsy was AD (57%), 
followed by PD (14%), VD (9%), LBD (9%), and PSP (6.8%). However, mixed 
forms were quite common (around 40%). Other causes are rarer and, as whole, 
account for about 12%. Reversible causes of dementia are extremely rare, such 
as vitamina B12 deficiency or hypothyroidism. 
In Portugal, it is estimated that AD and VD are equivalent, affecting about 
40% of the population (Nunes, Silva et al. 2010). However, in this paper the criteria 
for diagnosing the different dementia disorders were not clearly defined, and 
probably more accurate data on this subject is mandatory. In a study performed at 
our center, in MCI subjects, no reversible dementia was found (Pereira, Simoes do 
Couto et al. 2006).
a) AD
AD is the most common form of dementia, and is considered the most 
important dementia condition and a paradigm of dementia.
Although described more than a century ago, the histopathological changes 
described by Dr. Alzheimer are still used today, with some important refinements, 
for the definite diagnosis of the disease (Heyman, Fillenbaum et al. 1990, Braak 
and Braak 1991). AD is characterized by the presence of senile plaques (SPs), 
neurofibrillary tangles (NTs), and neurodegeneration and cell death specially in the 
hippocampus and in other medial temporal lobe structures. SPs (or neuritic 
plaques) are extracellular aggregates of a protein (beta-amyloid or Aβ) and NFTs 
are composed of hyperphosphorylated tau protein. The mechanisms of SPs and 
NFTs formation have been studied (reviewed by Blennow, de Leon et al. 2006). Aβ 
is released when a transmembrane protein, amyloid precursor protein (APP), is 
cleaved by two amyloidogenic enzymes, the β- and γ-secretases. APP can be 
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cleaved by a different secretase, called α-secretase, to yield two non-amyloid 
fragments, non pathogenic.
Drachman (1977) reported memory disturbances after the administration of 
scopolamine  to healthy volunteers, and the blockage of this effect with a 4
pretreatment with physostigmine, a cholinesterase inhibitor. A few years later, a 
significant neuronal loss in the nucleus basalis of Meynert - an important 
cholinergic nucleus in the brain - in AD patients was described (Whitehouse, 
Struble et al. 1982). Although a myriad of neurochemical deficits have been 
described in AD, these findings opened the way to the most consistent explanation 
for its cognitive disturbances - the cholinergic hypothesis. Cholinergic hypothesis 
implies that the disturbances in central muscarinic cholinergic mechanisms are 
related to the loss of memory present in AD (Bartus, Dean et al. 1982, de 
Mendonça and Simões do Couto 2005).
The relation between SPs, NFTs, and the neurodegeneration is certainly 
controversial. It has been proposed that amyloid is the key pathogenic element of 
AD and the process of amyloid induced degeneration is called amyloid cascade 
(Blennow, de Leon et al. 2006). The main support for this theory is driven from 
genetic mutations. Mutations that affect APP synthesis and proteolysis , lead to 5
and excessive production and early deposition of amyloid, and to an early-onset 
familiar form of AD (Wu, Rosa-Neto et al. 2012).
Although it has been considered the main pathogenic hypothesis for AD, it 
has been challenged repeatedly. Other researchers believe that NFGs play the 
most important role in the pathogenesis of the disease. They are called “tauoists", 
and their criticisms have become more consistent in the last few years (Herrup 
2015), especially because therapeutics that remove amyloid seem not to stop 
cognitive deterioration (Karran and Hardy 2014).
Another biological mechanism involved is glutamate mediated neuronal 
toxicity. Although essential for several cognitive processes, an excessive activation 
of glutamate receptors can lead to neuronal lesion, or even neuronal dead (Lipton 
and Rosenberg 1994).
 Scopolamine is competitive blocker of muscarinic receptors4
 Such as APP, Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) gene mutations 5
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The diagnosis of AD is based on the clinical features of the disease plus the 
exclusion of other causes (McKhann, Knopman et al. 2011). This approach, 
operationally defined by the first NINCDS-ADRDA criteria, can lead to a sensitivity 
of 81% and a specificity of 71% (Knopman, DeKosky et al. 2001).
The clinical picture of AD is characterized by an insidious onset of a decline 
in memory and learning. These deficits are progressive, without worsening periods 
related to cerebrovascular events. Although other cognitive deficits can occur, they 
usually are less severe than memory and learning. 
Remarkable advances happened in the last few years in the field of the 
diagnosis of AD (de Mendonca 2012). DSM-5 is actually reflecting in a small 
extent these changes, and included a biomarker for AD, specifically a mutation 
known to cause the disease. However, other biomarkers are also currently 
available in reference centers, and are a very important tool for the diagnosis of 
the disease (specially when the diagnosis is doubtful or have therapeutic or 
management implications). They are also quite often required as inclusion criteria 
for clinical trials.
The principal AD biomarkers that can detect the disease in the earlier 
stages are the quantification of Aβ in the cerebrospinal fluid (CSF) and the 
positron emission tomography (PET) scan with an amyloid marker (most 
commonly PIB (Pittsburgh compound), although others are under development). 
Lower levels of Aβ in CSF and increased captation of the radiolabeled Aβ ligand in 
the PET scan correlate with amyloid deposition in autopsy and seem to predict the 
development of dementia (Sperling, Aisen et al. 2011). Biomarkers of synaptic 
dysfunction, specially PET scan with radio labeled glucose (e.g. [18F]FDG or 
fludeoxyglucose), show a decreased metabolism in temporo-parietal cortex 
(McKhann, Knopman et al. 2011). Elevated CSF tau is not specific for AD and is 
thought to be a biomarker of neuronal injury. Although it appears later in the 
course of disease, hippocampal atrophy is a biomarker of AD-related 
neurodegeneration.
It is expected that the inclusion of these biomarkers in the diagnostic criteria 
will increase the diagnostic accuracy (McKhann, Knopman et al. 2011).
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b) Frontotemporal dementia (FTD)
FTD is a heterogeneous group of neurodegenerative disorders affecting 
frontotemporal areas. The clinical syndrome results from frontotemporal lobar 
degeneration (FTLD) associated with a range of heterogeneous pathologies 
(Rascovsky, Hodges et al. 2011). The first case was described in 1892 by Arnold 
Pick, and Pick’s disease was used for a synonymous of FTLD until recently. Today, 
Pick’s disease is used only to described a subgroup of FTLD with specific 
histopathological features. Based on early and predominant symptoms, DSM-5 
distinguishes two different clinical syndromes: the behavioral variant and a 
language variant. The language variant has often been subdivided in two: 
semantic dementia and nonfluent primary progressive aphasia (Waldo 2015).
FTLD is caused by an abnormal accumulation of proteins, and its 
neuropathological subtypes are defined by the different accumulating proteins. 
Although a considerable overlap existis between these conditions, efforts has 
been made to classify them (Riedl, Mackenzie et al. 2014). The best studied group 
represents roughly 40% of all FTLD and is called tau-positive. It is  characterized 
by the accumulation of microtubule-associated protein tau (MAPT) and is called 
FTLD-tau. It includes the classic Pick’s disease, the cases of familial FTLD caused 
by mutations in MAPT genes, and other neurological disorders (progressive 
supranuclear palsy and corticobasal degeneration). The tau-negative FTLD 
includes the accumulation of transactive response DNA-binding protein with 
molecular weight 43 kDa (TDP-43), and is called FTLD-TDP. This form represents 
roughly 50% of all forms, is related to mutations on the C9orf72 gene, and 
includes the FTLD condition and amyotrophic lateral sclerosis. The remaining 
5-10% cases are tau and TDP negative, and are  characterized by the deposition 
of another protein, called fused in sarcoma protein (FUS). Additional very rare 
conditions have been described.
The classification of FTD and FTLD is a controversial area. Each FTLD 
disease does not necessary presents with a specific FTD syndrome, and even 
mutated genes can have different clinical presentations. Furthermore, some 
clinical and histological defined conditions share common features, or can exist 
simultaneously, and overlap with other disorders, namely atypical Parkinsonian 
syndromes.
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Figure 1 The classification of Frontotemporal Lobar Degeneration and 
Frontotemporal Dementia 
Legend FTLD Frontoremporal Lobar Degeneration, FTD Frontotemporal dementia, PSP 
Progressive Supranuclear Palsy, MAPT Microtubule-Associated Protein Tau, TDP transactive 
response DNA-binding protein with molecular weight 43 kDa, FUS Fused with Sarcoma, BvFTD 
Behavioral variant, PPA Progressive Primary Aphasia, svPPA Semantic Variant, nfv Nonfluent 
Variant, L Left, R Right, # Associated with MAPT gene mutations, * Associated with Progranuline 
gene mutations, + Associated with C9orf72 gene mutations (Riedl, Mackenzie et al. 2014)
Both variants - behavioral and language - are characterized by progressive 
dementia with a relative sparing of learning and memory functions. Clinically, the 
behavioral variant (bv-FTD) can present itself with disinhibition, loss of empathy, 
apathy, repetitive behaviors, and hyperorality. The language variants are defined 
by a prominent decline in language ability. Three forms are usually described: (1) 
semantic dementia, with a decline in word meaning, but with a fluent speech and 
preservation of repetition; (2) agramatic/nonfluente, with a decline in speech 
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fluency and sentence construction, and anomia; (3) logopenic, with slow speech, 
impaired syntactic comprehension and naming (Harciarek and Kertesz 2011). 
The International Behavioural Variant FTD Criteria Consortium (Rascovsky, 
Hodges et al. 2011) and DSM-5 (American Psychiatric Association 2013) share 
globally the same criteria. The inclusion of biological markers is also a common 
feature, and the presence of a known causative mutation and a disproportionate 
frontal and/or temporal lobe involvement can turn the diagnoses from possible to 
probable. 
Neuroimaging is probably different in these variants (Harciarek and Kertesz 
2011, Kirshner 2014). In the bv-FTD the atrophy involves specially the medial 
frontal lobes and the anterior temporal lobes. In SD, the temporal lobes are 
atrophic, but asymmetrically (left side usually more affected). Agramatic/nonfluente 
is predominantly associated with left posterior frontal-insular atrophy, while 
logopenic variant has left posterior perisylvian or parietal atrophy. These findings 
were incorporated in the DSM-5, although were not considered diagnostic criteria.
c) Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD)
Parkinson’s disease (PD) was described almost 200 years ago and its 
characteristic neuropathological lesion - Lewy bodies (LB) - almost 100 years after 
(reviewed by Goedert, Spillantini et al. 2013). The LB are composed of α-
synuclein, ant it is believed that this protein is the key feature in the development 
of the clinical symptomatology (Beach, Adler et al. 2009). 
Although LB were found in the brain stem nuclei of PD patients, establishing 
the neuropathological basis of PD in 50s, it was believed that they were rarely 
found in the cerebral cortex. Later, some cases suffering from atypical AD with 
parkinsonism were found to have numerous intracytoplasmic eosinophilic 
inclusions at the deeper cortical layers and typical LB in the brain stem (Kosaka 
1978). The term Lewy Body Disease was proposed to these cases, and 4 types 
have proposed, with different degrees of brain stem and cortical involvement 
(Kosaka, Yoshimura et al. 1984, reviewed Kosaka 2014) . Diffuse Lewy Body 6
Disease was applied to the cases with predominant cortical involvement, and a 
 Type A (brain stem type, consistent with PD), type B (transitional type), type C (diffuse 6
type), and later a cerebral type of LBD was added (with LB in the cortex, but rare in the 
brain stem; no Parkinsonian symptoms).
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relative sparing of the brain stem. When diffuse Lewy body disease was found 
associated with dementia, it was not clear whether there was a “senile dementia of 
the Lewy body type” or a “Lewy body variant of Alzheimer’s disease”. Several 
international conferences and workshops took place and the term Dementia with 
Lewy Bodies was proposed and the operacional criteria set (McKeith, Galasko et 
al. 1996).
DLB criteria have refined more recently (McKeith, Dickson et al. 2005), and 
largely incorporated into DSM-5 (American Psychiatric Association 2013). LBD has 
been considered the second most frequent cause of neurodegenerative dementia 
in some series (Donaghy and McKeith 2014).
DLB is characterized by dementia, spontaneous parkinsonism (starting after 
the onset of the cognitive decline, or at a maximum of one year before), recurrent 
well formed visual hallucinations, fluctuating cognition, rapid eye movement sleep 
behavior disorder (RSBD), and severe sensitivity to antipsychotic medications 
(Beach, Adler et al. 2009). DLB consortium guidelines are considered the gold 
standard for diagnostic purposes (McKeith, Dickson et al. 2005). They include a 
central feature (dementia), 3 core features (parkinsonism, visual hallucinations and 
fluctuating cognition), and 3 suggestive features (RSBD, neuroleptic sensitivity and 
a biomarker - the low dopamine transporter (DAT) uptake in basal ganglia, 
demonstrated by PET our SPECT). Several supportive features are listed, 
considered to be commonly present, but of probably without an impact in the the 
diagnostic accuracy. DSM-5 (American Psychiatric Association 2013) follows in 
general the DLB consortium guidelines, although biomarkers were not included in 
the criteria.
The cognitive deficits seen in DLB include visuospatial, attention  and 
executive functions (Metzler-Baddeley 2007), rather than learning and memory.
d) Vascular dementia (VD)
As mentioned before, dementia caused by cerebrovascular disease was 
first suggested by Griesinger in the 19th century (Huppert, Brayne et al. 1994). 
Since then, several terms have been used to described this condition, such as 
arteriosclerotic dementia, multi-infarct dementia, post-stroke dementia, vascular 
dementia, vascular cognitive impairment (VCI), and vascular cognitive disorder 
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(Jellinger 2013). Vascular cognitive disorder encompasses all different types of 
cerebrovascular lesions that led to cognitive impairment and eventually to 
dementia.
Brain infarcts are the most important pathology that contributes to cognitive 
impairment. An increased number of infarcts, an increased infarct size, and certain 
locations (specially the thalamus, angular gyrus, and basal ganglia) have been 
associated with an increased risk for dementia, but determining the number, the 
exact location, or the volume needed to have dementia has not yet been 
established (Gorelick, Scuteri et al. 2011). 
The brain is critically dependent on blood supply, and sophisticated local 
mechanism regulate the amount of blood supply needed to match the brain energy 
requirements. These mechanisms are profoundly disrupted in VCI and in AD, 
leading to chronic hypoxia and inflammation. Besides these microvascular 
changes, also macrovascular changes are biological mechanisms associated with 
VCI (Gorelick, Scuteri et al. 2011).
The Religious Order Study (“Nun study”) found that only people with AD 
pathology and subcortical infarcts had dementia (Snowdon, Greiner et al. 1997), 
suggesting that cerebrovascular lesions increased the risk of developing dementia, 
or clinical AD, in patients with AD (Gorelick, Scuteri et al. 2011).
Although NINDS-AIREN criteria (Roman, Tatemichi et al. 1993) are still the 
gold-standard research criteria for VD, the concept of a spectrum of vascular 
cognitive impairment has been recently incorporated into DSM-5 (American 
Psychiatric Association 2013) and into other important guidelines (Gorelick, Scuteri 
et al. 2011).
The diagnosis is made when dementia is present, and the cerebrovascular 
lesions, shown by neuroimaging, can be related to the cognitive dysfunction. The 
clinical picture is classically of an acute onset of the cognitive deficit, a stepwise 
progression, and the presence of focal neurological signs suggesting a sufficient 
cerebrovascular burden to produce the cognitive deficits. Personality and mood 
changes are also common, such abulia, depression, and emocional lability. 
Complex attention and executive functions are usually affected. 
Obviously, neuroimaging is a powerful diagnostic tool, especially if silent 
infarcts exist. The diagnostic accuracy is increased if a genetic disease associated 
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with cerebrovascular disorder is present, such as cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
The term mixed dementia is used to describe a condition in which AD 
pathology and cerebrovascular lesions co-occur.
1.4. Treatment
The treatment of secondary dementias is the treatment, if possible, of the 
condition actually causing the disease. E.g., if the cause of dementia is B12 
vitamine deficiency or hypothyroidism, the treatment of these conditions would 
cure dementia, or at least stop the cognitive deterioration.
The treatment of neurodegenerative dementias is merely symptomatic. As 
the majority of these conditions is due to AD it is not surprising that the research 
on the treatment of this disorder is much more extensive.
Primary prevention trials have been done for dementia. A number of factors 
have been studied (stimulating cognitive, physical and social activities, vascular 
risk factors - obesity, diabetes, dyslipidemia, etc), but this trials have globally 
failed, and no therapy is recommended for the primary prevention, or for delaying 
the onset of dementia (Sorbi, Hort et al. 2012).
a) Alzheimer's disease 
There are several targets and approaches for the treatment of AD. The 
targets are (1) cognition, (2) activities of daily living (ADL), (3) behavioral and 
psychiatric symptoms of AD (Peter V. Rabins 2014). The approaches for each 
target can be either pharmacological or non-pharmacological or both.
Currently approved drug treatments for cognition in AD have only shown 
symptomatic improvement, meaning that an effect in disease progression has 
never been shown. They can be divided according to their mechanism of action in 
two classes, cholinesterase inhibitors and NMDA receptor modulators. 
Based on the cholinergic deficit of AD, several attempts have been made to 
increase cholinergic transmission (de Mendonça and Simões do Couto 2005), 
such as the administration of choline and other acetylcholine precursors, 
muscarinic receptor agonists, and neutrophic factors. However, the most 
successful strategy until now has been acetylcholinesterase inhibition, thereby 
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increasing acetylcholine in the synaptic cleft. There are three cholinesterase 
inhibitors (CholI) approved for the treatment of AD in Portugal - donepezil, 
rivastigmine, and galantamine. Although some differences can be found between 
these compounds, their efficacy does not differ significantly and, more important, 
an impact on the progression of the disease has not been shown (Rafii and Aisen 
2015). Their side effects are mainly an extension of their pharmacological 
properties, and so cholinergic effects emerge as the most common.
The other target for the treatment of AD has been the the NMDA receptor. 
As discussed above, glutamate and NMDA receptors involvement in the apoptosis 
and neurodegeneration of AD has been documented (Lipton and Rosenberg 1994, 
Cacabelos, Takeda et al. 1999). Therefore, their blockage seems a logical target. 
However, NMDA receptor has a primordial role in the processes of learning and 
memory, meaning that its antagonism would have significant cognitive effects. The 
use of NMDA antagonists for AD has been refined through the use of memantine, 
a moderate affinity inhibitor of this receptor. Memantine is also an uncompetitive 
antagonist, with a fast voltage dependent kinetics. These properties seem to 
explain its different actions with mM and µM glutamate concentrations. Memantine 
rapidly leave the NMDA channel during physiological activation by mM 
concentrations of glutamate. However, when sustained activation by µM 
concentrations of glutamate under moderate pathological conditions occur, 
memantine acts as antagonist, blocking the receptor (Rammes, Danysz et al. 
2008). Its mechanism of action can be understood as restoring the equilibrium of 
NMDA receptors (Rogawski and Wenk 2003, Zadori, Veres et al. 2014).
Other targets for cognitive improvement are currently being in development 
in clinical trials, such as BACE inhibition and monoclonal antibodies anti amyloid 
beta (Rafii and Aisen 2015).
Non-pharmacological approaches for AD have been developed since the 
60s and 70s. However, in recent years an increase in the interest in this area led 
to a significant increase in the number of publications, but also an increase in the 
heterogeneity of the approaches and their evaluation (Guerreiro 2005, Bahar-
Fuchs, Clare et al. 2013, Peter V. Rabins 2014). Nonspecific interventions 
targeting cognitive functioning, such as reality orientation therapy, have shown 
benefits in demented or AD patients. More recently, more specific approaches, 
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such as cognitive rehabilitation and cognitive training, designed to help 
maintaining or increasing cognition in demented and AD patients have been 
designed . The Cochrane review in this topic did not find evidence of a positive 7
effect on the cognition of cognitive training. Only one study addressing cognitive 
rehabilitation was included, and albeit the results seemed promising, no 
differences in cognition were found (Bahar-Fuchs, Clare et al. 2013).
Globally, non-pharmacological therapies for dementia and AD seem 
promising, but the heterogeneity and the low quality of the studies, inherent to the 
nature of the therapy , somehow precludes a definitive conclusion on their efficacy 8
(Guerreiro 2005).
b) Vascular dementia
Drug treatments approved for AD have also been tried on VD, but none has 
received regulatory approval. However, donepezil for VD and galantamine for 
mixed dementia have shown a symptomatic benefit in these conditions, and they 
are recommend by several guidelines (Sorbi, Hort et al. 2012), including the 
Portuguese guidelines (DGS 2011).
Few studies addressed the efficacy of non-pharmacological interventions in 
VD. Cognitive rehabilitation, cognitive stimulation and acupuncture studies in 
human VD were inconclusive or showed no efficacy (Sorbi, Hort et al. 2012).
Besides cognitive symptoms, management of vascular risk factors and 
symptomatic treatment are the recommend treatments for VD.
c) Other neurodegenerative dementias
Rivastigmine is approved for the treatment of PDD in Portugal and has 
shown efficacy for the symptomatic treatment of DLB (Sorbi, Hort et al. 2012).
Although inconsistent benefits, in several domains, have been shown to 
occur with several drugs in FTD, currently no drug treatments have been approved 
for the treatment of this condition (Sorbi, Hort et al. 2012).
 Cognitive rehabilitation is built to address individual needs and cognitive training 7
focusing on the improvement of cognitive functions, such as memory or problem solving.
 Other issues mentioned in the these studies are the heterogeneity in the outcome, in the 8
techniques used, in the sample and in the setting.
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2. Depression
2.1. Historical evolution
Depression is considered a mood disorder - a group of disorders in which 
the core symptom is a pathological mood, accompanied by related vegetative and 
psychomotor disturbances (American Psychiatric Association 2013).
Depression has been conceptualized in different ways, but in general it 
describes a condition characterized by low, sad or empty mood, less pleasure, 
changes in sleep and appetite, diminished libido, retardation, guilt, suicidal 
thoughts, pessimism, feelings  and thoughts of hopelessness, helplessness and 
worthlessness, and eventually psychotic symptoms (Bastos, Gonçalves-Ferreira et 
al. 2014).
The word depressão has been related to the latin etymon deprimere, to 
press down (Machado 2003). The first descriptions of a disease probably similar to 
what is today considered today depression have been attributed to the ancient 
Greek physician Hippocrates, and was called melancholia. He described 
melancholia as a distinct condition characterized by "aversion to food, 
despondency sleeplessness, irritability and restlessness” (Marneros and Angst 
2000). He provided a biochemical cause for this state - an excess of black bile - 
and called the disorder melancholia (meaning black bile).
Another mood state is called mania, and its etymology is not clear, as 
several hypothesis have been raised (Marneros and Angst 2000). Anyway, the 
disease fitting the actual concept of mania was also described by Hippocrates. It is 
characterized by expansive mood, talkativeness, increased energy, less need to 
sleep, and eventually psychotic symptoms (American Psychiatric Association 
2013, Figueira and Madeira 2014).
The historical concepts of depression, melancholia, mania and bipolar 
disorder do not correspond to the actual concepts. In fact, many classifications, 
and conceptualizations took placed throughout the years (reviewed by Marneros 
and Angst 2000). Mood disorders do not have a clear etiology, and their diagnosis 
and classification has relied mainly on symptoms. Other classic medical 
nosographic criteria, such as the evolution, prognosis, response to therapy and 
etiology (the latter largely unknown) played a secondary role (Sousa 2003).
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However, a milestone has been achieved with Kraeplin. Kraeplin cautiously 
followed his patients for many years, and used the above referred key medical 
criteria for the classification of mental diseases. The classification of mental 
disorders he provided is still the basis of the modern classifications. Kraeplin 
distinguished dementia praecox (the actual representative is schizophrenia) from 
manic depressive illness.  He used the term manic-depressive insanity to include, 
on the one hand, what was called melancholia and related states, and on the 
other, what was called circular insanity (and other forms of mania). He stressed 
out that, from a clinical point of view, it was impossible to distinguish depressive 
episodes occurring in a patient with a previous episode of mania from those 
without (Marneros and Angst 2000).
Kraeplin’s unified conceptualization was soon challenged. Wernick and 
Kleist proposed the terms and developed the concepts of unipolar (only mania or 
only depression) and bipolar disorder (merely a co-occurrence of the two 
disorders), still considering they were the same disorder (Marneros and Angst 
2000). Karl Leonhard in 1957 followed a cohort of depressed patients for a 
longtime and distinguished unipolar (only manic episodes or only depressive 
episodes) from bipolar (depressive and manic episodes concurring in the same 
patient). After Leonhard definition, in 1966 the independent seminal studies of 
Jules Angst (Angst 1966, reviewed by Marneros and Angst 2000, and by Bastos, 
Gonçalves-Ferreira et al. 2014) and Carl Perris (1966) provided consistency to the 
separation. Family history and evolution were different in these disorders and the 
data supported Leonhard's distinction. These studies then were translated into the 
Research Diagnostic Criteria and into DSMIII (Lara 1984).
Both DSM-5 (American Psychiatric Association 2013) and ICD10 (World 
Health Organization 1992) separate unipolar from bipolar affective disorders. 
DSM-5 even treats these disorders in separate chapters, although pure mania is 
considered a bipolar disorder.
With the rise of psychodynamic views, etiology started to play a determinant 
role for the classification of the disorders. The DSMI and DSMII largely reflect 
psychoanalytic views, classifying the disorders as reactions and did not provide 
diagnostic criteria. Probably, the disappointment with psychodynamic concepts, 
the use of psychopathological standard measures, and the development of 
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mathematical applications to clinical psychopathology (Sousa 2003) led a radically 
different approach to psychiatric disorders, called neokraeplinian (Compton and 
Guze 1995). These methods were used to establish profiles of symptoms, analyze 
the symptoms structure, and get the original nosologies, creating empirical 
classifications -  dimensional or typological (Sousa 2003).
These new methods led to a new definition of psychiatric diseases, 
translated into the Research Diagnostic Criteria (RDC) (or Feighner criteria), 
created at the Washington University School of Medicine in St. Louis (Spitzer, 
Endicott et al. 1975, Spitzer, Endicott et al. 1978). These criteria were largely the 
basis for the next DSM and ICD editions. 
In Portugal, Manoel Paes de Sousa and António Fernandes da Fonseca 
were important researchers of this current. António Fernandes da Fonseca 
proposed the concept “affective equivalents” to describe certain monosymptomatic 
conditions of psychic and somatic nature (not obviously mood phenomena) witch 
gave evidence of being connected to a latent mood state, and that should be 
considered forms of manic depressive illness (Da Fonseca 1963). He studied a 
group of patients, all having a twin sibling, and their relatives. He found an 
increased incidence of somatic disorders, of cyclic nature, with a tendency to resist 
to medical treatment, and to improve “after the first straightforward attack of 
periodic depression”. The long term careful observation of the symptoms, the 
rigorous registries, and the search for common features (personality, evolution, 
response to treatment, etc) were common features in the works of this current.
Manoel Paes de Sousa studied psychiatry with José Henrique Barahona-
Fernandes. Barahona-Fernandes was an eminent Portuguese psychiatrist, who 
worked with Karl Kleist in Frankfurt, and developed an extremely important work 
on the field of psychopathology. At 1982, in recognition of his work, Barahona-
Fernandes received the Julius Wagner von Jauregg medal, in the World 
Psychiatry Congress. Manoel Paes de Sousa was also en eminent 
psychopathologist, and performed a serie of psychopathological studies in a 
cohort of depressed patients, aiming a classification of depression based on 
psychopathology. He and his team (Maria Luísa Figueira, Carlos Roldão Vieira, 
among others) performed an extensive psycopathological evaluation, using among 
others, an AMDP derived depression scale. AMDP is an abbreviation of 
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Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie 
(Documentation and Methodology in Psychiatry Association), an international 
working group of German origin, that focus on standardizing data collection and 
psychopathological concepts (Sousa 1985). 
Using K-centroids method and a factorial analysis, three distinct depressive 
disorders were found - “neurotic”, “psychotic” and an intermediate mixed group 
(Sousa 1976). Several other studies were published, on the same cohort and with 
a similar methodology, generally providing a rational for the separation in two 
classes “neurotic” and “endogenous” (Sousa, Lopes et al. 1980). Unfortunately, 
the overall results were never published in peer reviewed journals (Sousa 2003) 
and, after his untimely death, in an extraordinary gesture of generosity, his widow 
donated Dr. Paes de Sousa files to be developed further research.
With this background of controversy in the classification of depression, we 
decided to follow as reference the most used research classification manual in 
psychiatry, the DSM-5. DSM-5 and ICD10 share the most important sub-types, 
although some differences exist.
2.2. Epidemiology
According to the Estudo Epidemiológico Nacional de Saúde Mental in 
Portugal (Almeida 2013), the anual prevalence for any mood disorder is 7,9% (1% 
dysthymia, 6,8% MDD and 1,1% BD). When compared to other European 
countries these figures are amongst the higher ones, only surpassed by France 
and Northern Ireland.
Lifetime prevalence of any mood disorder is 19,3% (1,4% dysthymia, 16,7% 
MDD and 2,6% BD). The most significant risk factors found were being a woman 
and having lower education. Again, in Portugal these numbers are amongst the 
highest, comparable to the USA and Lebanon (15% and 19%) (Weissman, Bland 
et al. 1996).
Depression is associated with an increased risk of dead, by suicide and 
cardiovascular diseases (Wulsin, Vaillant et al. 1999, Wulsin, Evans et al. 2005).
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2.3. Clinical features, diagnosis and neurobiology
a) Bipolar depression
This condition referes to a depressive episode that occurs in a patient with 
bipolar disorder. DSM-5 and ICD10 criteria does not distinguish the symptoms of a 
depressive unipolar episode from a depressive episode in a bipolar disorder.
b) Major depressive disorder
Major depressive disorder (MDD), called recurrent depressive disorder in 
ICD10, is the classic unipolar depression.
The core symptoms are low mood and loss of pleasure, accompanied by 
several other symptoms. Depressive symptoms have been divided in affective/
emotional (sadness, anxiety, anhedonia, etc), somatic (sleep and appetite 
changes or pain), motor/behavioral (inhibition or agitation) and cognitive (Bastos, 
Gonçalves-Ferreira et al. 2014). Cognitive symptoms include thought disorder 
(delusions, pessimism) and classical cognition disturbances, such as memory, 
attention, and executive functions (Reppermund, Ising et al. 2009, Marazziti, 
Consoli et al. 2010). Sometimes, cognitive symptoms are so severe, that the acute 
depressive disorder resembles a dementia disease - it is labelled pseudo 
dementia (Kiloh 1961, Berrios 1985). A recovery of cognition is expected (Keefe, 
McClintock et al. 2014), although this a controversial issue as discussed in the 
next section.
According to DSM-5, the diagnosis can be made with a single episode, 
although the disease tends to recur, with patients experiencing more than one 
episode. ICD10 distinguishes between a single depressive episode and a 
recurrent disorder.
c) Persistent depressive disorder or dysthymia
This disorder includes chronic depressions of a lesser severity than the 
MDD. It is a large and heterogenous group, that includes the previously called 
neurotic depressions, depressive neurosis, or depressive personality (Bastos, 
Gonçalves-Ferreira et al. 2014). The term was coined by Kahlbaum, to distinguish 
from cyclothymia (Marneros and Angst 2000), but throughout the years it has been 
found difficult to distinguish the depressive disorder from personality (Freeman 
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1994). Akiskal conceptualized the disorder as a mood disorder, and this is the 
actual point of view (Akiskal 1981).
ICD10 states that dysthymia is a very protracted depressive disorder 
(decades), but its severity is seldom sufficient to fulfill the recurrent depressive 
disorder criteria. DSM-5 has a pragmatical approach, including in this condition the 
chronic MDD (more than two years).
Probably due to its intrinsic heterogeneity, several conditions have been 
associated with this disorder (Akiskal, Lemmi et al. 1984, Arriaga, Cavaglia et al. 
1998). 
d) Melancholic depression
Both DSM-5 and ICD10 consider melancholic depression (or “somatic 
syndrome“ as it is called in ICD10) a specifier of a depressive episode. It is defined 
clinically by a distinct quality of the depressed mood, virtually irresponsive to all 
kind of pleasurable stimuli, along with a near complete loss of pleasure. Other 
classic melancholia features can be also present, such the morning mood 
worsening, terminal insomnia, significant psychomotor retardation or agitation, 
significant anorexia and weight lost, excessive guilt (self-blaming), and, for ICD10, 
diminished libido. Melancholic features can also be present in the depressive 
episodes of bipolar disorders.
Melancholia emerges among depressive disorders as a more 
quintessentially biological disorder, especially because it is characterized by a 
more favorable response to biological treatments than to psychotherapy, by a low 
placebo response, by a lower relevance of psychosocial determinants, and by the 
existence of abnormalities of the hypothalamic-adrenal-axis (HPA axis) (Fink and 
Taylor 2007, Parker, McCraw et al. 2013). 
HPA axis activity is controlled by the secretion of adrenocorticotrophic 
hormone-releasing factor (CRF) and anti-diuretic hormone (ADH) from the 
hypothalamus. These hormones stimulate the secretion of adrenocorticotrophic 
hormone (ACTH) from the pituitary, which in turn stimulates the adrenal cortex to 
secrete glucocorticoids. HPA is activated in stress situations. Glucocorticoids have 
several functions, at multiple targets, but in the brain their most significant actions 
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are at glucocorticoid receptors (GR) . They are responsible for the feedback 9
inhibition of CRF and ADH on the hypothalamus and of ACTH on the pituitary. 
When activated, HPA has profound effects in the acquisition of new memories and 
the emotional appraisal of events, in the regulation of neuronal survival, in 
neurogenesis, and affects the sizes of complex anatomical structures such as the 
hippocampus (Herbert, Goodyer et al. 2006, Pariante and Lightman 2008).
The association of glucocorticoids with mental disorders dates back to the 
late 40s of the XX century. Increased urinary excretion of glucocorticoid 
metabolites was found in mentally ill patients (Reiss, Hemphill et al. 1949). Many 
subsequent studies found evidences of an increased HPA axis drive in depression: 
elevated total and free cortisol concentrations in plasma, cerebrospinal fluid and 
urine, ACTH concentration reported as normal or increased (Carroll, Cassidy et al. 
2007), disruption of the orderliness of cortisol secretion (Posener, Charles et al. 
2004), non suppression of cortisol with use of dexamethasone (Carroll, Curtis et 
al. 1976), and more recently the cortisol awakening response (Dedovic and Ngiam 
2015). It seems that the glucocorticoid-mediated feedback inhibition is, at least 
partially, the mechanism responsible for this HPA overdrive in depression (Pariante 
and Lightman 2008).
HPA axis dysfunction also seems to reflect a susceptibility that can be 
induced in early life. Rodents pups separated from their mothers - an eventual 
equivalent of the human child abuse - showed hyperactivity of HPA axis that 
persists through adulthood (Sanchez, Ladd et al. 2001, Sousa, Vital et al. 2014). 
Also, patients that suffered from childhood trauma or abuse have an increased 
activation of HPA axis (Heim and Nemeroff 2001).
The consequences of this HPA dysfunction have been studied in rodents 
and in humans. Chronically elevated cortisol has been shown to induce decreased 
neurogenesis and monoamine dysfunction, regional brain changes, and impaired 
synaptic plasticity (Herbert, Goodyer et al. 2006).
Treatment with antidepressants has been shown to increase GR expression 
and function and GR-mediated HPA axis feedback inhibition in laboratory animals 
 Glucocorticoids also act on the brain mineralocorticoid receptor (MR), but their role is 9
less well understood
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as well as in humans (Pariante and Lightman 2008). It also seems that 
antidepressants correct HPA dysfunction (Schule 2007).
However, there is a marked heterogeneity in depressive patients with 
respect to HPA axis changes. Several causes have been appointed, such as 
frequency of sampling, analytic methods and heterogeneity of patients (Posener, 
DeBattista et al. 2000). As mentioned, homogenous samples of melancholic 
patients consistently show abnormalities related to HPA axis dysfunction 
(Rothermundt, Arolt et al. 2001, Kaestner, Hettich et al. 2005, Carroll, Cassidy et 
al. 2007, Fink and Taylor 2007, Parker, Fink et al. 2010, Lamers, Vogelzangs et al. 
2013, Parker, McCraw et al. 2013), when compared to non-melancholic patients.
The inclusion of melancholic depression as a distinct depressive disorder, 
and not as a mere specifier, has been repeatedly proposed (Parker, McClure et al. 
2015).
e) Atypical depression
Atypical depression is a form of depression, presenting reverted vegetative 
symptoms - hypersomnia and increased appetite or weight (Bastos, Gonçalves-
Ferreira et al. 2014). Additional symptoms are leaden paralysis, mood reactivity, 
and increased sensitivity to rejection in personal relations (American Psychiatric 
Association 2013). These are recognized as atypical features in DSM-5, although 
the concept is not present in ICD10.
Several studies found evidences for a distinct disorder, including brain 
laterality, psychological profile, psychiatric co-morbidity, (Pae, Tharwani et al. 
2009), differential treatment responses (Hyman Rapaport 2007), and different 
biological features, specially an excessive inhibition of the stress responses 
(O'Keane, Frodl et al. 2012, Gold 2015). However, the symptom profile has been 
frequently challenged (Parker, Parker et al. 2005, Thase 2009).
f) Psychotic depression
Psychotic depression is a depression with psychotic symptoms (delusions 
and/or hallucinations) according to DSM-5 and ICD10 (Bastos, Gonçalves-Ferreira 
et al. 2014). However, ICD10 also classifies depressive stupor under the psychotic 
depression subtype.
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Although the classic psychotic symptoms of depression are mood 
congruente delusions (guilt, hypochondria, deserved punishment, nihilism/Cotard, 
bankrupt), their significance is controversial. DSM-5 also allows of both congruent- 
and incongruent-mood psychotic features for the diagnosis.
Psychotic depression has been longtime (Lara 1984) considered a special 
type of depression, but more recente studies provided a scientific validation of 
psychotic depression (Johnson, Horwath et al. 1991, Schatzberg and Rothschild 
1992).
Psychotic depression has also significant biological abnormalities, although 
controversial. The most consistent findings describe changes similar to 
melancholia (Belanoff, Kalehzan et al. 2001), however others point to similarities 
with primary psychotic disorders (Domschke 2013).
g) Depression with mixed features
This specifier was added to latest DSM-5 edition. The DSM-5 definition of 
mixed features of major depressive episodes captures sub-syndromal manic/
hypomanic symptoms that can occur in MDD (Perugi, Quaranta et al. 2014). Mild 
mixed features are a risk factor for the development of bipolar disorder. To take 
this risk in account, it is clinically useful to use this specifier (American Psychiatric 
Association 2013).
h) Depression with anxious distress
The relation of anxiety and depression is a longstanding discussion in 
psychiatry (Lara 1984). Anxiety is a common symptom in depressive disorders, but 
for ICD10 and for DSM IV only pure depressive and pure anxiety disorders were 
considered. Whether they are (1) the same disorder with a different clinical picture, 
(2) totally independent disorders, or (3) independent disorders with significant 
overlapping areas is a matter of controversy (Arriaga, Cavaglia et al. 1998).
 Although ICD10 and DSMIV TR generally consider depression and anxiety 
disorders as different conditions, DSM-5 includes a specifier for depressive 
disorders with important anxiety symptoms. This specifier, named “With anxious 
distress” includes several anxiety symptoms, both mental and somatic. A 
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Pubmed® search with the quoted frase “With anxious distress” performed in 
August 2015, yielded no results, probably reflecting the low level of research and 
knowledge on this new feature.
i) Catatonic depression
Catatonia, originally described by the German psychiatrist Karl Kahlbaum, 
in 1874 (cited by Fink 2013), is etymologically derived from the greek cata, 
meaning down, and tone, meaning tone.
Historically, catatonia is related to a set of motor symptoms, such as 
mutism, a rigid posture, fixed staring, stereotypic movements and stupor, mainly 
associated with schizophrenia. However, it seems that, at least in inpatients, the 
vast majority of catatonias are mood disorders (Parker, McClure et al. 2015).
DSM-5 does not treat catatonia as an independent disorder, but it can be 
assigned to another psychiatric disorder (e.g. depression with catatonic features), 
to a medical disorder (e.g. malignant neuroleptic syndrome), or unspecified. 
DSM-5 diagnosis includes motor immobility (e.g. stupor, or way flexibility), 
decreased engagement during interview (e.g. mutism), and excessive or peculiar 
behaviors (e.g. stereotypy, echolalia). ICD10 does not recognize a catatonic 
depression, assigning a depression with stupor - a nearly complete loss in 
“reactivity to the environment and reduction of spontaneous movements and 
activity” - to a depression with psychotic symptoms.
Catatonia can be treated with benzodiazepines and electroconvulsive 
therapy, irrespectively of the underlying disorder. Though, it has been argued that, 
although its biological basis is not known, catatonia should be considered a 
disorder by its own (Fink 2013, Parker, McClure et al. 2015).
j) Other subtypes or specifiers
Other specifiers are recognized in DSM-5, including depression with a 
peripartum onset and depression with a seasonal pattern.
Both DSM-5 and ICD10 have criteria for the severity of the current episode 
(mild, moderate and severe).
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2.4. Treatment
The treatment of depressive disorder is specially dependent on the severity 
of the disorder and, with few exemptions, is quite different in unipolar and bipolar 
depressions (Yatham, Kennedy et al. 2013, Bastos, Gonçalves-Ferreira et al. 
2014, Figueira and Madeira 2014, reviewed by Jeong, Lee et al. 2015).
General measures (such as sleep hygiene, physical exercise, or meditation) 
are recommended for every stage of disease severity (NICE 2009, National 
Collaborating Centre for Mental Health 2010). Psychotherapy has also an 
important role in the treatment of depression, either unipolar or bipolar (National 
Collaborating Centre for Mental Health 2010, Bastos, Gonçalves-Ferreira et al. 
2014, Swartz and Swanson 2014, Driessen, Hollon et al. 2015, McQueen and 
Smith 2015).
However, drug therapy, especially in the moderate and severe stages of 
unipolar depressions and in every stage of BD, is the cornerstone of the treatment. 
The main drugs that can be used to treat depression are some mood stabilizers 
(MS) and, eventually, antidepressants for BD, and antidepressants for MDD, and 
eventually, for other unipolar depressions. Many other drugs can be used in the 
treatment of these conditions, such as benzodiazepines, other anxiolytics, thyroid 
hormones, or pindolol, e.g., but mainly as ancillary or potentiation therapies.
Antidepressants
The first drug that can be called antidepressant, and not merely a mood 
enhancer, was an agent to kill Koch Bacillus - iproniazid, a molecule similar to 
isoniazid. In the early 1950’s, doctors noted a unexpected happiness namely in 
severely ill patients, dying form tuberculosis, when they were treated with 
iproniazid. It was later found that iproniazid acts as a monoamine oxide inhibitor 
(MAOI) and several clinical studies were performed (Deverteuil and Lehmann 
1958). It was marketed in 1958, and discontinued 3 years after in almost all 
countries because of its hepatotoxicity, and replaced by other MAOI.
Almost simultaneously, a modified molecule of the tricyclic compound 
chlorpromazine - called imipramine - showed unexpected mood improvement in 
chronic psychotic patients in Switzerland. A German language paper was 
published initially (Kuhn 1957), followed by an English publication (Kuhn 1958), 
revealing the efficacy of this new compound in depressed patients. Imipramine 
 50
was shown to inhibit nor-epinephrine (NE), and later, also 5-hydroxytryptamine (5-
HT) (or serotonin) re-uptake (Allikmets, Vahing et al. 1969, Lapin and Oxenkrug 
1969). This re-uptake inhibition occurs through the inhibition of NE transporter 
(NET) and 5-HT transporter (SERT). This class of AD is known as TCAs - tricyclic 
antidepressants. Besides transporter inhibition, TCAs also interfere with an array 
of other receptors (specially adrenergenic alpha-1, muscarinic M1, and 
histaminergic H1), responsible for the majority of the severe adverse events 
associated with this class of drugs (Stahl 2008, Câmara-Pestana and Carmo 
2014).
The history of selective serotonin re-uptake inhibitors (SSRIs) is quite 
different. There was a need for safer antidepressants, and the evidences for a role 
of serotonine in depression were coming out (Coppen 1967). Researchers 
believed that a biochemical test would distinguish between the depressions that 
could improve with 5-HT or those with NE enhancers (Claassen, Davies et al. 
1977). In the search for such compounds, fluvoxamine was successfully tried 
(Saletu, Schjerve et al. 1977), followed by the other SSRIs (fluoxetine, sertraline, 
paroxetine, citalopram, and escitalopram).
More recently a fourth antidepressant class was introduced, the 5-HT/NE 
re-uptake inhibitors (SNRI). These antidepressants selectively block these 
transporters, without significantly interfering with other receptors (Stahl 2008, 
Câmara-Pestana and Carmo 2014).
Other classes of antidepressant have been discovered throughout the 
years, such has the selective 5-NE re-uptake inhibitors, the selective dopamine/
NE re-uptake inhibitors, among others.
The main criteria for prescribing a specific antidepressant is the adverse 
events profile, and the antidepressant with a worst adverse event profile tend to be 
used in refractory depressions (Bastos, Gonçalves-Ferreira et al. 2014).
Although 5-HT and NE re-uptake inhibition have been throughout the years 
the most important mechanism associated with antidepressant efficacy, an 
important issue arose soon after antidepressant’s discovery. The action of 
antidepressant on monoamine transporters, and on the monoamines boost, is very 
rapid, but the clinical effects of antidepressants take certainly a longer time to 
occur. TCAs induce a selective increase of the inhibitory response of 5-HT, but this 
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increase of serotonin response took 1 to 2 weeks to develop (de Montigny and 
Aghajanian 1978). A few years later, it was shown that if the SSRI zimelidine is 
applied to rat dorsal mesencephalic raphe nucleus, a total suppression of the firing 
rate  of these neurons is observed (Blier and De Montigny 1983). However, two 10
weeks later, under a continued zimelidine treatment, the 5-HT neurons firing rate 
returned to normal. In the same study, the use of LSD (an 5HT autoreceptor  11
agonist with high efficacy) completely blocked the firing rate, but had no effect on 
the longtime pretreated neurons. This indicated that a down regulation of the 
autoreceptor was the cause for the delay of the clinical antidepressants effect. 
Other antidepressants and ECT have been also been associated with the down 
regulation of several receptors (Invernizzi and Garattini 2004, Blier and El Mansari 
2013).
Further studies showed that these down regulations are not merely an 
acute desensitization of the receptors, but imply changes in gene expression and 
editing (Albert and Francois 2010). Chronic treatment with fluoxetine, and other 
AD, edits and/or increases the expression of several genes related to the 
neurotransmission of 5-HT, GABA, glutamate, BDNF, and others (Nestler, Barrot et 
al. 2002, Hertz, Rothman et al. 2015).
Mood stabilizers 
MS are the first choice in bipolar depression. The concept of MS is not 
universal, but in stricto sensu are drugs that treat and prevent affective episodes of 
bipolar patients. A broader definition encompasses those drugs that treat episodes 
of one pole, without inducing the other. The classic MS is lithium carbonate, 
although several anti epileptics (sodium valproate, carbamazepine and 
lamotrigine), and some second generation antipsychotics (aripiprazol, olanzapine 
and quetiapine) can be also considered MS.
The treatment of bipolar depression is complex, but most guidelines 
indicate a combination of lithium and/or sodium valproate with lamotrigine, or 
quetiapine, as first line. It is noteworthy that AD should not be used as first or 
second line therapy in most guidelines (Jeong, Lee et al. 2015). 
 Firing rate is crucial for 5-HT release10
 These autoreceptors decrease 5-HT release (actually most of them  are known as 5-HT1A)11
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3. Depression and dementia
3.1. How are they related?
As noted before, depressive symptoms are common in dementia - 
especially in the initial stages, reflecting an eventual reaction to the loss of 
capacities. Cognitive symptoms can be so severe in patients with depression that 
they can mimic dementia (so-called pseudomentia). Besides acute deficits, 
accumulating evidence reveals that depression, especially chronic, can be 
associated with persistent cognitive deficits. Finally, depression can be an an early 
risk factor, or a prodrome of, dementia (Byers and Yaffe 2011, Kessing 2012).
3.2. Is depression a risk factor for dementia?
It has been known for a longtime that cognitive deficits are present during 
acute mood episodes, so much they are a diagnostic criteria for MDD (American 
Psychiatric Association 2013). The presence of permanent (i.e. in periods without 
mood symptoms) cognitive deficits in depressed patients was recognized more 
recently (Robinson, Thompson et al. 2006, Rock, Roiser et al. 2014). Eventually 
because, according to the Kraepelinian nosology - that continues to provide a 
touchstone for modern classification systems of mood disorders - depression and 
bipolar disorder are non-degenerative disorders. However, even Kraepelin wrote 
about an autopsy report of bipolar patient “(…) widespread arterio-sclerosis of the 
blood vessels of the brain. This termination appears to be not altogether unusual is 
maniacal depressive insanity (…)” (Kraepelin, 1913; cit. by da Silva, Goncalves-
Pereira et al. 2013). But further than inducing permanent cognitive deficits, in 
recent years depression emerged as possible risk factor for dementia and AD, 
initially in case-control studies and later in cohort-studies.
Case-control studies are simpler, easier, and cheaper then cohort studies. 
In case-control studies demented patients are compared to non-demented patients 
in what concerns to a prior diagnosis of depression (Fronteira 2013). These 
studies yield an odds-ratio (OR) value, that must have a 95% confidence interval 
superior (or inferior) to one, to presume a positive (or a negative) risk association. 
However, the relative risks cannot be calculated (Grimes and Schulz 2008), and 
are subject to several biases, specially recall biases (Schulz and Grimes 2002, 
Fronteira 2013).
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Cohort-studies are very expensive and hard-working studies that generate 
very powerful information regarding causality (Fronteira 2013). In these studies, a 
cohort of individuals, with and without depression (exposed and non-exposed), are 
followed for a period of time. They are then examined and compared to their 
dementia status. The absolute risks can be calculated, so the power of the statistic 
is stronger.
Many studies have been published using both designs, and some of the 
most important are summarized in Table 2 and Table 3. 
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Table 2 Case-control studies
Study Sample Depression 
diagnosis/criteria
Dementia 
diagnosis
/criteria
Conclusions
1 40 AD
80 controls
Question to subject 
or family
“Rigorous clinical 
criteria”
NS
2 78 AD
78 controls
Psychiatric disorder, 
questioning
Histopathology
Author’s criteria
NS
3 188 AD                           
80 control
Chart review ICD9                    
DSM III R
2.90 (0.64-13.15)*
4 98 AD           
162 controls
Question to informant NINCDS-ADRDA 3.3 (1.1-10.1)
5 170 AD
170 controls
Question to subject 
or family
NINCDS-ADRDA 3.30 (1.20-8.70)
6 415 AD
415 controls
Episodic depression Author’s criteria 1.71 (1.03-2.83)
7 294 AD
300 controls
Question to subject 
or family
DSM III R
NINCDS-ADRDA
NS
8 81 AD
51 controls
Question to subject 
or family, DSMIIIR
NINCDS-ADRDA 
Neurological + NP
2.08 (1.22–3.52)
9 69 AD                    
69 controls
Question to subject 
or family
DSM IV      
NINCDS-ADRDA
2.60 (1.65-4.09)**
10 599 dementia    
599 controls
History  Medical Files       
ICD8-10
CAMDEX     
ICD8-10
2.31 (1.16-4.61) UP*
7.46 (1.50-7.07) BD**
11 65 twin pairs 
discordant for 
AD
Registries
Informant
DSM III R
NINCDS-ADRDA
4.00 (0.64-25.16)**
12 105 VD         
802 controls
Question to subject 
or family
DSM III
NINDS-AIREN  
2.41 (1.22-4.52)
13 1953 AD
2093 controls 
(relatives)
Question to subject 
or family (yes/no)
NINCDS-ADRDA 2.08 (1.70-2.55) General
4.57 (2.87-7.31) UP onset <1y
1.38 (1.03-1.85) UP onset 1-25y
1.71 (1.03-2.82) UP onset >25y
16 76 AD
109 controls
CIDI, DSMIIR,  
ICD10
DSMIIIR 8.99 (3.67-22.00)*
15 547 dementia       
12133 controls
Medical records and 
clinical history
ICD7-10
DSM IV
NINCDS/ADRDA   
NINDS-AIREN  
Dementia 1.72 (1.07- 2.76) 
AD            NS                       
Early onset depression    NS
Late onset depression     3.87 ( 2.10, 7.14)
Age of depression onset  NS
16 13568 
dementia
13568 controls
Registries ICD8-10 Registries ICD8-10 1.99 (1.56-2.53)
Legend (1) Heyman,1984; (2) French, 1985; (3) Agbayewa, 1986; (4) Shalat, 1987; (5) Broe, 1990; (6) Kokmen, 1991, (7) 
Speck, 1995; (8) Steffens, 1997; (9) Tsolaki, 1997); (10) Cooper, 1998; (11) Wetherell, 1999; (12) Hebert, 2000; (13) Green, 
2003; (14) Heun, 2003; (15) Brommelhoff, 2009; (16) (17) (16) Zilkens, 2014. Notes: * Computed based on crude data published, 
**retrieved from a meta-analyzes calculation [Silva, 2013]; NS nonsignificant, UP Unipolar depression, BD Bipolar disorder
Table 3 Cohort studies
Study Sample Duration Depression 
diagnosis
Dementia 
diagnosis
Conclusions
1 3180 non-
demented
3 years Self-report DSM-III-R 20.64 (2.84-150.20) for 
dementia
2 478 old age 
without 
dementia (>60 
years old)
1-5 years Informant 
report
“depressed 
mood”
HDRS
DSM-III-R      
NINCDS-
ADRDA
2.94 (1.76-4.91) for 
dementia, but NS in the 
multivariate model
3 1600 non 
demented
3 years CES-D MMSE NS for dementia
4 954 old age 
(>60 years old)
8 years CES-Dm DSM-III-R      
NINCDS-
ADRDA
NS for Dementia                             
NS for AD
5 3363 UP 
518    BD  
8946 neurotic  
5.5 M controls
21 years ICD 8 and 
ICD 10 
(admission 
diagnosis)
ICD 8 and ICD 
10 (admission 
diagnosis)
Affective disorders (UP
+BP) 13.7 (12.1-15.4) for 
dementia
Neurosis 11.2 (9.6-12.9) 
for dementia
6 227 non 
demented non 
depressed                     
62 non 
demented 
depressed
3 years DSM-III-R No reference to 
diagnostic 
criteria
1.50 (0.80–2.90) for 
dementia
7 1911 old age
highly educated
3.2 years Geriatric 
Mental State 
Schedule      
CES-D
DSM-III-R           
DSM IV                                                         
2.21 (1.09-4.48) for 
dementia
NS for dementia in the 
multivariate analysis               
> 8 years of education 
5.31 (1.88-15.00) for 
dementia
8 821 religious 
non-demented 
> 65 years
7 years            CES-D                      NINCDS-
ADRDA
Histopathology
1.19 (1.07-1.32) for each 
CES-D score at baseline
9 71 depressed
50 controls
25 years ICD 8 
(endogenous 
depressive 
vs other 
types)
DSM-III-R
or evidence 
from at least 
other 4 sources
10 cases of dementia in 
depressed cohort and 
zero in control cohort 
(Chi-Square =5.93; 
p<=0.005)                     
not computed
10 51 AD
79 controls
7 years CES-D NINCDS-
ADRDA
Histopathology
AD   1.33 (1.01-1.76) for 
each CES-D point 
increase
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11 11741 UP
2007 BD                                                       
Controls 81 380 
osteoarthritis 
and 69149 
diabetes
Time to 
dementia
(>20 
years)
ICD8
ICD10
Register-
based
ICD8
ICD10
Register-based
UP vs OE    2.13 
(2.00-2.26)
UP vs DM    1.77 
(1.66-1.89) 
BD vs OE   1.92 
(1.62-2.27)
BD vs DM    1.56 
(1.31-1.84) 
Both vs OE  2.11 
(1.31-1.84)
Both vs DM  1.75 
(1.65-1.87)
12 18726 UP
4248   BD
Time to 
dementia
(>20 
years)
ICD8
ICD10
Register-
based
ICD8
ICD10
Register-based
For dementia                           
UP vs BD 1.46 
(1.01-2.13)   
BD n. of episodes NS 
M D D d i s o r d e r > 4 
episodes higher r isk 
when compared to 1 
episode;
every episode increase 
the risk by 13%
13 3346 non 
demented 
2 and 5 
years
Self-report NINCDS-
ADRDA
NS at baseline for AD
NS at 2 years for AD
NS at 5 years for AD
14 1357 non 
demented
14 years CES-D DSM-III-R
NINCDS-
ADRDA
2.41 (1.50-3.87) for 
dementia*
2.92 (1.70-5.02) for AD* 
Woman  NS (both 
dementia and AD)                             
Man        NS (dementia) 
and AD 2.63 (1.28-5.40)    
15 766 >65 years 
old (mean age 
74.5)
5 years CES-D DSM-III-R 2.75 (1.04-3.79) for AD           
2.37 (1.32-5.54) for 
dementia   
Duration of depression 
NS
16 1932 men, 
mean age 76.3 
6 years CES-D DSM-III-R
NINCDS-
ADRDA
UP 2.5 (1.1-3.4) for 
dementia 
UP 3.0 (1.5-5.9) for AD           
UP. NS for VD
Table 3 Cohort studies
Sample Duration Depression 
diagnosis
Dementia 
diagnosis
ConclusionsStudy
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17 486 (60-90 
years old), 
without 
dementia
6 years Self 
reporting                 
CES-D
NCDS-ADRDA UP 2.44 (1.26-4.21) for 
dementia 
EODep 3.23 (1.36-7.70) 
for dementia 
LODep NS for dementia                   
UP 2.46 (1.15-5.26) for 
AD
EODep 3.76 (1.41-10.06) 
for AD
LODep NS for AD                     
18 949 community 
(mean age 71 
years)
17 years CES-D DSM-III-R
NINCDS-
ADRDA
Dementia 1.72 
(1.04-2.84)
AD 1.76 (1.03-3.01)
19 1239 community 
subjects, 
dementia free, 
mean age 55.5 
years
25 years CES-D DSM IIIR  
NINCDS-
ADRDA
Dementia One episode of 
EDS: HR 1.87 (1.21–
2.88)
Dementia  >1 episodes of 
EDS:  2.08 (1.23–3.52)
20 7989 dementia 
free >65 years 
old
5 years MINI, CES-D DSM IIIR IV
NINCDS-
ADRDA
NINCD-AIREN
Dementia 1.5 (1.2-2.2)               
AD            NS                                      
VD            4.8 
(2.20-10.70)      
21 280540 
veterans, non 
demented
Retrospe
ctive
ICD9 CM ICD9 CM Dementia  2.18 
(2.08-2.28)                   
AD            significant (not 
shown)                                   
VD            significant (not 
shown)
22 13535 subjects
3727 
depressed/
depressive 
symptoms
9808 non-
depressed    
(mean age 
81years)
30 years Question 
“Ever been 
sad or 
depressed?”
Admission 
for 
depressive 
disorder
ICD 9
ICD 9 Dementia 
Midlife only         1.19 
(1.07-1.32)
Late life only       1.72 
(1.54-1.92)
Midlife + late life 1.77 
(1.52-2.06)
AD                                         
Midlife only         NS
Late life only       1.9 
(1.6-2.4)
Midlife + late life 2.0 
(1.5-2.7)    
VD                                           
Midlife only        NS
Late life only      NS
Midlife + latelife  3.5 
(2.4-5.1)    
Table 3 Cohort studies
Sample Duration Depression 
diagnosis
Dementia 
diagnosis
ConclusionsStudy
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Legend (1) Minani, 1995; (2) Devanand, 1996; (3) Doufuil, 1996; (4) Chen, 1999; (5) Kessing, 
1999; (6) Pálsson, 1999; (7) Geerlings, 2000; (8) Wilson, 2002; (9) Brodaty, 2003; (10) Wilson, 
2002; (11) Kessing, 2003; (12) Kessing, 2004; (13) Andersen, 2005; (14) Dal Forno, 2005; (15) 
Gatz, 2005; (16) Irie, 2008; (17) Geerlings, 2008; (18) Saczynski, 2010; (19) Dotson, 2010; (20) 
Lenoir, 2011; (21) Byers, 2011; (22) Barnes, 2012; (23) Almeida, 2015; (24) Lugtenburg, 2015. 
Notes: * retrieved from a meta-analysis [Silva, 2013]; NS nonsignificant, UP Unipolar depression, 
BD Bipolar disorder; AD Alzheimer’s disease, HDRS Hamilton Depression Rating Scale, MADRS 
Montgomery-Åsberg Depression RatingS cale, EODep early onset depression, LODep late onset 
depression, GDS Geriatric Depression Scale, OE osteoarthritis, DM Diabetes mellitus, MDD Major 
depressive disorder.
23 4568 man 
(70-89)
5 years GDS for 
actual
Electronic 
records, self-
reported, 
use of AD for 
EOD
TICS, records Dementia
UP (study entry)   2.59 
(1.57-4.27)
EOD 1.09 (0.78–1.52)
24 1911 > 65 years 3 years Geriatric 
Mental State
Geriatric Mental 
State
1.48 (1.14-1.92) for 
dementia
Table 3 Cohort studies
Sample Duration Depression 
diagnosis
Dementia 
diagnosis
ConclusionsStudy
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Four important reviews and meta-analyzes have been performed on this 
topic. The first (Jorm, van Duijn et al. 1991) and second meta-analysis were 
performed by the same author (Jorm 2001). The second was a more embracing 
paper, and found an increased risk both in case-control studies (2.01; 95% CI 
1.16-3.50) and in prospective studies (1.87; 95% CI 1.09-3.20). A more recent 
meta-analysis (Ownby, Crocco et al. 2006), including very important studies 
(Green, Cupples et al. 2003, Kessing and Nilsson 2003) led to the same 
conclusion, generating OR of 2.03 (1.73-2.38; 95% CI) for case-control studies 
and 2.02 (1.80-2.26; 95% CI) for cohort studies. Interestingly, the last meta-
analysis published (Gao, Huang et al. 2013) was retracted due to multiple errors of 
citation, study description and data extraction. A well conducted review was 
published more recently (da Silva, Goncalves-Pereira et al. 2013), and reported 
that 11 out of 16 case-controls studies found depression as a risk factor for 
dementia/AD/VD. For cohort studies 18 in 46 did not find an association.
Despite the very discrepant results, the several meta-analyzes (Jorm 2001, 
Ownby, Crocco et al. 2006) and the most important reviews (da Silva, Goncalves-
Pereira et al. 2013) that have been performed confirmed, in general, an 
association. The risk (usually OR) for dementia in depressive disorders computed 
in the meta-analysis is relatively small - between 1.5 and 2.0. 
The obvious methodological differences among these studies could account 
for some of these discrepancies. Methodological differences include the study 
design, variations in the length of observation periods, different rates of attrition in 
the cohort studies, different ways to assess depressive disorders and dementia, 
and the use of different potentially confound variables as covariates (Wilson, 
Barnes et al. 2002). 
The accuracy of the diagnosis of dementia in most of the studies can be 
considered good. Most of them use DSMIII or IV for the diagnosis of dementia, 
and standard research criteria for the different disorders, such as the NINCDS/
ADRDA for AD, or NINDS-AIREN for VD. In some studies (Wilson, Barnes et al. 
2002) the diagnosis was histopathological, providing the strongest accuracy.
In what concerns depression, diagnostic methods vary widely. 
Retrospective assessment of prior depressive symptoms and episodes can 
underestimate prevalences. The prevalence of life time depression (and other 
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psychiatric disorders) is approximately half if retrospectively collected, when 
compared to prospectively obtained data (Moffitt, Caspi et al. 2010). Composite 
International Diagnostic Interview (CIDI) is a valid and frequently used instrument 
to assess major psychiatric diseases (Wittchen 1994). It has been found to to be 
valid in elderly populations (Heun, Kockler et al. 2003), but it has not been 
validated in demented or cognitively impaired subjects. Other standard measures 
used, such CES-D, although validated, cannot replace a clinical interview for the 
diagnosis of such a complex condition as depression.
Probably the strongest study would be a controlled cohort study, with most 
consensually accepted and accurate, diagnostic criteria for depression and 
dementia. 
3.3. What is the nature of this risk?
However, these discrepancies can also reflect a poor understanding on the 
nature of this association. Depression and dementia can be related in several 
ways, and the role of the several players need to be explored: a) depression is 
merely a prodrome, or a symptom, of dementia?, b) what is the role of different 
depression subtypes?, c) what is the role of different dementia subtypes?, and d) 
what is the role of antidepressants? (Byers and Yaffe 2011, Kessing 2012).
a) Depression is prodrome/initial manifestation of dementia, and not an early risk 
factor
This is one of the main issues that has been raised. Depression can be a 
prodrome of dementia or even symptom of the disorder. Depressive disorders are 
quite common, at least in the most common forms of dementia. In cognitively 
normal elderly people, the prevalence of depression is probably around 15%, but 
in AD it has been shown to be approximately 20-30%, in VD between 30-50%, and 
in MCI around 30% (Li, Meyer et al. 2001, Byers and Yaffe 2011). These numbers 
can be even higher, as 40% of AD patients have depressive symptoms (Chi, Wang 
et al. 2015). An important proportion of AD patients meet criteria for Major 
Depressive Episode, ranging from 3-24% (Heun, Kockler et al. 2003), depending 
on the population, on depression and dementia criteria, and on the type of the 
dementia.
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Three mechanisms have been proposed to characterize this association, 
not mutually exclusive. One of the mechanisms invoked is the psychological 
reaction to a self perceived deterioration on the cognitive abilities, although it has 
been shown that subjects without a cognitive deficit can become depressed and 
only then develop AD (Paterniti, Verdier-Taillefer et al. 2002). Another mechanism 
is the neurodegeneration of crucial areas for emotion, in a mechanism similar to 
the vascular depression. The last explanation is the misdiagnosis of MDD in 
demented patients, as these disorders share some symptoms, such as 
impairments in attention, memory and executive functions, changes in sleep 
patterns, and reduction in social and occupational functioning (Steffens and Potter 
2008).
It seems that, besides unipolar depression, demented patients could be 
also at increased risk of developing bipolar disorder (Nilsson, Kessing et al. 2002).
Studies with a short follow up could not be able to distinguish between 
these two conditions. Case control studies in general have not taken into account 
the time frame between the two diagnoses. We are aware of few exceptions, but 
showing discrepant results. Green et al (2003) showed an increased risk for AD 
regardless of the time mediating depression and dementia onset. More recently, 
Brommelholff (2009) showed the opposite, as no increased risk for dementia was 
found if the depressive disorder started more than 10 years before the onset of 
dementia.
Cohort studies with short a follow up also have the same limitation. The 
majority of longitudinal studies have follow up times of less than 5 years. Very few 
studies have a follow up of more than 20 years, and they all found an increased 
risk of dementia in depressed patients. However, most of these studies assessed 
depression retrospectively, and the quality of the diagnosis of depression raises 
important concerns, as discussed below.
One of the biggest criticisms to these studies is that depression can be a 
prodrome of dementia or even be misdiagnosed. Ownby (2006) addressed this 
criticism performing a sophisticated statistical technique (called random-effects 
metaregression analysis), studying the interval between the diagnosis of dementia 
and depression, wich was found to be positively related to this risk of developing 
AD. This interesting finding does not support the hypothesis of depression as a 
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mere prodrome of dementia. However, this time frame could only be calculated in 
a percentage of the studies.
Other strategy was to compute different risks for late onset depression and 
early onset depression, generally if it occurs after 45 or 60 years old, or before. 
Although not considered in the reference psychiatric diagnostic manuals, there are 
evidences - clinical, biological and epidemiological - supporting this distinction. 
Late onset depression is associated with more brain changes, such as frontal lobe 
atrophy (Almeida, Burton et al. 2003) and white matter changes (Lesser, Boone et 
al. 1996). However, the results are again discordant, as some studies found an 
increased risk only in early onset depression, while others found the opposite. 
Eventually, the distinction between early onset depression and late onset 
depression is not sufficiently grounded, or late onset depression is definitely not a 
dementia prodrome.
The studies with a short follow up (FU) are important, and may enable the 
study of depression as prodrome of dementia (Byers and Yaffe 2011), resulting in 
a deeper knowledge of the initial manifestations of dementia, and eventually 
providing earlier diagnosis and treatment.
However, it seems that a long follow up is the right method to distinguish 
depression as risk factor from a dementia prodrome. The newest diagnostic 
methods for AD and other dementias probably will help tremendously in 
distinguishing between depression and these different forms of dementia.
b) What is the role of different depression subtypes?
As mentioned in the previous chapters, depression is a clinically and 
biologically heterogenous disorder. These heterogeneity has been found to play an 
important role as a risk factor for other diseases. E.g., it has been proposed that a 
depression with a predominance of somatic symptoms increases the risk for 
coronary heart disease, when compared with a depression with cognitive 
symptoms (Carney and Freedland 2012).
 In what concernes to dementia, several subtypes and characteristics of 
depression have been studied.
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1. Early onset depression and late onset depression
The definition of the age limit of late onset depression varies across the 
studies, between the age of 45 years (Steffens, Plassman et al. 1997) and the age 
of 60 years (Byers and Yaffe 2011). This issue has been discussed before in this 
text, as late onset depression could be a prodrome of dementia, and not a true risk 
factor.
2. Severity: number of episodes, severity of the episodes and duration of 
the disorder
Each episode that determines an admission seems to increase the risk of 
dementia by 13% for unipolar depression and by 6% for BD (Kessing and 
Andersen 2004), when controlled for age, sex and calendar time, but not for 
education. For unipolar depression (ICD8 and ICD10 diagnosed), an increased 
risk of dementia was significant only if a patient had 4 or more episodes (HR 6.16; 
95% C.I. 1.39-22.72). In BD, however, when the number of episodes were 
included as a categorial variable, the difference between the number of episodes 
was not significant. Although a very high number of subjects was included (virtually 
all Danish population), the diagnosis of both dementia and affective disorders was 
only considered in patients with at least one admission. So, all outpatients with 
these diagnoses were excluded. This probably explains the low incidence of 
dementia found in that study.
Depression data from the Baltimore Longitudinal Study of Aging were also 
analyzed in what concerns to the severity of depression (Dotson, Beydoun et al. 
2010). A concept called “episodes of elevated depressive symptoms“ (EDS), 
based on CES-D score, was created to capture less severe depressive disorders. 
The risk for dementia increased about 80% to those who have one of these - EDS 
- and to more than 100% to those of have two or more. The clinical meaning of 
EDS remains largely obscure, but this study has one of the longest FU in the 
literature, and globally the results pointed to a role of the chronicity of depression 
on the risk for dementia. Another study, evaluating CES-D as a continuos variable, 
controlled for other important risk factors (such as age and education), the risk 
found was only marginal for both AD (1.04; 95% C.I. 0.99-1.08) and dementia 
(1.04; 95% C.I. 1.00-1.08) (Gatz, Tyas et al. 2005).
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This study also evaluated the risk according to depression duration (Gatz, 
Tyas et al. 2005). Although CES-D score at baseline predicted the risk for AD, 
informant-reported duration of depression was not a predictor of either AD or 
dementia. The computation of depression duration was dependent on the 
informant reports, clearly limiting the findings.
Although the results point to an increased risk associated with a more 
severe disorder, they seem to have limitations.
3. Clinical subtypes of depression
Bipolar disorder was found to carry a greater risk for dementia in some 
studies. Patients with a manic episode have a slightly increased risk for dementia 
1.46 (95% C.I. 1.01-2.13) (Kessing and Andersen 2004), 1.92 (95% C.I. 
1.62-2.27), and 1.56 (95% C.I. 1.31-1.84) (Kessing and Nilsson 2003), when 
compared to patients with one depressive episode, with patients suffering from 
osteoarthritis or diabetes, respectively. The Camberwell Dementia case register 
also found a 2-fold risk increase in BD (Cooper and Holmes 1998), although 
another register study failed to found a risk association (Kokmen, Beard et al. 
1991).
Although most depressive disorders, such MDD, are a clearly defined 
diagnosis, very few studies used standard clinical criteria in their diagnosis 
(Kessing, Olsen et al. 1999, Brodaty, Luscombe et al. 2003, Kessing and Nilsson 
2003, Kessing and Andersen 2004). In what concerns to other subtypes, or 
specifiers, such as melancholic, ICD10 defined somatic syndrome, atypical, 
psychotic, or catatonic, we found no studies specifically addressing these 
subtypes.
One study evaluated neurotic disorders (ICD8 defined), including neurotic 
depression, and found a 11.2-fold (95% C.I. 9.6-12.9) increase in risk for dementia 
(Kessing and Andersen 2004). Two studies used CES-D factors to evaluate their 
influence in the risk, as an approach to differentiate different depressive disorders. 
DalForno et al. (2005) performed a risk analysis using a CES-D sub-scale based 
on a cluster of negative affective symptoms, eventually related to melancholic 
features, but it did not influence the global risk for dementia. Another study tried to 
find an association between CES-D clusters (depressed affect, positive affect, 
somatic/vegetative and interpersonal) and the risk for dementia (Gatz, Tyas et al. 
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2005). Only the somatic/vegetative cluster showed a marginal increased risk (1.10; 
95% C.I. 1.02–1.18), and only for AD.
Neurotic disorders (including neurotic depression and anxiety disorders) 
were found to carry a higher risk for dementia in least one study (Kessing, Olsen 
et al. 1999). However, a treatment for anxiety - benzodiazepines - also seems to 
increase the risk (Billioti de Gage, Pariente et al. 2015).
c) What is the role of different dementia subtypes?
The same is true for dementia. AD, VD, FTD, and LBD have distinct risk 
factors and most studies, specially cohort studies, do not distinguish between 
them.
In the majority of the studies published, the outcome was dementia as a 
whole. However, as referred above, the causes of dementia have very different 
associated biological mechanisms. It is hard to conceptualize that depression 
could interfere with so different mechanisms such as amyloid deposition, brain 
irrigation, alpha-synuclein, ubiquitin, and many others. Some studies have 
determined AD as an outcome, very few VD, and to our knowledge, none has 
studied FTD or LBD. The finding of an increased risk for AD is more commonly 
found in a case-control studies than in cohort studies, probably because of the 
differences in the methodology. Although recall biases are a main caveat in case-
control studies, it is supposed to happen both in cases and controls, but specially 
in cases. This means that AD patient would not disclose a history of depression, 
increasing the chances of showing a lack of effect. So if a case-control study 
shows a difference, exclusively from this point of view, this difference probably 
exists. However, case-control studies have several other limitations discussed 
above.
Depression is not expected to be a risk factor for AD in a short time, as 
amyloid deposition occurs over decades (Braak and Braak 1991). Cohort studies 
with a short follow up probably would be unable to show an effect. Eventually, an 
increased risk for a more acute onset dementia, such as some forms of VD, could 
be found. We are not aware of cohort studies with a longer follow up (or controlled) 
that have studied different types of dementia. It has been shown that depressed 
non-demented subjects do not have increased amyloid when compared to non-
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depressed non-demented subjects, either detected by [11C]PET-PiB (Madsen, 
Hasselbalch et al. 2012) or by neuropathology (Wilson, Boyle et al. 2015).
Only one case-control study and three cohort studies with the diagnosis of 
VD as an outcome were performed. One of each group found an effect (Hebert, 
Lindsay et al. 2000, Lenoir, Dufouil et al. 2011). Interestingly, two studies searching 
for both outcomes, and with a similar methodology, found the opposite: depression 
is a risk factor for AD and not for VD (Irie, Masaki et al. 2008) and vice-versa 
(Lenoir, Dufouil et al. 2011).
In conclusion, studies addressing depression as a risk factor for dementia 
subtypes revealed discrepant results. Probably a controlled cohort study with 
longer follow ups would help to clarify this issue.
d) What is the role of antidepressants?
It is expected that antidepressants with strong anticholinergic properties 
induce cognitive impairment, specially in older adults (American Geriatrics Society 
Beers Criteria Update Expert 2012). This impairment should be acute and revert 
after antidepressant discontinuation, and probably will fulfill the criteria for a 
delirious disorder (American Psychiatric Association 2013).
On the other hand, a number of preclinical observations suggest that 
antidepressants may have neuroprotective abilities, in animals submitted to 
protocols known to induce depressive behaviors.
The study of depression using animal models is important, and has 
advantages, but reproducing or mimicking mental disorders in rodents has also 
limitations. The main advantage is to permit experiments that could not easily be 
carried out, or be ethically unacceptable, on human subjects, in the hope of 
shedding some light on the nature and mechanisms of the disorder (Willner 1990). 
Although reliability can be an issue for some models, the main limitation is the 
validity of the model. The principal validity criteria for animal models are construct 
and predictive validity, face validity being considered less important (Kalueff and 
Tuohimaa 2004). An ideal model would fit all these three criteria, but it rarely 
happens in animal models of depression, as discussed below.
Although conceptually it seems wise to separate the protocol inducing 
depressive-like behaviors from the evaluation of the behaviors themselves, the 
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paradigm is quite often the same, e.g learned helplessness. Learned helplessness 
was first described in dogs exposed to an uncontrollable shock (Seligman 1972). 
When experimentally naive dogs were given a painful electric shock, they “ran 
frantically about [the cage], defecating, urinating, and howling, until accidentally 
scramble the barrier and so escapes the shock”. These dogs learned quickly how 
to escape the shock. When other dog, who had been exposed to uncontrollable 
shock before the avoidance experiment, was given an escapable shock, also had 
an initial running reaction. However,  this reaction soon stops and the animal  “sits 
or lies, quietly whining, until shock terminates (…). Rather, it seems to give up and 
passively accepts the shock”, even in subsequent trials. In this exemple the 
protocol of inducing learned helplessness is different from the evaluation of the 
behavior “learned helplessness”. 
Animal models of depression can be divided according to the duration of the 
induced depressive behaviors, into acute and chronic, or according to the inducing 
event (drugs, gene mutations, brain lesions, stimulation or stressful external 
factors) (reviewed by Kalueff and Tuohimaa 2004). Acute depression models can 
be pharmacological (e.g. clonidine or reserpine induced) or stress induced (e.g. 
tail suspension). Chronic depression models can be stress-evoked (such as the 
unsigned inescapable shock, or the chronic mild stress), promoted by social 
disruption (such as the maternal or peer separation), and by sensory deprivation 
(e.g. olfactory bulbectomy or long-term ZnSO4-induced anosmia), among others.
Reserpine, an alkaloid obtained from Rauwolfia serpentina, is an important 
drug in the history of pharmacology. Reserpine is a classic exemple of the effects 
of the manipulation of the adrenergic synapse, and, on the other hand, is also one 
of the rationals for the monamine theory of depression. Reserpine was used as an 
antihypertensive drug (Winsor 1953). Reserpine lowers the concentration of 
catecholamines (Holzbauer and Vogt 1956), blocking sympathetic response 
(Muscholl and Vogt 1958), due to inhibition of the vesicular monoamine 
transporters (VMAT) (Scherman and Henry 1984) . However, soon “calming” and 12
“sedating” effects were reported (Earl 1954), and even the end of 
 Prior to secretion, monoamines are taken from the cytoplasm and concentrated into vesicles, by a 12
group of transporters, called vesicular monoamine transporters (VMAT). When these transporters are 
inhibited, monoamines are not stored, and are destroyed by local enzymes, such as the Catechol-O-
methyl transferase (COMT).
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electroconvulsive therapy was proposed (Fouks, Laine et al. 1954), because 
reserpine would be efficacious to treat acute agitations. However, significant 
depressive symptoms were reported (Freis 1954). The mechanism of action and 
the clinical effects were the basis for the proposal of the reserpine animal model of 
depression. In this model, the animal is injected with reserpine, and acute 
depressive-behaviors like are observed. 
Clonidine was initially used as a nasal decongestant, but the finding that it 
induces bradycardia and hypotension, drove its use as antihypertensive drug 
(MacDougall, Addis et al. 1970). Clonidine acts by the stimulation of the α2 pre-
synaptic adrenergic receptors, thereby reducing sympathetic efflux from central 
nervous system (reviewed by Giovannitti, Thoms et al. 2015). Some basic 
research and clinical studies found a dysregulation of α2 adrenergic receptores in 
depression (Siever and Davis 1985). This was probably the basis for the clonidine 
rodent model of depression. These models have some predictive validity, but also 
have crucial construct validity issues, mainly because they are based on a single 
mechanism of depression, and it is hard to considerer an homology with human 
depressive disorder. 
Stress induced-models, specially the chronic stress models, have been 
considered more valid, as they rely on the relations between stress and 
depression, and also on some common biological findings of these conditions. 
Although the inescapable shock model has questionable face and construct 
validity, the unpredictable chronic mild stress (CMS) is generally considered a valid 
animal model of depression (Willner 1990), and has been used in recent research 
involving AD and neuroprotection (see below).  In CMS the animals are exposed 
for several weeks to a variety of mild unpredictable stressors (lights or sounds, 
e.g.) (Hill, Hellemans et al. 2012). This model have shown to promote a state of 
impaired reward salience similar to anhedonia. Although this model have been 
considered to have some face and construct validity (Willner 1997), the depressive 
like-behaviors wane in a few weeks and its reliability is controversial (Hill, 
Hellemans et al. 2012).
The olfactory bulbectomy is the surgical removal of the olfactory bulbs. This 
model of depression is based on the findings that the rats submitted to this 
procedure showed decreased acquisition of behavioral tasks involving both reward 
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and avoidance training (van Riezen, Schnieden et al. 1976). These deficits are 
reverted by amitriptyline, and this model has been used specially to predict 
antidepressant effects of new compounds. Recently it was used to study 
neurodegeneration and the associated cognitive decline (Hendriksen, Korte et al. 
2015), although the variations between species are significant and their meaning 
in terms of translational value is not clear.
Maternal separation (MS) is another model of depression. This model has 
its roots on the experimental work on Rhesus monkeys, showing that when infant 
monkeys were separated from their mothers, they presented an initial stage of 
‘protest'  (agitation, changes in sleep pattern, and screaming). One or two  days 
after, a “despair” phase occurs, characterized by a decrease in activity, appetite, 
play and social interaction (Harwlow 1958-62, cited by McKinney and Bunney 
1969). These separation phenomena are present to some extent in other species, 
such as rodents (Willner 1990). This MS model has a significant face validity, as a 
similar sequence of protest followed by despair was described in institutionalized 
children, a condition called “anaclitic depression” (Spitz (1946) and Robertson and 
Bowlby (1952), cited by Willner 1990). And child trauma is a known risk factor for 
metal disorders in adulthood (Heim and Nemeroff 2001, Dvir, Ford et al. 2014). 
Additionally, rats submitted to a MS protocol show persistent changes of gene 
expression, neurochemistry, electrophysiology, and morphology (Bakshi and Kalin 
2000, Kaufman, Plotsky et al. 2000), altogether with behavioral, neuroendocrine 
and cognitive signs of over-activation of the HPA axis (Aisa, Tordera et al. 2007, 
Sousa, Vital et al. 2014).
In general, depending on the aim of the research, the more simple models 
tend to be used in simple research (such as the preliminary screening of 
antidepressant actions), while the more sophisticated models are used in more 
complex research (such as the manipulation of behavior by multiple drugs, or the 
assessment of a specific behavior).
A slightly different question is the evaluation of depressive-like behaviors in 
animal models. Behavioral tests are used to assess and quantify the extent to 
which the animal displays a depression-like phenotype. The most used tests to 
evaluate depressive-like behaviors in rodents are the Porsolt swimming test (and 
the tail suspension test), the sucrose preference test, and the novelty suppressed 
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feeding test, all aiming to measure different components of depression (Powell, 
Fernandes et al. 2012).
Briefly, the Porsolt behavior despair test, or forced swimming test (FST), is 
based on the learned helplessness (actually measuring behavioral despair) 
(Porsolt, Le Pichon et al. 1977). The 
animal is placed in a cylinder, full of water 
in such a way that he cannot escape and 
is forced to swim (Figure 1). After an initial 
period of vigorous activity, the animal 
eventually stops moving, making only 
movements necessary to keep its head 
above water. This immobility is considered 
a behavioral equivalente of the human 
depress ive he lp lessness, and AD 
dec rease immob i l i t y t ime . O the r 
evaluations have been proposed, such as 
the latency to immobility, but the standard 
measure is the immobility time (Castagne, 
Moser et al. 2011).
The sucrose preference test is based on anhedonia (Willner, Towell et al. 
1987). Rats have innate preference for sweet food, and when faced with normal 
tap water and water with sucrose, the animals prefer to drink the sweet water. The 
non preference is interpreted as a behavioral equivalente of anhedonia and 
antidepressants have been shown to reverse this non-preference (Willner 1990).
These models and tests have been used to assess the putative 
neuroprotective actions of antidepressants.
Neuroprotection is an intervention that reverts or prevents further neuronal 
damage (Brimble and Levi 2006). This intervention is intended to increase the 
resistance of neurons to an insult. It can be a procedure, such as human 
refrigeration - probably the first efficacious neuroprotective intervention 
(Henderson 1963), or the administration of drug. Pedro Hispano in the XIII century, 
described several neuroprotective strategies, naturally bounded by the erroneous 
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Figure 1 The FST
The rat, after an initial phase of 
actively trying to escape, stops moving. It 
is considered a behavioral equivalente of 
helplessness.
knowledge of the eras in which it was written: “Here is what is good for the brain 
(…) a salubrious place, (…) aloes sucotrinum with fennel juice, (…) thyme, 
rosemary, (…) soundly sleep, (…). Basil and rue for melancholy. Sage and 
castoreum for paralysis and memory conservation (…)” (Hispano XIII century).
The evidence for neuroprotection is different, depending on the paradigm 
being studied (Simões do Couto and Mendonça 2007). In cell cultures, neuronal 
damage or death (e.g. the number of live neurons, or an evidence of 
neurogenesis) caused by certain noxious stimuli can be attenuated by specific 
interventions, like the presence of a particular compound (for instance, adenosine) 
(Ribeiro, Sebastiao et al. 2003). In brain slices, not only neuronal damage (or 
death) can be attenuated, but also neuronal function (long-term potentiation, e.g.) 
can be preserved or recovered by neuroprotective interventions. In in vivo studies, 
a neuroprotective intervention can attenuate structural (such as the number of 
dendritic spines, the morphology of neurons, or the size of a stroke), behavioral 
(the performance in a memory test, e.g.), or functional deficits (e.g. a focal sign) 
(Simões do Couto and Mendonça 2007).
In preclinical studies of depression and antidepressants, neuroprotection 
has been assessed at the morphological, physiological, and behavioral levels 
(Pehrson, Leiser et al. 2015). At the morphological level neuroprotection has be 
evidenced by increased neurogenesis, increased number of dendrites, or 
increased synaptic contacts. Neuroprotection can be evident in hippocampal slices 
if an LTP dysfunction is attenuated. At the behavioral level, two cognitive tests 
have been used to assess an eventual neuroprotective action of AD: the novel 
object recognition (NOR) and the Morris water maze (MWM).
The NOR has emerged as the most popular test for assessing a rodent's 
ability to recognize a previously presented stimulus, so it is a test for object, non-
spacial, memory (Ennaceur and Delacour 1988, Cohen and Stackman 2015). The 
choice of the name was not very happy, and can be misleading, because the 
recognition of a novel object is impossible. Anyway, it involves two phases: in the 
first phase, or training phase, the animal is placed in a familiar arena with two 
identical novel objects. The animal is left a period of time to explore the objects 
(encoding) and then is removed from the arena. Later (consolidation of memory), 
the second phase, or test session, takes place. The animal is left in the same 
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arena with an exact replica of the initial object and another one, different. Rodents 
exhibit a natural trend to explore the novel object, and it is expected to exhibit a 
preference for exploring the novel object. Memory is computed from the 
percentages of time spent exploring both objects. However, the brain circuits 
implicated in the test are not fully understood, and discrepant results are common 
(Cohen and Stackman 2015).
The MWM, created by Morris et al (1982), is sensitive to hippocampal-
dependent spatial learning and memory. Several variations exist, but the classic 
test is the most used (Diogenes, Costenla et al. 2011, Sousa, Vital et al. 2014). 
The test takes place in a maze, which is a large circular tank, filled with water 
made opaque with the addition of a small amount of a non-toxic water-based black 
paint. An escape platform is submerged, non-visible, 1 cm below the water. 
Several visual cues for spatial reference are placed on the walls of the testing 
room. The test has two phases: the first phase, or spatial acquisition training, 
consistes of four trials/day for four consecutive days, in which the platform is 
placed at a fixed position in the center of one of the four quadrants of the tank. On 
each day the animals are randomly placed in four different positions facing the 
wall, and dropped into the water. The latency to find the platform is measured. At 
the fifth day a probe test was given - the platform is removed and the animals were 
allowed to swim freely for 60s. The percentage of time spent in the quadrant where 
the platform was is quantified.
As mentioned before, it has been shown that antidepressant actions extend 
beyond monoamines re-uptake to include neuroprotection. In non depressed 
animals, antidepressants increase gene expression of various neuroprotective 
agents, such as the cyclic AMP response element binding (CREB) or the brain 
derived neurotrophic factor (BDNF), among others (reviewed by Pehrson, Leiser et 
al. 2015). Antidepressants also induce changes in proteins related to 
neurogenesis, such as the Insuline Growth Factor-1 or Heat Shock Protein 10, 
among others, in normal animals (Khawaja, Xu et al. 2004, Tiraboschi, Tardito et 
al. 2004, reviewed by Pehrson, Leiser et al. 2015).
However, a direct evidence of neuroprotection in animal models of 
depression is less clear. Preclinical studies have shown that short-term treatment 
with fluoxetine and imipramine induces remodeling of dendrites and synapses in 
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rats submitted to CMS (Bessa, Ferreira et al. 2009). If a longterm treatment is 
given in the same conditions, increased neurogenesis is observed, paralleling the 
reversal of the depressive-like behaviors (Mateus-Pinheiro, Pinto et al. 2013). If 
neurogenesis is blocked (with the use the cytostatic agent methylazoxymethanol), 
the depressive-like behaviors do not change. Almost all antidepressants have 
shown similar neurogenic properties (Pehrson, Leiser et al. 2015).
If given for longer periods (although still short - 2-4 weeks), intraperitoneal 
fluoxetine was shown to reverse cognitive deficits induced by depression in some 
studies (Harvey, Naciti et al. 2004, Song, Che et al. 2006, Ibi, Takuma et al. 2008). 
Another study showed a partial reversion (Valluzzi and Chan 2007) and still 
another one a total absence of reversion (Bianchi, Fone et al. 2009).
In conclusion, although the evidence for a behavioral effect is less clear, in 
preclinical studies, antidepressants seem to have neuroprotective actions.
It is an appealing hypothesis that long-term treatment with antidepressants 
could decrease the risk for dementia in depressed patients, although it is not easy 
to test (Kessing 2012). In fact, clinical data are heterogenous, and seem not to 
reflect preclinical findings.
 Antidepressants use was associated with an increased risk for dementia 
in the first studies (Jorm, van Duijn et al. 1991). These results were explored in 
subsequent studies. In a Danish study, although the risk increased along with an 
increase in the number of prescriptions, actually, for a high number of 
prescriptions, the risk decreases (Kessing, Sondergard et al. 2009). These 
changes were found independently of the antidepressant class. These findings 
were essentially replicated for TCAs, but not for other antidepressants, in a 
subsequent study by the same researchers, performed in more severe depressed 
subjects that had been hospitalized due to depression (Kessing, Forman et al. 
2011). The authors proposed that increased prescriptions could be associated with 
a better depression treatment, and so a diminished risk for dementia. They also 
speculated that for the most severe cases of depression, non-TCAs 
antidepressants are not enough effective to counterbalance the risk induced by 
depression (Kessing 2012).
 74
C. Presenting the hypothesis under study
1. Is depression a risk factor for dementia?
We hypothesized that patients suffering from depression, carefully 
characterized, have an increased risk for dementia when compared to non-
depressed subjects, controlling for important confounders.
2. Is depression an early risk factor for dementia or a prodrome of dementia?
We hypothesized that patients suffering from depression, carefully 
characterized, occurring many years before dementia onset (at an early age), are 
at increased risk for dementia, controlling for important confounders.
3. What is the role of different depression subtypes?
We hypothesized that patients suffering from different types of depression, 
carefully characterized, have a different risk for dementia, controlling for important 
confounders.
4. What is the role of the different dementia disorders?
We hypothesized that patients suffering from depression, carefully 
characterized, have a different risk for AD, VD and other dementia conditions.
5. What is the role of antidepressants?
We hypothesized that antidepressants reverse the chronic memory deficits 
in rats submitted to a protocol known to induce depressive behaviors
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Depression with melancholic features is associated with higher 
long-term risk for dementia
Frederico Simões do Couto, Nuno Lunet, Sandra Ginó, Catarina Chester, 
Vanda Freitas, Carolina Maruta, Maria Luísa Figueira, Alexandre de Mendonça
Abstract
Background: Depression has been reported to increase the risk of subsequently 
developing dementia, but the nature of this relation remains to be elucidated. Two 
important unsolved issues have been raised: (1) depression can be a prodrome/
manifestation of dementia or an early risk factor, and (2) the effect may differ 
according to depression subtypes. Therefore, we aimed to study the association 
between early-onset depression, as well as between different depression subtypes 
and the occurrence of dementia.
Methods: We conducted a cohort study including a series of 322 subjects with 
depression, consecutively recruited between 1977 and 1984. Age and sex-
matched subjects without depression admitted for surgery at the same time were 
the group not exposed to depression. Subjects were contacted again between 
2009 and 2013, to assess their dementia status. The risk for dementia in patients 
with early onset depression was compared to the corresponding controls using 
binary logistic regression, and the odds ratio (OR) computed. To quantify the 
association between different depression subtypes (namely melancholic, anxious, 
and psychotic) and dementia we obtained adjusted hazard ratios (HR) with 95% 
confidence intervals (95% CI) using Cox proportional hazards regression.
Results: In 133 (41.3%) depressed subjects, followed-up for a mean (standard 
deviation) of 25.7 (7.2) years, the diagnosis of dementia could be established or 
excluded. Among these, 44 (33.1%) developed dementia, mostly Alzheimer’s 
dementia, versus 20 (15.0%) among the subjects with no depression at baseline. 
Depressed subjects had an increased risk of dementia when compared to the 
controls [OR 2.50 (1.14-5.49; 95% CI); p=0.022], as well as subjects with early 
onset depression. Patients suffering from depression with melancholic features 
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had an increased risk of developing dementia compared to those without 
melancholic features [HR 3.64 (1.78-11.26; 95% CI); p=0.025].
Limitations: The inclusion of biological biomarkers would provide a biological 
ground and strengthen the results. No formal cognitive evaluation was performed 
at baseline. About 60% of the subjects with depression at baseline were lost 
during follow up. 
Conclusions: The present study supports early onset depression and depression 
with melancholic features as important risk factors for dementia. Melancholic 
features may play an important role in the relation between these diseases, and 
should be actively included in further studies.
Keywords: dementia; depression; melancholia; hypothalamus-hypophysis-adrenal 
axis; risk factor
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1. Introduction
As most dementing conditions are irreversible, and the available therapies have 
limited beneficial effects, primary prevention is of paramount importance for 
reducing the societal impact of dementia (Ritchie et al., 2010; Norton el al, 2014). 
Among the several risk factors so far identified, depression emerges as a 
potentially important target (Reitz et al., 2011), because is amenable to prevention, 
has a high prevalence, and can be diagnosed inexpensively and treated effectively 
(Kupfer et al., 2012).
Depression has been found to be a risk factor for dementia in several case-
control (Cooper and Holmes 1998, Green, Cupples et al. 2003) and cohort studies 
(DalForno, 2005; Kessing, 2003; Saczynski, 2010; Irie, 2008; Dotson, 2010; Byers, 
2011), but not all (see Chen, 1999; Gatz, 2005; Chen, 2008; Brommelholf, 2009). 
The meta-analyses and recent reviews performed have confirmed this association 
in general, finding that depression approximately doubles the risk for dementia 
(Jorm, 2001; Ownby et al., 2006; Silva, 2013).
However, the nature of this relation remains poorly understood. Two 
unsolved issues have been repeatedly raised (Byers and Yaffe, 2011, Kessing, 
2012). The first is that depression, especially if occurring after 60 (called late onset 
depression) or next to a diagnosis of dementia, can be a prodrome/manifestation 
of dementia disorder, instead of an early risk factor. In fact, depressive symptoms 
are quite common in dementia, and depressive symptoms may arise from the 
anatomic lesions that are part of the neuropathological course of dementia 
(Boland, 2000). Case-control studies that do not take into account the time 
between dementia and depression diagnosis, and cohort studies with a short 
follow up may not be able to distinguish between these two situations. The few 
studies that specifically compared late onset depression with early onset 
depression found discrepant results (Green, 2003; Geerlings, 2008; Brommelhoff, 
2009; Lenoir, 2011; Almeida, 2015).
The second issue is the subtype of depression. The heterogeneity of 
depression has seldom been taken into account. A more severe disorder 
(expressed by higher frequency, duration, and severity of the depressive episodes) 
has been inconsistently associated with a higher risk for dementia (Geerlings et 
al., 2008; Kessing et al., 2012; Silva et al., 2013). Bipolar disorder has also been 
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associated with a higher risk of dementia, but only in some studies (reviewed by 
Silva et al., 2013). Brodady et al. (2003) explored the role of comorbid anxiety in 
depression on the risk for dementia and found no influence. On the other hand, the 
use of benzodiazepines has been reported to carry a higher risk (Billioti de Gage 
et al., 2012). Psychotic symptoms have been associated with a higher risk for 
cognitive deficits only in bipolar patients (Martínez-Arán et al., 2004). Few studies 
looked at the risk for dementia in DSM-5 or ICD10 defined depression subtypes. 
DalForno et al. (2005) performed an additional risk analysis and found that a 
Center for Epidemiologic Study–Depression (CES-D) sub-scale based on a cluster 
of negative affective symptoms, related to melancholic features, did not influence 
the global risk for dementia.
Different biological mechanisms underlying these different depressive 
conditions can carry different risk factors for dementia. Late-onset depression may 
reflect a prodromal symptom of dementia, and unlikely early-onset depression, has 
been associated with structural brain abnormalities of vascular origin, and may be 
characterized by a more severe course and a higher prevalence of psychosis 
(Kessing et al., 2012). Melancholic features, and to a lesser extent psychotic 
symptoms, have been associated with more consistent biological abnormalities 
and response to treatment (Brown, 2007; Parker et al., 2013) when compared to 
their absence.
These unsolved issues - prodrome versus early risk factor and the 
heterogeneity of depression - regarding the risk for dementia in depressed 
patients, encouraged us to perform the current study. The objectives were to 
quantify the association between early onset depression, as well as between 
different depression subtypes, and the long-term risk for dementia, controlling for 
well known risk factors for dementia. 
2. Methodology 
2.1 Study design
This study is based on a cohort of depressed patients followed in average 25 
years for development of dementia. The cohort comprised 325 patients from the 
Hospital de Santa Maria, Lisbon, either inpatients or outpatients, with the clinical 
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diagnosis of depression, recruited between 1977 and 1984 in a taxonomic cluster 
analysis study of depression.
A surgical comparison sample was recruited retrospectively, to include 
eligible subjects who were consecutively admitted to Hospital de Santa Maria, 
Lisbon, for routine surgery (appendicectomy or cholecystectomy) between 1977 
and 1984.
All participants were re-evaluated between 2009 and 2013, to establish the 
outcome - dementia status.
2.2. Baseline assessment
The depressed cohort was submitted to a comprehensive psychiatric and 
psychological evaluation was performed, and data on demography, clinical 
features, and personal and family history were collected (Paes de Sousa et al., 
1980). This evaluation notably allowed the classification of depression by virtually 
any diagnostic system.
Surgical cohort demographic and clinical data were collected from clinical 
files.
2.2.1. Depressed cohort evaluations 
a) Association for Methodology and Documentation in Psychiatry System (AMDP) 
The AMDP-System was created in Nuremberg in 1960 and has been widely used 
in Europe in 1970-1980. The Psychopathology Scale contains 100 
psychopathology items, including symptoms and other clinical features, derived 
from classic psychopathology studies from Jaspers, Bleuler, Schneider, and 
others. It renders a very detailed and standardized evaluation, including affective, 
behavioral, cognitive, psychotic, sensory, and social dimensions of 
psychopathology (Busch et al., 1980; Paes de Sousa et al., 1980).
This system has been used for diagnostic or reclassification purposes with 
other diagnostic systems, such as the DSM IV (Salvatore et al., 2007; Seemuller 
et al., 2008).
Each symptom is scored for severity (0–3: absent, mild, moderate, severe).
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b) Eysenck Personality Questionnaire (EPQ)
This questionnaire (Eysenck & Eysenck, 1975) includes 83 items (full version), 
allowing the evaluation of the three basic personality dimensions, according to 
Eysenck’s Personality theory: extroversion, neuroticism and psychoticism. The 
subject responds yes or no, and a positive answer is scored 1. The final result is 
the sum of the points in each scale (0-23 for extroversion and 0-23 for 
neuroticism).
The neuroticism dimension assesses emotional stability versus instability 
and identifies individuals prone to psychological distress. Low scores indicate a 
trend to more relaxed, unemotional, and self-satisfied subjects. The extraversion 
dimension measures interpersonal interaction, activity level, need for stimulation, 
and capacity for joy. The subjects with a low score tend to be more reserved, 
sober, task-oriented, and quiet.
A low extroversion (a score lower then median) and high neuroticism group 
(a score higher than median) of subjects was created, as these subjects were 
previously found to be at a higher risk for dementia (Wang et al., 2009).
c) Clinical Global Impression (CGI))
Clinical global impression - severity (CGI S; Guy, 1976) is 7-point scale to evaluate 
the current severity of the patient's illness, according to the clinician’s total past 
experience, ranging from 1 (not at all ill) to 7 (extremely ill).
2.2.2. Diagnosis of depression
Using AMDP symptoms at baseline, DSM 5 diagnostic criteria for Persistent 
Depressive Disorder (dysthymia), Major Depressive Disorder (MDD), melancholic 
and psychotic features were applied. Through baseline chart review, subjects were 
considered to have bipolar disorder if they met DSM 5 criteria for bipolar disorder.
The specifier of anxious distress could not be defined by AMDP as only two 
anxious symptoms (“psychic anxiety” and “somatic anxiety”) are present in the 
scale. A numerical variable “anxiety symptoms” was created adding both scores. 
Chronic disease was defined if MDD symptoms were present continuously for 
more than two years.
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Based on the information gathered during the follow-up, the initial diagnosis 
was reviewed and three patients were excluded from the cohort because the 
diagnosis of depression was found wrong, namely one had schizophrenia, another 
schizoaffective disorder and the third a brain tumor. So, the cohort recruited 322 
subjects.
2.3. Follow-up
2.3.1. Follow up procedures
The Hospital de Santa Maria, the Institute of Notaries and Records, and the 
National Health Service databases were used to get the subjects’ address and 
next of kin, phone number, vital status, General Practitioner (GP) and other 
relevant doctors’ names. This search was used to find and contact subjects, or 
next of kin if the subject was dead.
a) Depressive cohort
It was not possible to ascertain the vital status of 125 subjects (data illegible, no 
records, or too many records found).
In the remaining 197, additional information was sought to establish a 
diagnosis of dementia. In the 75 subjects found to be dead, the next of kin was 
contacted to collect demographic information and to apply the Dementia 
Questionnaire (DQ). GP records, psychiatrist records, neurologist records, hospital 
clinical files, death certificates and nursing home records were reviewed to collect 
information regarding dementia diagnosis. In 43 subjects no contact with next of 
kin was possible or the clinical information in clinical files was not enough to 
establish or exclude the diagnosis of dementia.
The 124 alive subjects were contacted first by mail, presenting the study 
and indicating that a later phone contact would be done. Then, a clinical interview 
and a neuropsychological assessment (NA) were offered. If a subject was living far 
away, too ill to be submitted to NA, or not willing to come for the clinical/NA, 
telephone interviews (TICS and/or DQ) to evaluate the cognitive status were 
applied. Patient’s GPs, or other relevant doctors were contacted, and hospital 
records reviewed when appropriate. No contact at all, and no clinical records were 
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found in 7 subjects, and a total of 16 subjects refused to participate in the study.  
In 133 (41.3%) subjects the outcome could be established (Figure 1). 
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Initial sample  
322 cases; 285 controls 
NHS and hospital databases 
Next of a kin contact
Without 
FU information 
Cases 43 
Controls 23 
No records 
Cases 123 
Controls 109
FU 
cohort  
Cases 133 
Controls 133
Vital status
Alive (Cases 124; Controls 117) 
Clinical interview 
Neuropsychological Assessment 
Dementia Questionnaire/Telephone Interview for 
Caregiver Status 
General Practitioner records 
Other doctors files 
Dead (Cases 75; Controls 55) 
Dementia Questionnaire 
General Practitioner records 
Other doctors files 
Hospital clinical files 
Death certificates 
Nursing home records
Fig. 2. Diagram displaying the flow of subjects cases in the study. NHS National Health Service, 
FU Follow up.
Without 
FU information 
Cases 32 
Controls 32
With 
FU information 
Cases 101 
Controls 101
Without 
FU information 
Cases 7 
Controls 15
Refused 
Cases 16 
Controls 5
b) Surgical cohort
Patients admitted at the Surgery Department of the same hospital, for routine 
appendectomy or cholecistectomy at the same time as cases, were recruited. The 
initial sample comprised 287 potentially eligible subjects. A subject was considered 
eligible if they had not a mood disorder illness prior to or at the time of index 
surgical hospitalization. This was determined by the interview and by reviewing all 
the information available from clinical files. Two subjects found to have a mood 
disorder (one bipolar, one MDD) at time of the index hospitalization were excluded 
from the cohort. So the cohort included 285 subjects. The same processes 
described for cases were conducted, reaching a follow up group of 133 subjects.
2.3.2. Follow up assessment (evaluations performed in 2009-2013)
Both cohorts were submitted to the same FU assessments.
a) Neuropsychological assessment (NA)
A comprehensive evaluation was performed, either at patients’ home or in the 
hospital, by experienced neuropsychologists. The evaluation included (1) Battery 
of Lisbon for the Assessment of Dementia (BLAD; Garcia, 1984), (2) Trail Making 
Test – part A and part B (TMT; Reitan, 1958, (3) Toulouse-Piéron Test (TP; 
Toulouse and Piéron, 1986; Mendelsohn, 2000), and (4) California Verbal Learning 
Test (CVLT; Delis et al., 1987; Ribeiro et al., 2007).
b) Other assessments
1) Telephone Interview for Cognitive Status (TICS)
This instrument (Brandt et al., 1988; Madureira et al., 2006) was initially developed 
for the assessment of AD patients unwilling or unable to return for follow-up. It 
gathers information on the domains of orientation, concentration, short-term 
memory, mathematical skills, praxis and language. It was proven to be sensitive 
and specific, and to have high test–retest reliability. The cutoff used for dementia 
was less than 26.
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2) Dementia Questionnaire (DQ)
The Dementia Questionnaire (Silverman et al., 1986) is applied by telephone to 
caregivers of patients with dementia allowing to quickly diagnose dementia in 
patients by the DSM IIIR criteria, and in some cases even to suggest the dementia 
subtype. The DQ can also be applied to caregivers of already dead patients with 
dementia. A validated version including the age of onset of dementia and dementia 
subtype was used (Teixeira et al., 2011).
3) Vascular risk factors assessment
Subjects with a previous diagnosis of hypertension, diabetes, dyslipidemia, 
ischemic heart disease or cerebrovascular disease were considered to have 
vascular risk factors.
2.3.3. Diagnosis of dementia
Dementia was diagnosed at a case conference, including a psychiatrist (F.S.doC.), 
a neurologist (A.deM.) and a neuropsychologist (C.C.), all experienced in 
dementia. Cases were determined based on the best available information, using 
DSM-5 criteria for Major Neurocognitive Disorder (dementia) (APA, 2013).
The clinical and NA information were reviewed if the subject attended the 
clinical interview and neuropsychological assessment. If a subject was dead or did 
not attend the formal evaluation, case conference reviewed all the available 
evidence. In these cases, the diagnosis of dementia was based on at least two of 
the following: TICS score of 26 or less; DQ yielded a diagnosis of dementia; GPs 
records with a diagnosis of dementia; a diagnosis of dementia performed by either 
a neurologist or a psychiatrist; hospital records of dementia; death certificate with 
a diagnosis of dementia; retrospective case audit to meet DSM-5 dementia 
criteria; diagnosis of dementia recorded in nursing-home notes. If a diagnosis of 
dementia was established, reference to a Dementia Clinics was offered to the 
subject, to undergo the standard of care for evaluation and treatment of dementia.
The type of dementia was determined in the case conference referred 
above, using all the available information. The criteria for the diagnosis of the most 
common types of dementia were used: probable Alzheimer’s disease according to 
NINCDS-ADRDA criteria (McKhann et al., 2011), probable vascular dementia 
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according to NINDS-AIREN criteria (Roman et al., 1993), probable dementia with 
Lewy bodies (DLB) according to the criteria proposed by McKeith et al. (2005), 
and behavioral variant of fronto-temporal dementia (FTD) according to the criteria 
of the International Behavioural Variant FTD Criteria Consortium (Rascovsky et al., 
2011). If none of these criteria was met, or no sufficient information could be 
gathered, the diagnosis made was dementia non-otherwise specified (NOS).
Date of onset of dementia was determined during the clinical interview, by 
DQ, or chart review.
2.4. Statistical analysis
Statistical Package for Social Sciences® v19 (SPSS) and STATA® version 11.1 
(College Station, TX, 2009) were used for the statistical analysis.
Baseline characteristics were compared between subjects in whom the 
outcome was assessed and in those lost during follow-up, using independent 
samples t Student’s test for continuous variables, after verification of homogeneity 
of variances, and Pearson Chi-square test for categorical variables, with Yates 
continuity correction for 2X2 tables (CCχ2).
We used a binary logistic regression (with the dependent variable 
constituted by the conversion to dementia during the follow-up period) to compute 
the odds ratio (OR) for the association between depression and dementia. 
Because subjects from the depressed cohort were more tightly followed by the 
health services, it was possible to have the exact age of dementia onset for the 
vast majority of them. On the other hand, the data were  hard to obtain for surgical 
cohort subjects, thus preventing the performance of Cox analysis including this 
group. However, Cox proportional hazards models were used in the depressed 
cohort to compute crude and adjusted hazard ratios (HR) and 95% confidence 
intervals (95% CI) to quantify the relation between the different exposures, 
including depression subtypes, and dementia. For multivariate analyses we 
considered the variables that were significantly associated (p<0.05) with dementia 
in univariate analysis, as well as variables considered to be potentially relevant 
confounding factors, according to the literature (Ritchie el al, 2012; Reitz et al, 
2011). Age of onset and the presence of vascular risk factors were considered only 
in sensitivity analyses because data on these variables was available for a subset 
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of all patients (77 and 123, respectively), and due to the fact that the latter was 
assessed at follow-up. The proportional hazards assumption was evaluated 
graphically using “log-log” plots. We estimated the cumulative incidence of 
dementia, across the follow-up period, taking into account the competing risk of 
death, using a competing-risks regression model, according to the method of Fine 
and Gray (Fine & Gray, 1999).
Statistical significance was accepted for p < 0.05.
2.5. Ethics
This study was conducted in accordance with the Helsinki Declaration as well as 
national ethical guidelines. The local Ethics Committee, the National Data 
Protection Committee, and the national Institute of Notaries and Records approved 
the protocol.
Subjects who performed follow up evaluation were required to provide 
informed consent. 
If a diagnosis of dementia was established, reference to a Dementia Clinics 
was offered to the subject, to undergo the standard of care for evaluation and 
treatment of dementia.
3. Results
3.1. Baseline and descriptive characteristics of both cohorts
In 133 (41.3%) depressed cohort subjects, followed-up for a mean (standard 
deviation) of 25.7 (7.2) years, the diagnosis of dementia could be established or 
excluded. Comparing baseline data of the subjects with and without a known 
outcome, the mean age was lower and the proportion of men was smaller in the 
subjects with a known outcome, but no statistically significant differences were 
observed regarding other socio-demographic and clinical characteristics (Table 4). 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Characteristics Depressive cohort Surgical cohort
Lost 
during 
follow up           
(n= 189)
With 
known 
outcome         
(n=133)
Total 
    (n=322)
p 
valuea
Lost 
during 
follow up           
(n= 152)
With known 
outcome         
(n=133)
Total 
    (n=289)
p valuea
Age, mean 
(SD), y
50.8 
(12.7)b
41.8 
(11.6)
46.9 (13.0) <0.001 47.7 
(14.5)
41.0 (12.1) 44.6 (13.8) <0.001
Male sex, % 
(n)
27.0 % 
(51)
15.0% 
(20)
22.0% (71) 0.014 20.4% 
(31)
15.0% (20) 17.9 (51) 0.280
Education, 
mean (SD), y
6.4 (4.6) 7.1 (4.5) 6.7 (4.6) 0.165 not 
available
6.63 (4.6)c
Bipolar 
disorder, % (n)
10.6% 
(20)
16.5% 
(22)
13.0% (42) 0.326
Melancholic 
features, % (n)
33.3% 
(63)
35.3% 
(47)
34.2% (110) 0.722
Psychotic 
features, % (n)
24.3% 
(46)
24.1% 
(32)
24.2% (78) 0.999
Anxiety 
symptoms 
severity, mean 
(SD)
1.6 (2.6) 1.9 (2.8) 1.7 (2.7) 0.288
Clinical Global 
Impression 
(CGI), mean 
(SD)
5.0 (0.8) 5.0 (0.7) 5.1 (0.7) 0.978
Table 4. Baseline characteristics of both cohort subjects to known outcome
Legend       aComparing, within each cohort, those with a known outcome with those without known 
outcome, based on chi-square test for category variables and independent samples t test for 
continuous variables; bbaseline age available only for 182 subjects; ceducation years available for 
111 subjects. Education years were not written in surgical files. 
In both cohorts, baseline age was lower in those whose outcome was 
determined than in those it was not), but no significant diferences were found in 
sex proportions.
Almost all subjects were Caucasian, in depressed and surgical cohort (98% 
and 99%, respectively). For those in whom the outcome was determined, no 
differences were found in age and years of education between cases and controls.
3.2. Depression as a risk factor for dementia
Forty-four (33.1%), of the 133 depressed subjects included in the analysis, 
developed dementia. Dementia cause could be assessed in about half of these 
cases (n=21), and the most prevalent was Alzheimer’s disease (AD) (57%), 
followed by vascular dementia (19%), and Parkinson’s disease (14%). Other 
causes were vitamin B12 deficiency and HIV dementia.
The characteristics of subjects who developed dementia and those that 
have not are displayed in Table 4. At follow-up 4 patients with unipolar depression 
were rediagnosed as bipolar, due to a later emergence of a manic episode, and 2 
non bipolar patients fulfilled DSM-5 criteria for Persistent Depressive Disorder at 
baseline, but were re-classified later as MDD.
In the control group, 20 subjects (15.0%) developed dementia, the most 
common assed cause was AD (n=5). The odds of dementia were increased by 
2.50 times (95% C.I. 1.14-5.49; p=0.022) for the depressed cohort when compared 
to the surgical cohort, controlled for sex and education, computed by logistic 
binary regression. 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Table 5. Cohort characteristics and outcome
Depressed cohort Surgical cohort
Characteristics Non 
demented           
(n= 89)
Demented         
(n=44)
Non 
demented           
(n= 113)
Demented         
(n=20)
Age, mean (SD), y 38.9 (10.4) 47.8 (11.5) 38.6 (11.0) 55.90 (8.6)
                     <35 years, % (n) 46.1% (41) 11.4% (5) 46.0% (52) 0.0 %(0)
                     35-45 years, % (n) 23.6% (21) 29.5% (13) 23.9% (27) 10.0% (2)
                     >45 years, % (n) 30.3% (27) 59.1% (26) 30.1% (34) 90.0% (18)
Male sex 14.6 % (13) 15.9% (7) 14.2 % (16) 20 % (4)
Education, mean (SD), ya 7.8 (4.5) 5.9 (4.4) 7.3 (4.7) 2.9 (1.7)
                     <4 years, % (n) 39.3% (35) 61.4% (27) 56.4 % (53) 100 % (17)
                     4-9 years, % (n) 31.5% (28) 22.7% (10) 17.0 % (16) 0.0 % (0)
                     >9 years, % (n) 29.2% (26) 15.9% (7) 26.6 % (25) 0.0 % (0)
Follow up time, mean (SD), y 26.3 (7.2) 24.5 (7.3) 30.4 (5.4) 25.7 (8.0)
Age of onset of the disorder, 
mean (SD), yb
28.4 (10.2) 34.8 (10.2)
Bipolar disorder, % (n) 14.6% (13) 18.2% (8)
DSM-5 Diagnosed MDD, % (n) 84.3% (75) 79.5% (35)
Melancholic features, % (n) 24.7% (22) 56.8% (25)
Psychotic features, % (n) 20.2% (18) 31.8% (14)
Anxiety symptoms severity, 
mean (SD), AMDP score
1.48 (2.59) 2.86 (2.95)
Clinical Global Impression 
(CGI), mean (SD)
4.9 (0.7) 5.1 (0.7)
Chronic Disorder, % (n) 71.3% (57) 92.3% (36)
Inpatient at baseline, % (n) 55.1% (49) 65.9% (29)
Ever been admitted for 
depression, % (n)c
82.7% (62) 94.6% (35)
Suicide attempts, % (n)d 43.9% (25) 66.7% (12)
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Notes: MDD Major Depressive Disorder, EPQ Eysenck Personality Questionnaire. 
aData available only in 111 controls; bData available only in 77 subjects; cData on 
admission status was available in 82 subjects; d58 subjects had suicide data; e87 
subjects had baseline EPQ; fData obtained at follow up, available in 123 
depressed subjects and in 101 controls.
3.3. Role of early-onset depression and depression heterogeneity
When the analysis is restricted to subjects younger than 45 years old (to 
compute the risk for early onset depression) were excluded from both cohorts, the 
risk for dementia is still significantly increased [OR 6.85 (95% C.I. 1.38-34.00); 
p=0,019] when compared to the surgical cohort, using a binary logistic regression, 
controlled for age and years of education.
In the depressed cohort, the probability of dementia increased significantly 
with age, was not influenced by education and was significantly higher for 
melancholic features, anxiety symptoms, and severity of the episode assessed 
with the CGI, in the univariate Cox regression analysis (Table 6). In the 
multivariate Cox analysis (Table 6), older subjects at baseline and those with 
depression with melancholic features had an increased risk for developing 
dementia compared to those without melancholic features (HR=3.64; 95% C.I. 
EPQ (Extroversion), mean 
(SD)e
38.0 (21.2) 35.1 (17.5)
EPQ (Neuroticism), mean (SD)e 81.8 (14.9) 78.8 (14.8)
High Neuroticism/Low 
Extroversion Group, % (n)e
24.6% (14) 23.3% (7)
Vascular risk factors, % (n)f 59.8% (52) 80.6% (29) 60.6% (57) 75.0% (9)
FU time to dementia (y), mean 
(SD)
24.5 (7.3) 25.6 (8.0)
Died, % (n) 18.0% (16) 36.4% (16) 20.4% (23) 60.0% (12)
Depressed cohort Surgical cohort
Characteristics Non 
demented           
(n= 89)
Demented         
(n=44)
Non 
demented           
(n= 113)
Demented         
(n=20)
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1.78-11.26). The other depression characteristics and education were not 
associated with a higher risk for dementia. 
Two sensitivity analyses were performed in this cohort, including age of the 
affective disorder (determined in few cases) and vascular risk factors (data 
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Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Baseline Age, y
             <35 1 [reference] 1 [reference]
             35-45 7.55 (2.15-26.52) 0.002 7.26 (1.99-26.51) 0.003
             >45 15.17 (4.55-50.58) <0.001 13.18 (3.72-47.50) <0.001
Baseline Education, y
             0-4 1 [reference] 1 [reference]
             5-9 0.88 (0.42-1.84) 0.730 1.40 (0.60-3.28) 0.437
             >9 0.47 (0.19-1.15) 0.097 0.461 (0.16-1.34) 0.156
Bipolar Disorder 1.88 (0.86-4.14) 0.116 0.64 (0.22-1.84) 0.408
Melancholic features 4.48 (2.40-8.39) <0.001 3.64 (1.78-11.26) 0.025
Psychotic features 1.55 (0.81-2.96) 0.182 1.55 (0.76-3.14) 0.224
Anxiety symptoms 1.18 (1.08-1.30) 0.001 0.97 (0.82-1.22) 0.969
Clinical Global Impression 
(Severity)
1.84 (1.18-2.87) 0.008 1.19 (0.74-2.36) 0.345
Chronic disorder 1.85 (0.96-3.55) 0.065 1.24 (0.58-2.61) 0.581
Male sex 0.98 (0.39-32.51) 0.974
Inpatient at baseline 1.01 (0.53-1.92) 0.980
Ever been admitted for 
depression
2.20 (0.51-9.52) 0.290
Suicide attempts 2.03 (0.74-5.63) 0.172
High Neuroticism/Low 
Extroversion Group
0.71 (0.33-1.82) 0.568
Notes: Variables found significant in the preliminary analysis and those known to 
influence the risk for dementia were included in the Cox proporcional hazards models.
Table 6 Depressed Cohort: Association between demographic variables, clinical characteristics and 
other well established risks for dementia, and the risk of dementia
obtained prospectively). In a new model, the inclusion of age of affective disorder 
onset and vascular risk factors did not change the significance of the associations 
between both melancholic features and age at baseline with dementia risk.
Studies with a very long follow up, especially including geriatric outcomes 
and depressed subjects, are faced with the difficult problem of how to account for 
the competing risk of death (Wulsin et al, 1999). Because Cox proportional 
hazards regression can overestimate the risk of disease, a risk competing analysis 
was performed. The cumulative incidence of dementia, according to melancholic 
features of depression, was higher among subjects with melancholic features 
during most of the follow-up period, reaching approximately 50% at around 30 
years of follow-up, according to a competitive risk model (Figure 3).
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Figure 3 Cumulative incidence of dementia in the depressed cohort, across 
the follow-up period, taking into account the competing risk of death, using a 
competing-risks regression model.
When comparing both melancholic and non-melancholic depressed patients 
with non-depressed subjects, only melancholic patients showed a statistically 
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significant increased risk for dementia, using age and education were used as 
covariates in a binary logistic regression (Table 6).
Table 6 Association between depression, melancholia, and risk of dementia
4. Discussion
The main finding of the present study is that melancholic features of depression 
are an important and independent risk factor for dementia.
Depression has been globally associated with a two-fold increase risk of 
dementia (Silva et al, 2013), just like we found in this study. But, as far as we 
know, melancholic features have not been previously specifically assessed as a 
risk factor for dementia. Melancholia has been associated with persistent cognitive 
impairment after depression remission (Lin et al, 2014; Roca et al, 2015), but not 
with dementia. It is possible that the follow up time has been too short in both 
studies (6 weeks and 6 months, respectively) to detect an increased incidence of 
dementia. Remarkably, in the present study, melancholic features were 
independently associated with dementia. As previously mentioned, the study from 
DalForno et al (2005), failed to find an association of negative affective symptoms 
with dementia risk. However, the assessment of negative affective symptoms was 
OR (95% CI) p value
Surgical cohort 1 [reference]
Depressed non-melancholic 1.60 (0.80-3.22) 0.062
Depressed melancholic 6.42 (3.05-13.52) <0.001
Baseline Age, y
             <35 1 [reference]
             35-45 4.52 (1.45-14.10) 0.013
             >45 11.57 (4.08-32.76) <0.001
Baseline Education, y 0.87 (0.793-0.948) 0.002
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based on a CES-D subscale which does not match exactly international standard 
criteria for melancholic features. Most risk factors that have been studied in 
previous investigations, such as more severe disorder, greater severity of the 
episode, diagnosis of bipolar disorder, and the presence of psychotic and anxious 
symptoms, were associated with an increased risk for dementia in the univariate 
analysis, but their significance disappeared in the multivariate analysis. Since 
melancholic features tend to repeat across lifetime episodes (Coryell et al, 1994), 
are associated with a more severe course, occur in virtually all psychotic episodes, 
and happen more frequently in bipolar patients (Taylor and Fink, 2008), it is 
possible that the higher risk associated with those characteristics in previous 
studies could be at least partially mediated by melancholia. However, the role of 
bipolar disorder as a risk factor for dementia might have been underestimated 
because of the small number of bipolar patients in the present cohort. In any case, 
the present results strongly emphasize that analysis of melancholic features 
should be included in future studies.
There is a biological rational for the association between melancholic 
features and dementia, as an important body of evidence pinpoints the biological 
mechanisms underlying melancholia with cognitive impairment. Melancholia has 
been associated with hypothalmus-pituitary-adrenal (HPA) axis dysfunction 
(Brown, 2007; Parker et al, 2013), and hyper- and hypocortisolism characterize 
different subtypes of depression (Hasler el al, 2004). This HPA axis dysfunction 
has been widely studied in animal models and in human disorders (Lupien et al., 
1998; Finsterwald et al., 2013), and involves down regulation of glucocorticoid 
receptors and/or increased circulating glucocorticoids triggering a cascade of 
events that leads to cognitive impairment (McEwen & Margarinos, 1997; Lupien et 
al, 2008). Melancholia may particularly induce hippocampal damage (Lamers et 
al., 2012), and has been associated with cognitive decline (Withall et al., 2010; 
Sachs-Ericsson et al., 2013).
Present results also support a role of depression as an early risk factor for 
dementia. The depressed cohort included mainly patients with early onset 
depression, that is, with a young age both at baseline and, when available, at 
depression onset. The follow up time between the diagnosis of depression and of 
dementia was very long making it highly improbable that depression was a 
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manifestation of dementia. To confirm these impressions we performed an 
additional analysis on depression occurring before 45 years, and found they carry 
an 11-fold increase in the risk for dementia. Our results are in line with studies with 
a long follow up (Kessing, 1999; Broadly, 2003; Saczynski, 2010; Dotson, 2010; 
Barnes, 2012), with a low probability of misdiagnosing the depressive disorder. 
The few studies that specifically explored the differences between late and early 
onset depression and found a very small increased risk or no differences for EOD 
assessed depression retrospectively by a simple questioning (Green, 2003; 
Almeida, 2015), using CES-D or GDS (Lenoir, 2011; Almeida, 2015), or included 
subjects mainly with neurotic depression (Brommelhofl, 2009). The accuracy of 
depression diagnosis is probably lower when compared to the present study, and 
this could have led to the inclusion of less severe depressive disorders or, 
according to these results, non-melancholic patients.
The precise diagnosis of dementia was not possible to ascertain in about 
half the cases in the depressed cohort and in about 2/3 of the controls, a natural 
consequence of the way clinical information was collected. So it was not possible 
to identify if depressive subtypes are associated with a specific dementia. It has 
been suggested that depression is a risk factor for vascular dementia (VD) and for 
Alzheimer’s disease (AD) (Lenoir et al., 2011; Brunnström et al, 2013). The 
Honolulu-Asia aging study (Irie et al., 2008) found a higher risk for AD, however a 
higher load of cortical plaques and tangles was not associated with AD and 
depression (Wilson, 2003). Although in half of the cases the dementia cause could 
not be identified, the present results suggest that depression could be associated 
essentially with an increased risk of AD and not VD. 
This study has important strengths. It is one of longest longitudinal studies 
performed to evaluate the risk of dementia in depressed patients. Another 
strength, is that the diagnosis of depression was done with extreme detail and 
rigor. The vast majority of previous studies assessed depression with very simple 
instruments, such as CES-D, that cannot capture the complexity and 
heterogeneity of the depressive disorder. Still another strength is that important 
and different risk factors and confounders were assessed (such as personality, 
severity of the episode, or vascular risk factors), that have been seldom evaluated 
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together. If different subtypes of depression carry different risks for dementia, it 
would be elicited by a study with this design. 
4.1. Limitations
We should also note the limitations of this study. Melancholia definition is 
controversial, and DSM-5 definition has been challenged, on the grounds of the 
limitation of defining melancholia by reliance on symptoms (Parker & Paterson, 
2014). These authors propose the inclusion of biological markers related to HPA 
dysfunction. The inclusion of a biological biomarker would strengthen the findings 
of this study. Another limitation is the absence of a formal cognitive evaluation at 
baseline. However, dementia was excluded clinically, the mean age for the onset 
of the affective disorder was around 35 years old and the mean time to the event 
was more than 25 years, making it very unlikely that dementia was present at 
baseline. Losses to follow-up may limit the validity of longitudinal studies, 
particularly very long studies. Even though, the present study was able to include 
more than other similar studies (41% versus, for instance, 33% in Brodaty et al., 
2003), and, except for sex and age, no significant differences were found between 
subjects lost to follow up and those with a known outcome.
4.2. Conclusions
Depression is an early risk factor for dementia and a mere prodrome. 
Depression is a heterogeneous disorder, and it is possible that the frequency of 
melancholic features could explain the discrepancies found in the risk for 
depression as a whole in the different studies. Melancholic features of depression 
should be actively identified in the clinical setting, and DSM-5 criteria seem 
appropriate for this purpose. Due to a more favorable response to biological 
therapies, appropriate treatment of melancholia could decrease the risk for 
dementia.
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Escitalopram improves memory deficits induced by maternal separation in 
the rat
Frederico Simões do Couto, Vânia L. Batalha, Jorge S. Valadas, João Data-
Franco, Joaquim A. Ribeiro, Luísa V. Lopes
Abstract
Maternal separation (MS) induces depressive-like behavior and long-term changes 
in cognition in rats. Escitalopram is an antidepressant drug shown to reverse the 
depressive-like features caused by this stress model. However, it is not known if it 
can ameliorate the affected cognition. We now characterized the effect of 
escitalopram on hippocampal-dependent memory in rats submitted to the MS 
protocol. Male Wistar rats were assigned either to control (CTR) or maternal 
separated (MS) group. MS were separated from their dams between 2–14 
postnatal days (PND) for 180 min daily. Escitalopram was given in food pellets 
(0.34  g/kg/day first 2 weeks and 0.41  g/kg/day the subsequent period, average 
dose 25 mg/kg) from PND 43 onwards, during 1 month. Depressive behavior was 
assessed in the forced swimming test (FST), and memory performance in the 
Morris water maze (MWM). Escitalopram significantly improved the FST’s latency 
to despair in the MS group (n=6), but did not change the immobility time. All 
groups showed a significant learning effect in the MWM over time, but no 
differences have been found upon treatment (n=6). However, escitalopram 
treatment significantly increased the time spent on the platform quadrant in the 
probe trial in the MS group. We report here that chronic treatment with 
escitalopram is able to improve hippocampal dependent memory in a chronic 
stress model, while not changing the learning ability. Moreover, this is 
accompanied by an amelioration of the depressive like behavior. These results 
support the use of escitalopram to tackle underlying cognitive deficits caused by 
stress in early-life.
Keywords
Hippocampus; Stress; Morris water maze; Forced swimming test; Antidepressant 
 109
1. Introduction
Depression can induce long-term cognitive deficits or even be a risk factor for 
dementia (Ownby, Crocco et al. 2006). As there is no cure for most dementia 
conditions, strategies directed to the correction of risk factors amenable to 
prevention are extremely important. Depression can be effectively treated in the 
majority of cases, so it emerges as an important target for the prevention of 
cognitive deficits and dementia. Treatment of depression is complex and 
multidisciplinary, but usually implies drug treatment with antidepressants. The 
long-term effect of antidepressants on human cognition (and eventually on the 
prevention of dementia) has been poorly studied and clearly remains to be 
elucidated (Kessing, Sondergard et al. 2009).
Maternal separation (MS) is an animal model of depression that can be 
induced in rodents in a manner that is not easily amenable or ethically allowed to 
humans, and permitting a reliable evaluation of a number of internal and external 
factors (e.g. pharmacological interventions). This model is considered a validated 
model of depression and anxiety (Ladd, Huot et al. 2000, Kalueff and Tuohimaa 
2004). We and others have previously shown that rodents separated from their 
mothers, according to this protocol, have poorer cognitive performances on 
memory tasks, probably related to the effect of hypothalamus-pituitary-adrenal 
(HPA) axis disruption (Aisa, Tordera et al. 2007, Batalha, Pego et al. 2013) on the 
hippocampus (Huot, Plotsky et al. 2002, Aisa, Elizalde et al. 2009).
Escitalopram is a widely used and highly efficacious antidepressant 
belonging to the Selective Serotonin Reuptake Inhibitors (SSRI) class. 
Escitalopram and other antidepressants can reverse depressive-like behaviors in 
rodents in the Forced swimming test (FST) (El Khoury, Gruber et al. 2006). 
Although MS impacts in memory and learning and escitalopram is effective in 
reversing depressive – like behavior, it is not known if this antidepressant can 
improve cognitive deficits induced by MS.
To study the effect of antidepressant treatment on cognition in a rat model 
of depression, we have submitted rats to the MS protocol and then to widely used 
tests for depressive-like behavior – FST – and for memory – the Morris water 
maze (MWM). We hereby report that the escitalopram diminished FST latency-to-
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despair and improved the latency in the probe test of the MWM, in MS treated 
animals.
2. Material and methods
2.1. Animals
Pregnant Wistar rats were purchased (Harlan, Barcelona) on gestation days 12–
15 and were due in our animal facility. All animals were handled according to 
European Community guidelines and Local Law on animal care (1005/92). The 
animals were kept on an environment controlled for temperature (22±2  °C), 
humidity (55±10%) and light (12-h light/dark schedule; lights on at 7:00 a.m. and 
off at 7:00 p.m.).
Pups were randomly assigned to the MS protocol (n=12) or to animal facility 
rearing (CTR, n=12). Local Ethics Committee has approved the research protocol.
2.2. Maternal separation protocol
The MS protocol followed has been validated and described before (Lopes, 
Marvin-Guy et al. 2008, Batalha, Pego et al. 2013). At postnatal day (PND) 2, pups 
from four different litters, were collected together, gender assessed, and the pups 
were randomly distributed to foster dams (male/female ratio kept constant). Pups 
assigned to MS group were removed from their cages and dams at postnatal days 
(PND) 2–14 for 180  min daily. They were removed as a group from the nest, 
weighed and placed as a group in an isolation cage in an adjacent room kept at 
32.0±0.5 °C. At the end of the separation period pups were returned to their home 
cage and rolled in the soiled home cage bedding before reuniting them with the 
mother. CTR animals were only briefly manipulated to change the beddings in their 
cages twice/weekly. At day 21 the pup’s sex was determined and they were 
weaned and housed in individual cages. Only male rats were in included in the 
study. After weaning, pups were weighed weekly. No changes were found in 
weight due to MS protocol as observed before (Lopes, Marvin-Guy et al. 2008).
2.3. Treatment procedures
The majority of hippocampal granule neurons develops and extends their axons 
between PND 1 and 21 (Amaral and Dent 1981). We have initiated the treatment 
 111
in puberty, after the full development of hippocampal circuitry, period when 
interventions, either drugs or stimulation, are more effective in the hippocampus 
(El Khoury, Gruber et al. 2006).
Rats were left undisturbed from PND 15–42. On postnatal day 43, half of 
the rats from each group (MS and CTR) were assigned to dietary treatments with 
the antidepressant escitalopram (0.34 g/kg/day chow for the first 2 weeks; 0.41 g/
kg/day chow during the rest of the experiment) (CTR+AD; MS+AD), or were given 
placebo, admixed to food pellets (CTR; MS). The escitalopram doses were 
increased sequentially, according to the method developed by H. Lundbeck A/S 
(Copenhagen, Denmark) and tested by A. Mørk (El Khoury, Gruber et al. 2006), 
resembling the clinical situation where a range of escitalopram (or other 
antidepressants) is used to treat depressed patients. These doses have been 
shown effective in reverting depressive-like behaviors in the forced swimming test 
(FST) in the MS model of depression (El Khoury, Gruber et al. 2006). Lactamin AB, 
Sweden, prepared Denmark dietary escitalopram according to instructions from H. 
Lundbeck A/S, Denmark. The escitalopram intake was controlled by weighing the 
animals and monitoring the food intake per animal (weekly intake in Table 7). The 
pellets made available were weighed prior and post intake and dose estimated 
according to the weight of each animal. The administered escitalopram dose was 
approximately 25 mg/kg/day. Animals were kept on their respective diet until the 
end of the experiment on PND 73.
Table 7
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All animals have been handled for 5 days prior to behavioral testing.
2.4. Forced swimming test
Forced swimming test (FST) was used as a behavior equivalent of learned 
helplessness to test AD action (Porsolt, Le Pichon et al. 1977, Castagne, Moser et 
al. 2011). It was carried out on PND 64 and 65 (note that the escitalopram or 
vehicle diets were continued until PND 73). On the first of the two test days, all 
animals were gently placed individually in a vertical Plexiglas cylinder (height: 
45 cm, diameter: 19 cm) filled with 26 °C water at a depth that makes it impossible 
to reach the bottom with hind paws (28–30 cm). The animals were removed from 
the water after 10 min, and dried before being returned to their home cages. The 
water was changed after each session. On the second day, the animals were 
placed in the same cylinders for 5 min. This session was video-recorded and an 
observer blinded to the animals group subsequently scored the behavior of the 
animals. According to the criteria of Porsolt et al. (1977), the rat was judged to be 
immobile when it floated passively, making only small movements to keep its nose 
above the surface. This test measures the latency to immobility (or to despair, 
LTD) and the time spent swimming versus the time spent floating, i.e. the 
percentage of time spent immobile or immobility time (IT).
2.5. Morris water maze
The protocol used was the classical Morris water maze test, which is sensitive to 
hippocampal-dependent spatial learning and memory (Morris, Garrud et al. 1982). 
The protocol was used as before (Diogenes, Costenla et al. 2011). The maze 
consisted of a large circular tank (1.8 m in diameter, 0.6 m in height) of water 
(temperature, 25±1 °C) made opaque with the addition of a small amount of non-
toxic water-based black paint. An escape platform (10  cm in diameter) was 
submerged, non-visible, 1  cm below the water. Several visual cues for spatial 
reference were placed on the walls of the testing room. The performances were 
continuously monitored using an automated tracking system (Smart 2.5, PanLab, 
Barcelona). From PND 80 to 84, rats were given spatial acquisition training 
consisting of four trials/day for four consecutive days, in which the platform was 
placed at a fixed position in the center of one of the four quadrants of the tank 
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(platform Q, left, right and across). On each day the subjects were randomly 
placed in four different positions facing the wall, and never in the platform 
quadrant. The inter-trial interval was of at least 15 min, during which animals were 
towel-dried and placed under an infrared light to prevent hypothermia. The 
maximum trial duration was 60 s, after which animals were manually guided to the 
platform if they failed to locate it, and they were allowed to remain there for 20 s. 
At the fifth day a probe test was given in which the platform was removed and 
animals were allowed to swim freely for 60  s while recording the percentage of 
time spent on each quadrant. The latency to find the platform during acquisition 
and the percentage of time in the platform quadrant in probe test were used to 
evaluate hippocampal dependent memory.
2.6. Statistics
Statistical Package for Social Sciences v19 (SPSS) was used for the statistical 
treatment of data. After establishing homogeneity of variances, a two-way ANOVA 
was carried out for analyzing FST (LTD and IT) and time spent on quadrant after 
platform withdrawal (using MS (⁎) and AD (#) treatment as factors). Simple main 
effect analyses were performed, following significant interactions. Two-way ANOVA 
repeated measures was used for the learning curve of MWM. Statistical 
significance was accepted for P<0.05. Results are expressed as mean±standard 
error of mean (SEM).
3. Results
3.1. Forced swimming test
As observed in Fig. 4, latency-to-despair (LTD) was found to be decreased by MS 
(F(1,21)=8.373; ⁎P=0.010). LTD decreased from 71.8±7.71 in CTR to 38.8±6.25 s 
in MS animals. The treatment with escitalopram significantly improved LTD in MS
+AD animals to 65.6±7.35 s (F(1,20)=5.015; #P=0.038).
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Fig. 4. 
Escitalopram reverts MS-induced increase in latency-to-despair. Learned helplessness was 
assessed by the Porsolt forced swim test, in which latency to despair (LTD) and immobility time (IT) 
were evaluated. Results are the mean±SEM of 5–7 animals; (⁎) P=0.010 for MS effect and (#) 
P=0.038 for AD effect, calculated using two-way ANOVA, followed by simple main affect analysis.
Escitalopram also affected the immobility time (IT) in all groups of rats 
(F(1,23)=4.658; P=0.043) but no differences were found when comparing MS and 
CTR animals (F(1,23)=0.413; P=0.528).
3.2. Morris water maze
3.2.1. Learning curve
A significant learning effect throughout the 4 days was present, for all groups. The 
latency to reach the platform significantly improved from 49.4±2.16 s on day 1, to 
18.3±2.87 s on day 4 (F(3,66)=77.542; P<0.001). However, no significant changes 
between different groups were found (F(3,22)=0.575; P=0.456; Fig. 5a).
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Fig. 5. 
Escitalopram reverts MS-induced impairment in the probe trial. Hippocampal dependent memory 
performance was assessed by the Morris water maze test, in which acquisition (a) and retention (b) 
were evaluated. Results are the mean±SEM of 5–7 animals; (⁎) P<0.01 for MS effect and (#) 
P=0.004 for AD effect, calculated using two-way ANOVA, followed by simple main affect analysis.
3.2.2. Probe trial
The ability to recall spatial memory is tested following the learning period, by 
withdrawing the platform. MS animals displayed less time (23.5±7.98%) in the 
quadrant as compared to the CTR group (38.8±9.18%; Fig. 2b). However, 
escitalopram reverted this, improving the performance of MS animals 
(F(1.23)=10.764; ⁎P=0.004). The time spent on the platform quadrant increased to 
34.3±7.04% in MS AD group (Fig. 5b). Escitalopram alone seems to induce a 
slight decrease in time spent on platform for CTR animals, but this difference is not 
statistically significant.
The average speed and total swimming distance on probe trial were similar among 
groups (data not shown).
4. Discussion and conclusions
Maternal separation is known to induce deficits in memory related tasks that 
persist throughout adulthood. We hypothesized that treatment with an anti-
depressant, escitalopram, would be beneficial in reverting these deficits. We now 
report that chronic treatment with escitalopram for one-month given to adult 
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animals can improve hippocampal-dependent memory and latency to despair 
deficits induced by maternal separation (MS).
We found a significant effect of MS for acquisition, but not for learning. Due 
to the heterogeneity of MS protocols, animal strains (Huot, Plotsky et al. 2002, Hui, 
Zhang et al. 2011) or both (Anisman, Zaharia et al. 1998, Oitzl, Workel et al. 2000, 
Frisone, Frye et al. 2002, Zhu, Peng et al. 2011) it is difficult to find a pattern of the 
cognitive deficits induced by MS. In experimental conditions similar to ours, results 
are consistent, showing a difference in acquisition and not in learning, as if an 
effect in learning was more resistant to MS action than the acquisition (Aisa, 
Tordera et al. 2007, Aisa, Elizalde et al. 2009, Mello, Benetti et al. 2009). The 
mechanism for this MS induced cognitive deficits has been mostly related to the 
induction of HPA axis disruption, shown by elevated corticosteroids and 
corticosterone levels (Aisa, Tordera et al. 2007, Batalha, Pego et al. 2013), similar 
to what has been observed in depressed patients (Sachar, Hellman et al. 1970, 
Carroll, Feinberg et al. 1981). This state of hypercortisolism promotes the 
shrinkage and the degeneration of hippocampal neurons, both in humans 
(reviewed by Brown, Rush et al. 1999) and animals (Lupien and McEwen 1997, 
Batalha, Pego et al. 2013). 
The main goal of the present study was to evaluate if an antidepressant 
could decrease these deficits. Antidepressants have several neuroprotective 
effects in the hippocampus of rats displaying depressive-like behaviors, either 
neurogenic (Malberg, Eisch et al. 2000) or neuroremodeling (Bessa, Ferreira et al. 
2009). However, the impact of these putatively benefic changes is not known, as a 
direct effect of escitalopram has never been shown before on a memory task in 
this model of depression.
All groups showed a significant learning effect in the MWM over the days, 
but no differences have been found upon treatment. However, escitalopram 
treatment significantly improved the time spent on the platform quadrant in the 
probe trial in the MS group. The mechanisms underlying the antidepressant-
related cognitive effects, reside either on a direct action on hippocampus, by 
stimulation of the neuronal remodeling (Bessa, Ferreira et al. 2009) or through 
restoring the normal physiology of the HPA axis (Manthey, Leeds et al. 2011).
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MS is an appealing model of depression because it mimics the mother–
infant interaction, which is a key factor for developing psychiatric disorders in the 
future (Freud 1995, Heim and Nemeroff 2001). MS does not induce very strong 
depressive-like behavior, when compared to some genetically selected strains, 
such as the “depressed” flinders sensitive line (El Khoury, Gruber et al. 2006). 
However, it is a more pertinent model when studying susceptibility to early-life 
events and more related to human conditions. We now report that, in assessing 
depression, statistical significance was only reached when measuring the effect of 
escitalopram in latency-to-despair (LTD), but not in immobility time (IT). IT use has 
been criticized for its low sensitivity in detecting antidepressant actions of SSRI 
and for having a positive response to psychostimulants (Borsini and Meli 1988, 
Rupniak 2003). Adding the LTD parameter can improve the sensibility to detect AD 
actions, especially for tricyclic antidepressants (TCA), and LTD is not affected by 
psychostimulants (Castagne, Porsolt et al. 2009), excluding changes due to 
general motor stimulation. Current results reinforce the advantage of assessing 
LTD to improve sensibility to SSRI antidepressant activity in rats.
Escitalopram alone seemed to induce a slight decrease in the probe test 
time in the MWM, for CTR rats. This did not reach statistical significance and we 
do not attribute it to any motor effect since we have used the same dose range as 
previous studies that found no impact in specific motor parameters (Mello, Benetti 
et al. 2009). An explanation for the findings is difficult, because its use in healthy 
subjects is not ethically allowed. However, escitalopram has some, although 
moderate, anticholinergic properties, and a tendency to cause “cognitive” flattening 
(Stahl 2009). This could indicate that its beneficial action is limited to animals with 
underlying deficits. On the other hand, it reinforces the idea that care must be 
taken and confirms the need to use healthy controls treated with antidepressants 
in such paradigms. The use of p.o. antidepressant could strengthen the findings, 
as these methodological approaches can be considered closer to human reality. 
However, other variables such as genetics and individual susceptibility to dosage 
must be accounted for. The present data focused on a specific class of 
antidepressant, the SSRIs. Whether the observed effects are due to a general 
antidepressant effect or instead to a specific mechanism of action of this class 
would be interesting to evaluate, testing distinct classes of drugs.
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The present results may support a potential effective role of 
antidepressants, at least of the SSRI class, in the prevention of dementia 
associated to depression, in patients.
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E. Discussion
1. Is depression a risk factor for dementia?
Present results show that a subject with depression has roughly a 2.5 times 
higher risk of having dementia when compared to subjects without depression, 
controlled for important variables known to influence the risk. This is a slightly 
higher value than most studies, despite a magnitude similar to the three major 
meta-analyzes carried out earlier.
Most of the case-control studies found a lower risk for dementia in 
depressed patients than the present study. As previously referred, case-control 
design relies on a retrospective diagnosis of depression, that tend to be 
underestimated even in non-demented subjects (Schulz and Grimes 2002). The 
demented group probably did not accurately report the presence of depression, 
blurring the differences between groups. Diagnostic criteria for depression are not 
clear in some studies, and the inclusion of minor forms of depression could have 
underestimated the risk.
Some longitudinal studies also reported lower risk magnitudes (Chen, 
Ganguli et al. 1999) for dementia, but the diagnosis of depression in most of these 
studies was based on CES-D. If the diagnosis of depression was based on more 
clinical criteria (such as ICD or DSM) (Kessing, Olsen et al. 1999, Brodaty, 
Luscombe et al. 2003, Kessing and Nilsson 2003), the risk magnitude is higher. 
Another explanation is the severity of depression. Danish studies relied on 
inpatients, usually with more severe depressive disorders and, on the other hand, 
usually with a more accurate diagnosis. In one Danish study (Kessing, Olsen et al. 
1999), a much higher risk was found (more than 10-fold), but dementia was only 
considered in the subset of patients readmitted to a psychiatric ward.
We have reasons to believe that the present study has a strong design. It is 
a controlled, longitudinal study with a very long follow up - one of the longest the 
literature. It is hard to imagine a higher accuracy of the depression diagnosis, as 
the basis of Paes de Sousa cohort was the diagnosis of depression. We tried to 
use the most recent clinical and research criteria for the diagnosis of dementia and 
dementia diseases.
In conclusion, present results are in line with studies with a stronger design 
and a better accuracy of depression diagnosis, yielding similar risk magnitudes.
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2. What is the nature of the risk?
a) Is depression a prodrome or an early risk factor?
The subjects with early onset depression are also at an increased risk for 
dementia [OR 6.42 (95% C.I. 3.05-13.52); p<0.001] when compared to the surgical 
cohort. Moreover, the cohort included mainly patients with early onset depression, 
that is, with a young age both at baseline (mean 41.8±11.6 years) and, when 
available, at depression onset (28.4±10.2 and 34.8±10.2, respectively for 
demented and non-demented), making it highly improbable that depression was a 
manifestation of dementia. The time to dementia or to the end of the study was 
also very long (mean 25.7±7.2). Although no formal cognitive evaluation was 
performed at baseline, it was highly improbable that dementia was the cause for 
the depressive disorder. Present study supports the hypothesis of depression as 
an early risk factor for dementia.
However, several case-control and cohort studies found an increased risk 
only for late onset depression, eventually supporting the prodrome hypothesis. 
Two case-control studies found a decrease in the risk as the time between the two 
diagnosis increases (Green, Cupples et al. 2003, Brommelhoff, Gatz et al. 2009). 
Green (2003) diagnosed depression by direct questioning, and a recall bias cannot 
be ruled out. Brommelhoff study (2009) had higher standards for the diagnosis of 
depression (registry based), but only for some subjects. Self report by direct 
questioning was also enough to be considered depressed, so the inclusion of 
milder or doubtful forms of depression could have happened.
Although cohort studies with a short follow up seem to support depression 
as a prodrome of dementia, they do not exclude depression as an early risk factor 
(Devanand, Sano et al. 1996, Wilson, Schneider et al. 2003, Geerlings, den Heijer 
et al. 2008). Geerlings et al (2008) found an increased risk in early onset 
depression, but this is limited by the accuracy of depression diagnosis. Some 
cohort studies with a long FU time also support the prodrome explanation (Dal 
Forno, Palermo et al. 2005, Barnes, Yaffe et al. 2012), but both studies essentially 
rely on the self report of depression. Again, our study is in line with studies with a 
longer follow up, with a careful diagnosis of depression (Kessing, Olsen et al. 
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1999, Brodaty, Luscombe et al. 2003, Kessing and Nilsson 2003). Besides being 
amongst the studies with the longest FU, the present study was very careful on the 
accuracy of the diagnosis. We believe it provides strong evidence for considering 
depression as an early risk factor for dementia, and not merely a prodrome.
b) What is the role of different depression subtypes?
One of the main findings of the present work is that depression with 
melancholic features is an independent risk factor for dementia. When compared 
to depression without melancholic features, patients with melancholic features 
have 3.6 more risk per year of suffering from dementia (HR=3.64; 95% C.I. 
1.78-11.26).
All the other depression characteristics evaluated (age of onset of 
depression, bipolar disorder, psychotic features, anxiety symptoms, chronicity of 
the disorder, severity of the episode, personality, and hospitalization) seem not to 
be predictors of dementia in depressed patients. Although some of these 
characteristics were significant in univariate analysis, their significance 
disappeared in the multivariate model. This could indicate that the risk of causing 
dementia is driven through melancholic features.
To our knowledge this is the first study addressing melancholia as a risk 
factor for dementia. DalForno et al (2005) failed to find an association of negative 
affective symptoms with dementia risk. However, the assessment of negative 
affective symptoms was based on a CES-D subscale, which does not match 
exactly the international standard criteria for melancholic features. Melancholia 
has also been associated with persistent cognitive impairment in euthymic patients 
(Lin et al, 2014; Roca et al, 2015), but not with dementia. It is possible that, in both 
studies, the FU time had been too short (6 weeks and 6 months, respectively) to 
detect an increased incidence of dementia.
Melancholic features tend to be more frequent in bipolar disorder (Mitchell 
and Malhi 2004), to confer more severity to the episodes, to occur concomitantly 
with psychotic symptoms, and to repeat across episodes (Parker, Fink et al. 2010). 
Eventually, the increased risk found in several studies for an increased number or 
severity of episodes (Kessing and Andersen 2004, Dotson, Beydoun et al. 2010, 
Saczynski, Beiser et al. 2010) was due to melancholia. Although the same 
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explanation could be given for bipolar disorder - the risk for dementia is driven 
through melancholic features, our study has a relatively low number of bipolar 
patients, and could be underpowered to show a difference.
Interestingly, a relatively strong biological rational existis for the association. 
As mentioned previously, melancholia is associated with several biological 
changes, the most consistent is HPA overactivity (Parker, Fink et al. 2010), with 
increased cortisol levels. The involvement of cortisol in the stress response 
(McEwen, Weiss et al. 1968), and its actions in the hippocampus have been fairly 
studied. Chronic stress, maternal separation, and chronic administration of 
corticosterone (the equivalent of cortisol in rats) produces hippocampal dendritic 
retraction and reduces neuropil volume in several hippocampal areas (Sousa, 
Lukoyanov et al. 2000, Ortiz, McLaughlin et al. 2013, Sousa, Vital et al. 2014). In 
humans suffering from Cushing syndrome, the hippocampus is smaller (Starkman, 
Gebarski et al. 1992), and the same is true in a classic stress disorder, the post-
traumatic stress disorder patients (Bremner, Randall et al. 1995).However, the 
relation between childhood trauma, HPA dysfunction, and depression is not totally 
clear (Suzuki, Poon et al. 2014). As far as we know, there is no direct evidence of 
hippocampal atrophy specifically in melancholic patients, but the evidences, 
including the present study, point to the same direction.
c) What is the the role of different dementia disorders
AD was the most prevalent cause of dementia in both cohorts, although it 
seems to be much more prevalent in the depressed cohort (57% vs 20%). 
However, in a large number of subjects dementia causes were not determined, a 
natural consequence of the rigorous criteria applied. A direct comparative analysis 
could not be performed.
Anyway, the very few Portuguese epidemiological data published (Nunes, 
Silva et al. 2010) found roughly the same prevalence for AD and VD (around 
40%), and thus lower for AD than our depressed cohort. As previously mentioned, 
this study has several limitations regarding VD diagnosis. 
A higher risk for AD in depressed patients has been found in several case-
control and cohort studies, but not in others  (Table 2. and 3.), and the same is true 
for VD. The few studies that examined depression as a risk factor for different 
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dementia causes (comparing different risks) used CES-D or SCL-90 to diagnose 
depression, with the limitations discussed before. Two cohort studies (Kohler, van 
Boxtel et al. 2011, Lenoir, Dufouil et al. 2011) followed elderly community 
individuals free of dementia for 9 and 4 years respectively, and found that a 
depressed mood at baseline predicted the occurrence of VD, but not AD. Another 
study, in which around 2000 men with a mean age of 76 years were followed for 5 
years, found exactly the opposite (Irie, Masaki et al. 2008). In a recent analysis of 
the Religious Order study (Wilson, Capuano et al. 2014) it has been found that late 
life depression is not associated with the neuropathological findings of AD or VD. 
The high level of AD patients in Paes de Sousa depressed cohort does not 
support the hypothesis of a higher risk of VD in depressed patients. However, the 
limitations referred do not allow the conclusion that the risk is higher for AD.
3. What is the role of antidepressants?
We have shown that rats submitted to a MS protocol have cognitive 
changes that are reversed by longterm treatment with escitalopram, an 
antidepressant from the SSRI class. 
Our results are in line with the neuroprotective action of antidepressants 
shown by the several studies referred above (Pehrson, Leiser et al. 2015), but we 
have shown that antidepressants also improve cognition in rats submitted to this 
MS protocol. If rats submitted to a MS protocol have biological changes similar to 
those found in melancholic patients, if these changes induce cognitive deficits, and 
if cognitive improvement is observed with escitalopram, this supports a protective 
role of escitalopram, and eventually of other antidepressants, in dementia 
prevention.
After the publication of our work, a few papers replicated these findings with 
citalopram (Eriksson, Holst et al. 2012), venlafaxine (Martisova, Aisa et al. 2013), 
and fluoxetine (LeGates, Altimus et al. 2012). Generally, short-term treatment with 
antidepressants was not shown to reverse cognitive deficits (Pehrson, Leiser et al. 
2015). A few papers also reported a role of escitalopram in the pathological 
mechanisms of AD. Escitalopram decreases tau phosphorylation in a cell line 
(Ren, Wang et al. 2015) and a similar action of citalopram was found in rats, 
improving spatial memory (Ren, Gong et al. 2015). A clinical study describes a 
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decreased new Aβ production in patients treated with citalopram, using a 
radiolabelled leucine isotope do detect new amyloid production (Sheline, West et 
al. 2014). Amyloid clearance difference was not statistically significant.
The MS protocol is quite interesting for several reasons. First, it is an 
empirically appealing protocol, especially for psychiatrists, because it somehow 
mimics the childhood trauma, a known risk factor for depression later in life (Heim 
and Nemeroff 2001, Heim, Young et al. 2009). Second, rats submitted to this 
protocol show permanent over activation of HPA axis, expressed by high 
corticosterone levels, loss of cortisol circadian rhythm, and blunted 
dexamethasone suppression (Nishi, Horii-Hayashi et al. 2014). Similar biological 
changes are found in melancholic patients. Third, rats submitted to this protocol 
show hippocampal dendritic retraction (Chocyk, Bobula et al. 2013), long term 
potentiation (LTP) impairment, and longterm cognitive impairment, essentially 
memory and learning changes (Sousa, Vital et al. 2014).
One limitation is that the cognitive deficits found in these rats could not be 
considered dementia. However, rats do not spontaneously produce amyloid, and 
the concept of dementia (impairment of daily life activities) can hardly be applied to 
rats. Even more importantly, our lab showed that these deficits persist in old 
animals (Sousa, Vital et al. 2014).
The other limitation is related to the use of animal models in psychiatric 
disorders. With few exemptions, rats are different from humans, and the direct 
transposition of animal data to humans must be done cautiously. Psychiatric 
symptoms such as guilt, shame, delusions or hallucinations are extremely difficult 
to reproduce in animals. However, the behavioral manifestations of despair or of 
anhedonia, or more cognitive functions, such memory or attention, were 
considered reasonably mimicked in rodents (Kalueff and Murphy 2007).
However, we acknowledge that the ideal study to clarify the role of 
antidepressants in the modulation of dementia risk in depressed patients would be 
a clinical trial. Such trial should have a long follow up, comparing depressed 
patients treated and non treated with antidepressants, and having dementia as the 
outcome. This clearly would be an extremely expensive trial, and ethically hard to 
justify.
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Anyway some papers published recently have addressed this issue. An 
analysis of the Religious Order Study found that antidepressants did not influence 
the development of AD, VD or LBD neuropathology (Wilson, 2015).  However, this 
study only included late life depression, and if they are to have an effect, 
antidepressants should have been taken longer. Very recently, a retrospective 
study involving 3688 depressed patients (Wang, Gao et al. 2015), found that 
patients on antidepressants have an increased risk for dementia. This increased 
risk is found even when compared to patients with severe depression not on 
antidepressants. The amount, and duration, of antidepressants taken seems to be 
crucial in the development of their action, and the study had not taken this into 
account.
We believe that our work provided a rational for a putative effect of 
antidepressants in preventing dementia in depressed people. 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F. Conclusion
The results presented seem to support a role of depression as a risk factor 
for dementia, and add novel information regarding the nature of this risk. 
According to these results, depression is not merely a prodrome of dementia, but 
an early risk factor, and melancholia is the only subtype associated with an 
increased risk. Also, they point to a neuroprotective action of escitalopram in 
depression, eventually leading to dementia prevention.
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Background: Depression has been reported to increase the risk of subsequently developing dementia, but
the nature of this relation remains to be elucidated. Depression can be a prodrome/manifestation of
dementia or an early risk factor, and the effect may differ according to depression subtypes. Our aim was
to study the association between early-onset depression and different depression subtypes, and the later
occurrence of dementia.
Methods: We conducted a cohort study including 322 subjects with depression, recruited between 1977
and 1984. A comparison cohort (non-exposed) was recruited retrospectively, to include 322 subjects
admitted at the same hospital for routine surgery (appendicectomy or cholecystectomy), at the same
period as the depressed cohort. Subjects were contacted again between 2009 and 2014, to assess their
dementia status. We computed the risk for dementia in subjects with early onset depression and
quantiﬁed the association between different depression subtypes (namely melancholic, anxious, and
psychotic) and dementia.
Results: The odds of dementia were increased by 2.90 times (95% C.I. 1.61–5.21; po0.0001) for the
depressed cohort when compared to the surgical cohort. When the analysis was restricted to patients
younger than 45 years old at baseline, the odds for dementia in the depressed cohort were also sig-
niﬁcantly higher when compared to the surgical cohort (8.53; 95% C.I. 2.40–30.16). In the multivariate
Cox analysis, subjects having depression with melancholic features had an increased risk for developing
dementia compared to those without melancholic features (HR¼3.64; 95% C.I. 1.78–11.26; p¼0.025).
Limitations: About 59% of the participants with depression and 53% of those non-exposed were lost
during follow up. The inclusion of biological biomarkers would strengthen the results. The sample in-
cluded a low number of bipolar patients.
Conclusions: These results support depression as an early risk factor for dementia. Depression with
melancholic features was found as an important risk factor for dementia, playing a main role in the
relation between these disorders.
& 2016 Elsevier B.V. All rights reserved.
1. Introduction
As most dementing conditions are irreversible, and the avail-
able therapies have limited beneﬁcial effects, primary prevention
of cognitive decline is of paramount importance (Ritchie et al.,
2010; Norton et al., 2014). Among the several risk factors so far
identiﬁed, depression emerges as a potentially important target
(Reitz et al., 2011), because is amenable to prevention, has a high
prevalence, and can be diagnosed inexpensively and treated ef-
fectively (Kupfer et al., 2012; Malhi et al., 2015).
Depression has been found to be a risk factor for dementia or
Alzheimer's dementia (AD) in several case-control (Cooper and
Holmes, 1998; Green et al., 2003) and cohort studies (DalForno
et al., 2005; Kessing and Nilsson, 2003; Saczynski et al., 2010; Irie
et al., 2008; Dotson et al., 2010; Byers and Yaffe, 2011), but not all
(Chen et al., 1999, 2008; Gatz et al., 2005; Brommelhoff et al.,
2009). The meta-analyses and reviews performed have conﬁrmed
this association in general, ﬁnding that depression approximately
doubles the risk for dementia (Jorm, 2001; Ownby et al., 2006;
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Silva et al., 2013).
However, the nature of this relation remains poorly under-
stood. Two unsolved issues have been repeatedly raised (Byers and
Yaffe, 2011; Kessing, 2012). The ﬁrst is that depression, especially if
occurring after 60 years old (called late onset depression) or next
to the diagnosis of dementia, can be a prodrome/manifestation of a
dementing disorder, instead of an early risk factor. Depressive
symptoms are quite common in dementia, and depressive symp-
toms may arise from the anatomic lesions that are part of the
neuropathological changes of dementing disorders (Boland, 2000).
Case-control studies that do not take in account the time between
dementia and depression diagnosis, and cohort studies with a
short follow up, may not be able to distinguish between these two
situations. The few studies that speciﬁcally compared late-onset
depression with early-onset depression found discrepant results
(Green et al., 2003; Geerlings et al., 2008; Brommelhoff et al.,
2009; Lenoir et al., 2011; Almeida et al., 2016).
The second issue is the subtype of depression. The hetero-
geneity of depression has seldom been taken into account. A more
severe disorder (expressed by higher frequency, duration, and
severity of the depressive episodes) has been inconsistently as-
sociated with a higher risk for dementia (Kessing and Andersen,
2004; Geerlings et al., 2008; Kessing, 2012; Silva et al., 2013). Bi-
polar disorder has also been associated with a higher risk of de-
mentia. In the review and meta-analysis by Silva et al. (2013) the
majority of studies conﬁrmed the association in accordance with
subsequent published studies. Brodaty et al. (2003) explored the
role of comorbid anxiety in depression on the risk for dementia
and found no inﬂuence. On the other hand, the use of benzodia-
zepines has been reported to carry a higher risk (Billioti de Gage
et al., 2012). Psychotic symptoms have been associated with a
higher risk for cognitive deﬁcits only in bipolar patients (Martínez-
Arán et al., 2004). Few studies looked at the risk for dementia in
DSM5 or ICD10 deﬁned depression subtypes. DalForno et al.
(2005), in a community based study, performed an additional risk
analysis ﬁnding that a Center for Epidemiologic Study–Depression
(CES-D) sub-scale based on a cluster of negative affective symp-
toms, related to melancholic features, did not inﬂuence the global
risk for dementia. Different biological mechanisms underlying
these different depressive conditions can carry different risks for
dementia. Melancholic features, and to a lesser extent psychotic
symptoms, have been associated with more consistent biological
abnormalities and response to treatment (Brown, 2007; Parker
et al., 2013) when compared to their absence.
These unsolved issues – prodrome versus early risk factor and
the heterogeneity of depression – regarding the risk for dementia
in depressed patients, encouraged us to perform the current study.
The objectives were to assess the association between early-onset
depression and the long-term risk for dementia, and to analyze the
risk for dementia of different depression subtypes, controlling for
well known risk factors for dementia.
2. Methodology
2.1. Study design
This study is based on two cohorts followed in average 25 years
for development of dementia. The exposed cohort (depression
cohort) comprised 325 patients from the Hospital de Santa Maria,
Lisbon, with the clinical diagnosis of depression, recruited be-
tween 1977 and 1984 in a taxonomic cluster analysis study of
depression (Paes de Sousa et al., 1980).
A surgical comparison cohort (non-exposed) was recruited
retrospectively, to include 325 subjects who were consecutively
admitted to Hospital de Santa Maria, Lisbon, for routine surgery
(appendicectomy or cholecystectomy) at the same period as the
depressed cohort.
Participants were re-evaluated between 2009 and 2014, to es-
tablish the outcome - dementia status.
2.2. Baseline assessment
Data on demography, clinical history, and personal and family
history as part of routine clinical ﬁles were collected for both co-
horts. For the depressed cohort a comprehensive psychiatric and
psychological evaluation was performed.
2.2.1. Evaluations
2.2.1.1. Association for methodology and documentation in psychiatry
system (AMDP). The AMDP-System was created in Nuremberg in
1960 and has been widely used in Europe in 1970–1980. The
Psychopathology Scale contains 100 psychopathology items, in-
cluding symptoms and other clinical features, derived from classic
psychopathology studies from Jaspers, Bleuler, Schneider, and
others. It renders a very detailed and standardized evaluation,
including affective, behavioral, cognitive, psychotic, sensory, and
social dimensions of psychopathology (Busch et al., 1980; Paes de
Sousa et al., 1980).
Each symptom is scored for severity (0–3: absent, mild, mod-
erate, severe).
This evaluation notably allowed the classiﬁcation of depression
by virtually any diagnostic system and has been used for diag-
nostic or reclassiﬁcation purposes with other diagnostic systems,
such as the DSM IV (Salvatore et al., 2007; Seemüller et al., 2008).
2.2.1.2. Eysenck personality questionnaire (EPQ). This questionnaire
(Eysenck and Eysenck, 1975) includes 83 items (full version), al-
lowing the evaluation of the three basic personality dimensions,
according to Eysenck's personality theory: extroversion, neuroti-
cism and psychoticism. Only the extroversion and neuroticism
dimensions were analyzed in this study. The subject responds yes
or no, and a positive answer is scored 1. The ﬁnal result is the sum
of the points in each scale (0–23 for extroversion and 0–23 for
neuroticism).
The neuroticism dimension assesses emotional stability versus
instability and identiﬁes individuals prone to psychological dis-
tress. Low scores indicate a trend to more relaxed, unemotional,
and self-satisﬁed subjects. The extraversion dimension measures
interpersonal interaction, activity level, need for stimulation, and
capacity for joy. The subjects with a low score tend to be more
reserved, sober, task-oriented, and quiet.
A low extroversion (a score lower then median) and high
neuroticism group (a score higher than median) of subjects was
created, as these subjects were previously found to be at a higher
risk for dementia (Wang et al., 2009).
2.2.1.3. Clinical global impression (CGI)). Clinical global impression
– severity (CGI S; Guy, 1976) is 7-point scale to evaluate the current
severity of the patient's illness, according to the clinician's total
past experience, ranging from 1 (not at all ill) to 7 (extremely ill).
2.2.2. Diagnosis of depression
Using AMDP symptoms at baseline, DSM 5 diagnostic criteria
for Persistent Depressive Disorder (dysthymia), Major Depressive
Disorder (MDD), melancholic and psychotic features were applied.
Through baseline chart review, subjects were considered to have
bipolar disorder if they met DSM 5 criteria for bipolar disorder.
The speciﬁer of anxious distress could not be deﬁned by AMDP
as only two anxious symptoms (“psychic anxiety” and “somatic
anxiety”) are present in the scale. A numerical variable “anxiety
symptoms” was created adding both scores. Chronic disease was
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deﬁned if MDD symptoms were present continuously for more
than two years.
2.3. Follow-up
2.3.1. Follow up procedures
The Hospital de Santa Maria, the Institute of Notaries and Re-
cords, and the National Health Service databases were contacted
to get the subjects' address and next of kin, phone number, vital
status, General Practitioner (GP) and other relevant doctors'
names. This search allowed to ﬁnd and contact subjects, or next of
kin if the subject was dead.
2.3.1.1. Depressed cohort. Based on the information gathered dur-
ing the follow-up, the initial diagnosis was reviewed and 3 pa-
tients were excluded from the depressed cohort because the di-
agnosis of depression was found wrong, namely one had schizo-
phrenia, another schizoaffective disorder and the third a brain
tumor. So, the depressed cohort recruited 322 subjects (Fig. 1).
It was not possible to ascertain the vital status of 123 subjects
(no records found, data illegible or too many records found for a
given name).
In the remaining 199 (61.2%), additional information was
sought to establish a diagnosis of dementia. In the 75 subjects
found to be dead, the next of kin was contacted to collect demo-
graphic information and to apply the Dementia Questionnaire
(DQ). GP records, psychiatrist records, neurologist records, hospital
clinical ﬁles, death certiﬁcates and nursing home records were
reviewed to collect information regarding dementia diagnosis. In
43 subjects no contact with next of kin was possible or the clinical
information in clinical ﬁles was not enough to establish or exclude
the diagnosis of dementia.
The 124 alive subjects were contacted ﬁrst by mail, presenting
the study and indicating that a later phone contact would be done.
Then, a clinical interview and a neuropsychological assessment
were offered. If a subject was living far away, too ill to be sub-
mitted to neuropsychological assessment, or not willing to come
for the clinical/neuropsychological assessment, telephone inter-
views (Telephone Interview for Cognitive Status (TICS) and/or DQ)
to evaluate the cognitive status were applied. Patient's GPs, or
other relevant doctors were contacted, and hospital records re-
viewed when appropriate. No contact at all was possible and no
clinical records were found in 7 subjects, and a total of 16 subjects
refused to participate in the study. In 133 (41.3%) subjects the
outcome could be established (Fig. 1).
Initial sample  
322 exposed; 322 non-exposed 
NHS and hospital databases 
Next of a kin contact
Without 
FU information 
Exposed 43 
Non-exposed 24 
No records 
Exposed 123 
Non-exposed 128
FU cohort  
Exposed 133 
Non-exposed 144
Vital status
Alive (Exposed 124; Non-exposed 134)
Clinical interview 
Neuropsychological Assessment 
Dementia Questionnaire/Telephone Interview for Care-
giver Status 
General Practitioner records 
Other doctors files 
Hospital clinical files
Dead (Exposed 75; Non-exposed 60)
Dementia Questionnaire 
General Practitioner records 
Other doctors files 
Hospital clinical files 
Death certificates 
Nursing home records
With 
FU information 
Exposed 32 
Non-exposed 36
With 
FU information 
Exposed 101 
Non-exposed 108
Without 
FU information 
Exposed 7 
Non-exposed 21
Refused 
Exposed 16 
Non-exposed 5
Fig. 1. Diagram displaying the ﬂow of subjects cases in the study. NHS National Health Service, FU Follow up. In 278 (43.2%) cohort subjects the diagnosis of dementia could
be established or excluded. The rates of follow up in relation to death are 42.7% in the exposed group and 60.0% in the non-exposed group.
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2.3.1.2. Surgical cohort. For the non-exposed cohort, we followed
the methodology of a similar study (Brodaty et al., 2003). The ﬁrst
325 subjects who were admitted for routine appendectomy or
cholecystectomy at the same period as cases, and who could be
matched to cases for age (72 years) and sex were identiﬁed from
surgical lists (Fig. 1). For each depressed subject, the ﬁrst identiﬁed
matched control in the surgical list was assessed for his/her elig-
ibility status. A subject was considered eligible if a mood disorder
was not present prior to or at the time of index surgical hospita-
lization. This assessment was made by the review of the subject
clinical ﬁles at the index hospitalization, and a diagnosis of a mood
disorder and prescription of antidepressants, mood stabilizers or
antipsychotics were considered exclusion criteria. A further as-
sessment was performed at follow up by direct questioning. Three
subjects were excluded from the surgical cohort, because they
were found to be depressed (n¼2) or to have a diagnosis of bipolar
disorder (n¼1) at inclusion time. The surgical (non-exposed) co-
hort included 322 subjects.
Identical procedures were taken to assess their dementia status
as with the depressed participants. It was possible to ascertain the
vital status of 128 subjects (60.2%). Among these, 5 refused to
participate in the study, and in 45 the diagnosis of dementia could
be not conﬁrmed or excluded. The diagnosis of dementia could be
established or excluded in 144 subjects (44,3%).
2.3.2. Follow up assessment (evaluations performed in 2009–2014)
2.3.2.1. Neuropsychological assessment. A comprehensive evalua-
tion was performed, either at patients' home or in the hospital, by
experienced neuropsychologists. The evaluation included (1) Bat-
tery of Lisbon for the Assessment of Dementia (BLAD; Garcia,
1984), (2) Trail Making Test – parts A and B (TMT; Reitan, 1958),
(3) Toulouse-Pie ́ron Test (TP; Toulouse and Pie ́ron, 1986; Men-
delsohn, 2000), and (4) California Verbal Learning Test (CVLT; Delis
et al., 1987; Ribeiro et al., 2007).
2.3.2.2. Other assessments
1) Telephone Interview for Cognitive Status (TICS)
This instrument (Brandt et al., 1988; Madureira et al., 2006) was
initially developed for the assessment of AD patients unwilling
or unable to return for follow-up. It gathers information on the
domains of orientation, concentration, short-term memory,
mathematical skills, praxis and language. It was proven to be
sensitive and speciﬁc, and to have high test–retest reliability.
The cutoff used for dementia was less than 26.
2) Dementia Questionnaire (DQ)
The Dementia Questionnaire (Silverman et al., 1986) is applied
by telephone to caregivers of patients with dementia allowing
to quickly diagnose dementia in patients by the DSM IIIR
criteria, and in some cases even to suggest the dementia
subtype. The DQ can also be applied to care givers of already
dead patients with dementia. A validated version including the
age of onset of dementia and dementia subtype was used
(Teixeira et al., 2011).
3) Vascular risk factors assessment
Subjects with a previous diagnosis of hypertension, diabetes,
dyslipidemia, ischemic heart disease or cerebrovascular disease
were considered to have vascular risk factors.
2.3.3. Diagnosis of dementia
Dementia was diagnosed at a case conference, including a
psychiatrist (F.S.doC.), a neurologist (A.deM.) and a neu-
ropsychologist (C.C.), all experienced in dementia. Cases were
determined based on the best available information, using DSM-5
criteria for Major Neurocognitive Disorder (dementia) (American
Psychiatric Association, 2013).
Clinical and neuropsychological assessment information were
reviewed. If a subject was dead or did not attend the formal eva-
luation, case conference reviewed all the available evidence. In
these cases, the diagnosis of dementia was based on at least two of
the following: TICS score of 26 or less; DQ yielded a diagnosis of
dementia; GPs records with a diagnosis of dementia; a diagnosis of
dementia performed by either a neurologist or a psychiatrist;
hospital records of dementia; death certiﬁcate with a diagnosis of
dementia; retrospective case audit to meet DSM-5 dementia cri-
teria; diagnosis of dementia recorded in nursing-home notes. If a
diagnosis of dementia was established, reference to a Dementia
Clinics was offered to the subject, to undergo the standard of care
for evaluation and treatment of dementia.
The type of dementia was determined in the case conference
referred above, using all the available information. The criteria for
the diagnosis of the most common types of dementia were used:
probable Alzheimer's disease according to NINCDS-ADRDA criteria
(McKhann et al., 2011), probable vascular dementia according to
NINDS-AIREN criteria (Roman et al., 1993), probable dementia
with Lewy bodies (DLB) according to the criteria proposed by
McKeith et al. (2005), and behavioral variant of frontotemporal
dementia (FTD) according to the criteria of the International Be-
havioral Variant FTD Criteria Consortium (Rascovsky et al., 2011). If
none of these criteria was met, or no sufﬁcient information could
be gathered, the diagnosis made was dementia non-otherwise
speciﬁed (NOS). Date of onset of dementia was determined during
the clinical interview, by DQ, or chart review.
2.4. Statistical analysis
IBM SPSS Statistics for Windows, version 19.0 (IBM Corp, Ar-
monk, NY, 2010) and Stata Statistical Software: Release 11 (Stata-
Corp LP, College Station, TX, 2009) were used for the statistical
analysis.
Baseline characteristics were compared between subjects in
whom the outcome was assessed and in those lost during follow-
up, using independent samples t Student's test for continuous
variables, after veriﬁcation of homogeneity of variances, and
Pearson Chi-square test for categorical variables, with Yates con-
tinuity correction for 2"2 tables.
We used a binary logistic regression analysis (with the de-
pendent variable constituted by the conversion to dementia dur-
ing the follow-up period) to compute the odds ratio (OR) for the
associations between depression and dementia. Because data on
age of dementia onset in the non-exposed cohort were available
only in a minority of subjects, it was not possible to perform a Cox-
regression analysis in this group.
Cox proportional hazards models were used to compute crude
and adjusted hazard ratios (HR) and 95% conﬁdence intervals (95%
CI) to quantify the relation between the different exposures, in-
cluding depression subtypes, and dementia. For multivariate
analyses we considered the variables that were signiﬁcantly as-
sociated (po0.05) with dementia in univariate analysis (baseline
age, depression with melancholic features, depression with anxi-
ety symptoms, and severity of the index episode (CGI)), as well as
variables considered to be potentially relevant confounding factors
(sex, years of education, bipolar disorder, depression with psy-
chotic features, and chronic disorder), according to the literature
(Kessing and Andersen, 2004; Ritchie et al. 2010; Reitz et al., 2011;
Silva et al., 2013). Age of onset and the presence of vascular risk
factors were considered only in sensitivity analyses because data
on these variables was available for a subset of all patients (77 and
123, respectively), and due to the fact that the latter was assessed
at follow-up. For each participant the follow-up started at the date
of diagnosis of depression, or corresponding index data in the
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surgical cohort, and ended at the estimated data of onset of de-
mentia, date of follow-up assessment or date of death, whichever
occurred ﬁrst, as applicable. The proportional hazards assumption
was evaluated graphically using “log-log” plots.
The cumulative incidence of dementia was estimated, across
the follow-up period, taking into account the competing risk of
death, using a competing-risks regression model, according to the
method of Fine and Gray (Fine and Gray, 1999).
Statistical signiﬁcance was accepted for po0.05.
2.5. Ethics
This study was conducted in accordance with the Helsinki
Declaration as well as national ethical guidelines. The local Ethics
Committee, the National Data Protection Committee, and the Na-
tional Institute of Notaries and Records approved the protocol.
Subjects who performed follow up evaluation were required to
provide informed consent. If a diagnosis of dementia was estab-
lished, reference to a Dementia Clinics was offered to the subject,
to undergo the standard of care for evaluation and treatment of
dementia.
3. Results
Comparing baseline data of the subjects with and without a
known outcome, the mean age was lower in both cohorts, and the
proportion of men was smaller in the subjects with a known
outcome only in the depressed cohort. No statistically signiﬁcant
differences were observed regarding other socio-demographic and
clinical characteristics (Table 1). Almost all subjects were Cauca-
sian (98%).
3.1. Depression as a risk factor for dementia
Forty-four (22.3%) of the 133 subjects from the depressed co-
hort developed dementia, compared to 21 (14.6%) of the 144
subjects from de surgical cohort. Dementia cause could be as-
sessed in about half of the cases (in 21 and 8 subjects, depressed
and surgical respectively). The most prevalent cause in both
groups was Alzheimer's disease (AD) (57% and 63%), followed by
vascular dementia (19% and 25%), and Parkinson's disease (14%
only in the depressed cohort). Other causes, found only in one
patient each, were vitamin B12 deﬁciency and HIV dementia in the
depressed cohort and neurosyphilis in the surgical cohort.
The characteristics of subjects who developed dementia and
those that have not are displayed in Table 2. At follow-up 4 pa-
tients were rediagnosed as bipolar, due to a later emergence of a
manic episode, and 2 non bipolar patients fulﬁlled DSM5 criteria
for Persistent Depressive Disorder at baseline, but were re-classi-
ﬁed later as MDD.
A logistic binary regression analysis showed that the odds of
dementia were increased by 2.90 times (95% C.I. 1.61–5.21;
po0.0001) for the depressed cohort when compared to the sur-
gical cohort. The higher risk for dementia in the depressed cohort
was still signiﬁcant after adjusting for sex, age, and education
years (OR¼3.36; 95% C.I. 7.76–6.80; po0.0001).
3.2. Depression as an early risk factor
To address the issue of depression as a prodrome of dementia
we repeated the analysis considering the subjects with an early
onset of depression and those with a longer time frame between
the two diagnoses. The deﬁnition of the age limit of late onset
depression varies across the studies, between the age of 45
(Steffens et al., 1997) and the age of 60 years (Byers and Yaffe,
2011). When the analysis was restricted to patients younger than
45, or 60 years old at baseline, the odds for dementia in the de-
pressed cohort were still signiﬁcantly higher when compared to
the surgical cohort (8.53; 95% C.I. 2.40–30.16 and 3.30; 95% C.I.
1.75–6.33, for those younger than 45 and 60, respectively). When
adjusting for age, sex, and education years, similar results were
found (8.69; 95% C.I. 2.21–34.23 and 4.00; 95% C.I. 1.87–8.60, for
those younger than 45 and 60, respectively).
Age of depression onset was only available in 77 subjects. In
those with depression onset before the age of 60 the odds of de-
veloping dementia were not different for those with depression
onset after the age of 60 (0.84; 95% C.I. 0.38–1.84), even after
controlling for age, sex, and education years (0.72; 95% C.I. 0.30–
1.74).
A 10 years difference between depression diagnosis and de-
mentia onset has been used as a criterion to reduce the risk of
misdiagnosing depression as prodrome of dementia (Brunnström
et al., 2013). When restricting the analysis to the subjects with a
follow up time longer than 10 years (94.0% in the exposed group
and 97.9% in the non-exposed group), depression still emerged as a
risk factor for dementia when compared to the surgical cohort
(2.95; 95% C.I. 1.62–5.40 and 4.16; 95% C.I. 1.96–8.83, for crude and
adjusted OR, respectively).
Table 1
Baseline characteristics of both cohort subjects to known outcome.
Depressive cohort Surgical cohort
Lost during follow
up (n¼189)
With known out-
come (n¼133)
Total
(n¼322)
p Valuea Lost during follow
up (n¼178)
With known out-
come (n¼144)
Total
(n¼322)
p Valuea
Age, mean (SD), y 50.8 (12.7)b 41.8 (11.6) 46.9 (13.0) o0.001 47.7 (14.5) 41.0 (12.1) 44.6 (13.8) o0.001
Male sex, % (n) 27.0% (51) 15.0% (20) 22.0% (71) 0.014 24.2% (43) 19.4% (28) 22.0 (71) 0.212
Education, mean (SD), y 6.4 (4.6) 7.1 (4.5) 6.7 (4.6) 0.165 N.A. 6.63 (4.6)c
Bipolar disorder, % (n) 10.6% (20) 16.5% (22) 13.0% (42) 0.326
Melancholic features, % (n) 33.3% (63) 35.3% (47) 34.2% (110) 0.722
Psychotic features, % (n) 24.3% (46) 24.1% (32) 24.2% (78) 0.999
Anxiety symptoms severity,
mean (SD)
1.6 (2.6) 1.9 (2.8) 1.7 (2.7) 0.288
Clinical Global Impression
(CGI), mean (SD)
5.0 (0.8) 5.0 (0.7) 5.1 (0.7) 0.978
N.A. not available. Education years were not written in most surgical ﬁles.
a Comparing, within each cohort, those with a known outcome with those without known outcome, based on chi-square test for category variables and independent
samples t test for continuous variables.
b Baseline age available only for 182 subjects.
c Education years available for 111 subjects.
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3.3. Role of depression heterogeneity
In the depressed cohort, the probability of dementia increased
signiﬁcantly with age, was not inﬂuenced by education and was
signiﬁcantly higher for melancholic features, anxiety symptoms,
and severity of the episode assessed with the CGI, in the univariate
Cox regression analysis (Table 3). In the multivariate Cox analysis
(Table 3), older subjects at baseline and those with depression
with melancholic features had an increased risk for developing
dementia compared to those without melancholic features
(HR¼3.64; 95% C.I. 1.78–11.26). The other depression character-
istics and education were not associated with a higher risk for
Table 2
Cohort characteristics and outcome.
Depressed cohort Surgical cohort
Non-demented (n¼89) Demented (n¼44) Non-demented (n¼123) Demented (n¼21)
Age, mean (SD), y 38.9 (10.4) 47.8 (11.5) 37.7 (11.0) 54.2 (9.1)
o35 years, % (n) 46.1% (41) 11.4% (5) 48.8% (60) 0.0%(0)
35–45 years, % (n) 23.6% (21) 29.5% (13) 22.8% (28) 14.3% (3)
445 years, % (n) 30.3% (27) 59.1% (26) 28.5% (35) 85.7% (18)
Male % (n) 14.6% (13) 15.9% (7) 19.5% (24) 19% (4)
Education, mean (SD), ya 7.8 (4.5) 5.9 (4.4) 7.3 (4.7) 2.9 (1.7)
o5 years, % (n) 39.3% (35) 61.4% (27) 48.4% (59) 85.7% (18)
5–9 years, % (n) 31.5% (28) 22.7% (10) 14.8% (18) 0.0% (0)
49 years, % (n) 29.2% (26) 15.9% (7) 36.9% (45) 14.3% (3)
Follow up time, mean (SD), y 26.3 (7.2) 24.5 (7.3) 29.0 (6.8) 25.1 (7.6)
Age of onset of the disorder, mean (SD), yb 28.4 (10.2) 34.8 (10.2)
Bipolar disorder, % (n) 14.6% (13) 18.2% (8)
DSM5 Diagnosed MDD, % (n) 84.3% (75) 79.5% (35)
Melancholic features, % (n) 24.7% (22) 56.8% (25)
Psychotic features, % (n) 20.2% (18) 31.8% (14)
Anxiety symptoms severity, mean (SD), AMDP score 1.48 (2.59) 2.86 (2.95)
Clinical Global Impression (CGI), mean (SD) 4.9 (0.7) 5.1 (0.7)
Chronic Disorder, % (n) 71.3% (57) 92.3% (36)
Inpatient at baseline, % (n) 55.1% (49) 65.9% (29)
Ever been admitted for depression, % (n)c 82.7% (62) 94.6% (35)
Suicide attempts, % (n)d 43.9% (25) 66.7% (12)
EPQ (Extroversion), mean (SD)e 38.0 (21.2) 35.1 (17.5)
EPQ (Neuroticism), mean (SD)e 81.8 (14.9) 78.8 (14.8)
High Neuroticism/Low Extroversion Group, % (n)e 24.6% (14) 23.3% (7)
Vascular risk factors, % (n)f 59.8% (52) 80.6% (29) 61.2% (63) 76.9% (10)
Age of dementia onset (y), mean (SD) 72.3 (8.8) 81.5 (8.5)
Died, % (n) 18.0% (16) 36.4% (16) 19.5% (24) 57.1% (12)
MDD Major Depressive Disorder, EPQ Eysenck Personality Questionnaire.
a Data available only in 111 controls.
b Data available only in 77 subjects.
c Data on admission status was available in 82 subjects.
d 58 subjects had suicide data.
e 87 subjects had baseline EPQ.
f Data obtained at follow up, available in 123 depressed and in 116 surgical subjects.
Table 3
Depressed cohort: association between demographic variables, clinical characteristics and other well established risks for dementia, and the risk of dementia.
Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value
Baseline age, y
o35 1 [reference] 1 [reference]
35–45 7.55 (2.15–26.52) 0.002 7.26 (1.99–26.51) 0.003
445 15.17 (4.55–50.58) o0.001 13.18 (3.72–47.50) o0.001
Baseline education, y
0-4 1 [reference] 1 [reference]
5–9 0.88 (0.42–1.84) 0.730 1.40 (0.60–3.28) 0.437
49 0.47 (0.19–1.15) 0.097 0.461 (0.16–1.34) 0.156
Bipolar disorder 1.88 (0.86–4.14) 0.116 0.64 (0.22–1.84) 0.408
Melancholic features 4.48 (2.40–8.39) o0.001 3.64 (1.78–11.26) 0.025
Psychotic features 1.55 (0.81–2.96) 0.182 1.55 (0.76–3.14) 0.224
Anxiety symptoms 1.18 (1.08–1.30) 0.001 0.97 (0.82–1.22) 0.969
Clinical Global Impression (Severity) 1.84 (1.18–2.87) 0.008 1.19 (0.74–2.36) 0.345
Chronic disorder 1.85 (0.96–3.55) 0.065 1.24 (0.58–2.61) 0.581
Male sex 0.98 (0.39–32.51) 0.974
Inpatient at baseline 1.01 (0.53–1.92) 0.980
Ever been admitted for depression 2.20 (0.51–9.52) 0.290
Suicide attempts 2.03 (0.74–5.63) 0.172
High Neuroticism/Low Extroversion Group 0.71 (0.33–1.82) 0.568
Notes: variables found signiﬁcant in the preliminary analysis and those known to inﬂuence the risk for dementia were included in the Cox proporcional hazards models.
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dementia.
Two sensitivity analyses were performed, including age of the
affective disorder (determined in few cases) and vascular risk
factors (data obtained at follow up). In a new model, the inclusion
of age of affective disorder onset and vascular risk factors did not
change the statistical signiﬁcance of the associations between both
melancholic features and age at baseline with dementia risk.
Studies with a very long follow up, especially including ger-
iatric outcomes and depressed patients, are faced with the difﬁcult
problem of how to account for the competing risk of death
(Wulsin et al., 1999). Because Cox proportional hazards regression
can overestimate the risk of disease, a risk competing analysis was
performed. The cumulative incidence of dementia, according to
melancholic features of depression, was higher among subjects
with melancholic features during most of the follow-up period,
reaching approximately 50% at around 30 years of follow-up, ac-
cording to a competitive risk model (Fig. 2).
When comparing melancholic (n¼47, 25 events), non-melan-
cholic depressed patients (n¼86, 19 events) and surgical cohort
subjects (n¼144, 21 events), logistic binary regression analysis
showed a signiﬁcantly increased risk for dementia only in mel-
ancholic subjects when compared to the surgical cohort subjects
(OR¼6.66; 95% C.I. 3.19–13.90 and OR¼7.72; 95% C.I. 3.18–18.77,
for crude and adjusted for baseline age and years of education OR,
respectively). Non-melancholic subjects were not at increased risk
for dementia, in the same analysis (OR¼1.66; 95% C.I. 0.84–3.31
and 2.25; 95% C.I. 0.99–5.10, for crude and adjusted OR,
respectively).
Since the precise age of dementia onset was not possible to
ascertain in about half the subjects from the surgical cohort, Cox
regression analysis was not done in this cohort.
4. Discussion
The main ﬁnding of the present study is that melancholic fea-
tures of depression are an important and independent risk factor
for dementia.
Depression has been globally associated with a two-fold in-
crease risk of dementia (Silva et al., 2013), just like we found in this
study. But, as far as we know, melancholic features have not been
previously speciﬁcally assessed as a risk factor for dementia.
Melancholia has been associated with persistent cognitive
impairment after depression remission (Lin et al., 2014; Roca et al.,
2015), but not with dementia. It is possible that the follow up time
has been too short in both studies (6 weeks and 6 months, re-
spectively) to detect an increased incidence of dementia. Re-
markably, in the present study, melancholic features were in-
dependently associated with dementia. As previously mentioned,
the study from DalForno et al. (2005) failed to ﬁnd an association
of negative affective symptoms with dementia risk. However, the
assessment of negative affective symptoms was based on a CES-D
subscale which does not match exactly the standard criteria for
melancholic features. Most risk factors that have been studied in
previous investigations, such as more severe disorder, greater se-
verity of the episode, diagnosis of bipolar disorder, and the pre-
sence of psychotic and anxious symptoms, were associated with
an increased risk for dementia in the univariate analysis, but their
signiﬁcance disappeared in the multivariate analysis. Since mel-
ancholic features tend to repeat across lifetime episodes (Coryell
et al., 1994), are associated with a more severe course, occur in
virtually all psychotic episodes, and happen more frequently in
bipolar patients (Taylor and Fink, 2008), it is possible that the
higher risk associated with those characteristics in previous stu-
dies could be at least partially mediated by melancholia. However,
the role of bipolar disorder as a risk factor for dementia might have
been underestimated because of the small number of bipolar pa-
tients in the present cohort. Also, non-melancholic subjects were
not found to be at a signiﬁcantly increased risk for dementia,
though results were close to statistical signiﬁcance, despite the
relatively small sample size in this subgroup. In any case, the
present results strongly emphasize that analysis of melancholic
features should be included in future studies.
There is a biological rational for the association between mel-
ancholic features and dementia, as an important body of evidence
pinpoints the biological mechanisms underlying melancholia with
cognitive impairment. Melancholia has been associated with hy-
pothalamus-pituitary-adrenal (HPA) axis dysfunction (Brown,
2007; Parker et al., 2013), and hyper- and hypocortisolism char-
acterize different subtypes of depression (Hasler et al., 2004). This
HPA axis dysfunction has been widely studied in animal models
and in human disorders (Lupien et al., 1998; Finsterwald and Al-
berini, 2013; Suzuki et al., 2014), and involves down regulation of
glucocorticoid receptors and/or increased circulating glucocorti-
coids triggering a cascade of events that leads to cognitive im-
pairment (McEwen and Magariños, 1997; Lupien et al., 2008).
Melancholia may particularly induce hippocampal damage (La-
mers et al., 2013), and has been associated with cognitive decline
(Withall et al., 2010; Sachs-Ericsson et al., 2014).
Present results support a role of depression as an early risk
factor for dementia, and not merely a prodrome. Our results are in
line with studies with a long follow up (Kessing, 1999; Brodaty
et al., 2003; Saczynski et al., 2010; Dotson et al., 2010; Barnes et al.,
2012), with a low probability of misdiagnosing dementia as a
depressive disorder. The few studies that speciﬁcally explored the
differences between early- and late-onset depression found a very
small increased risk for dementia, or no differences in early onset
depression as compared to late-onset depression, however they
assessed depression retrospectively by simply questioning (Green
et al., 2003), using CES-D or Geriatric Depression Scale (Lenoir
et al., 2011; Almeida et al., 2016), or included subjects mainly with
neurotic depression (Brommelhoff et al., 2009). The accuracy of
depression diagnosis was probably lower when compared to the
present study, and this could have led to the inclusion of less se-
vere depressive or non-melancholic patients.
The precise diagnosis of dementia was not possible to ascertain
in about half the cases in the depressed cohort and in about 2/3 of
the controls, a natural consequence of the way clinical information
was collected. So, it was not possible to identify whether
Fig. 2. Cumulative incidence of dementia, across the follow-up period, taking into
account the competing risk of death, using a competing-risks regression model.
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depressive subtypes were associated with speciﬁc dementing
disorders. It has been suggested that depression is a risk factor
both for vascular dementia (VD) and for Alzheimer's disease (AD)
(Lenoir et al., 2011; Brunnström et al., 2013). The Honolulu-Asia
aging study (Irie et al., 2008) found a higher risk for AD, however a
higher load of cortical plaques and tangles was not associated with
AD and depression (Wilson et al., 2003). Although in half of the
cases the dementia cause could not be identiﬁed, the present re-
sults suggest that depression would be associated essentially with
an increased risk for AD and not VD.
This study has important strengths. It is one of longest long-
itudinal studies performed to evaluate the risk of dementia in
depressed patients. Another strength is that the diagnosis of de-
pression was done very reliably using an extensive and compre-
hensive psychiatric and psychological evaluation. The vast major-
ity of previous studies assessed depression with rather simple
instruments, such as CES-D, that cannot capture the complexity
and heterogeneity of the depressive disorder. Still another strength
is that important and different risk factors and confounders were
assessed (such as personality, severity of the episode, or vascular
risk factors), that have been seldom evaluated together. If different
subtypes of depression carry different risks for dementia, it would
be elicited by a study with this design.
4.1. Limitations
We should also note the limitations of this study. The major
limitation is the large proportion of subjects without follow-up
information, since only 43% of individuals included in the cohorts
had follow-up data. This proportion is high, as compared to case
register based studies with a complete follow-up of data on de-
mentia and death (Kessing et al., 1999; Kessing and Nilsson, 2003).
Attrition may limit the validity of ﬁndings from longitudinal stu-
dies, and is more likely to occur in investigations with long follow-
up periods; however, the latter are essential to evaluate long-term
effects and resemble more closely inception cohorts, which con-
tributes for survival-related biases to be less likely (Saracci, 2006).
Shorter studies evaluate short term effects and often include
predominantly survivors instead of participants selected closer to
the onset of the exposures of interest. Despite the robustness of
our ﬁndings could be improved with a more complete follow-up,
our design allows the evaluation of long-term effects, contributes
to minimize survival-related biases and adds to previous research
on this topic the assessment of the effects of different depression
subtypes. Furthermore, in the present study the completeness of
follow-up was greater than in other similar studies (43% versus, for
instance, 33% in Brodaty et al. (2003)). Melancholia deﬁnition is
controversial, and DSM5 deﬁnition has been challenged, on the
grounds of the limitation of deﬁning melancholia by reliance on
symptoms (Parker and Paterson, 2014). These authors propose the
inclusion of biological markers related to HPA dysfunction. The
inclusion of a biological biomarker would strengthen the ﬁndings
of this study. Another limitation is the absence of a formal cog-
nitive evaluation at baseline. However, dementia was excluded
clinically, the mean age for the onset of the affective disorder was
about 35 years old and the mean time to the event was more than
25 years, making it very unlikely that dementia was present at
baseline.
4.2. Conclusions
This study supports depression as an early risk factor for de-
mentia, and not only a prodrome. Depression is a heterogeneous
disorder, and it is possible that the frequency of melancholic fea-
tures could explain the discrepancies found in the risk for de-
pression as a whole in the different studies. Melancholic features
of depression should be actively identiﬁed in the clinical setting,
and DSM5 criteria seem appropriate for this purpose. Due to a
more favorable response to biological therapies, appropriate
treatment of melancholia could decrease the risk for dementia.
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a b s t r a c t
Maternal separation (MS) induces depressive-like behavior and long-term changes in cognition in rats.
Escitalopram is an antidepressant drug shown to reverse the depressive-like features caused by this
stress model. However, it is not known if it can ameliorate the affected cognition. We now
characterized the effect of escitalopram on hippocampal-dependent memory in rats submitted to the
MS protocol. Male Wistar rats were assigned either to control (CTR) or maternal separated (MS) group.
MS were separated from their dams between 2–14 postnatal days (PND) for 180 min daily.
Escitalopram was given in food pellets (0.34 g/kg/day first 2 weeks and 0.41 g/kg/day the subsequent
period, average dose 25 mg/kg) from PND 43 onwards, during 1 month. Depressive behavior was
assessed in the forced swimming test (FST), and memory performance in the Morris water maze
(MWM). Escitalopram significantly improved the FST’s latency to despair in the MS group (n¼6), but
did not change the immobility time. All groups showed a significant learning effect in the MWM over
time, but no differences have been found upon treatment (n¼6). However, escitalopram treatment
significantly increased the time spent on the platform quadrant in the probe trial in the MS group. We
report here that chronic treatment with escitalopram is able to improve hippocampal dependent
memory in a chronic stress model, while not changing the learning ability. Moreover, this is
accompanied by an amelioration of the depressive like behavior. These results support the use of
escitalopram to tackle underlying cognitive deficits caused by stress in early-life.
& 2012 Elsevier B.V. All rights reserved.
1. Introduction
Depression can induce long-term cognitive deficits or even be a
risk factor for dementia (Ownby et al., 2006). As there is no cure for
most dementia conditions, strategies directed to the correction of
risk factors amenable to prevention are extremely important.
Depression can be effectively treated in the majority of cases, so it
emerges as an important target for the prevention of cognitive
deficits and dementia. Treatment of depression is complex and
multidisciplinary, but usually implies drug treatment with antide-
pressants. The long-term effect of antidepressants on human cogni-
tion (and eventually on the prevention of dementia) has been poorly
studied and clearly remains to be elucidated (Kessing et al., 2009).
Maternal separation (MS) is an animal model of depression
that can be induced in rodents in a manner that is not easily
amenable or ethically allowed to humans, and permitting a
reliable evaluation of a number of internal and external factors
(e.g. pharmacological interventions). This model is considered a
validated model of depression and anxiety (Ladd et al., 2000;
Kalueff and Tuohimaa, 2004). We and others have previously
shown that rodents separated from their mothers, according to
this protocol, have poorer cognitive performances on memory
tasks, probably related to the effect of hypothalamus-pituitary-
adrenal (HPA) axis disruption (Aisa et al., 2007; Batalha et al.,
2012) on the hippocampus (Huot et al., 2002; Aisa et al., 2009).
Escitalopram is a widely used and highly efficacious antide-
pressant belonging to the Selective Serotonin Reuptake Inhibitors
(SSRI) class. Escitalopram and other antidepressants can reverse
depressive-like behaviors in rodents in the Forced swimming test
(FST) (El-Khoury et al., 2006). Although MS impacts in memory
and learning and escitalopram is effective in reversing depressive
– like behavior, it is not known if this antidepressant can improve
cognitive deficits induced by MS.
To study the effect of antidepressant treatment on cognition in a
rat model of depression, we have submitted rats to the MS protocol
and then to widely used tests for depressive-like behavior – FST – and
for memory – the Morris water maze (MWM). We hereby report that
the escitalopram diminished FST latency-to-despair and improved the
latency in the probe test of the MWM, in MS treated animals.
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2. Material and methods
2.1. Animals
Pregnant Wistar rats were purchased (Harlan, Barcelona) on
gestation days 12–15 and were due in our animal facility. All
animals were handled according to European Community guide-
lines and Local Law on animal care (1005/92). The animals were
kept on an environment controlled for temperature (2272 1C),
humidity (55710%) and light (12-h light/dark schedule; lights on
at 7:00 a.m. and off at 7:00 p.m.).
Pups were randomly assigned to the MS protocol (n¼12) or to
animal facility rearing (CTR, n¼12). Local Ethics Committee has
approved the research protocol.
2.2. Maternal separation protocol
The MS protocol followed has been validated and described
before (Batalha et al., 2012; Lopes et al., 2008). At postnatal day
(PND) 2, pups from four different litters, were collected together,
gender assessed, and the pups were randomly distributed to foster
dams (male/female ratio kept constant). Pups assigned to MS group
were removed from their cages and dams at postnatal days (PND)
2–14 for 180 min daily. They were removed as a group from the
nest, weighed and placed as a group in an isolation cage in an
adjacent room kept at 32.070.5 1C. At the end of the separation
period pups were returned to their home cage and rolled in the
soiled home cage bedding before reuniting them with the mother.
CTR animals were only briefly manipulated to change the beddings
in their cages twice/weekly. At day 21 the pup’s sex was determined
and they were weaned and housed in individual cages. Only male
rats were in included in the study. After weaning, pups were
weighed weekly. No changes were found in weight due to MS
protocol as observed before (Lopes et al., 2008).
2.3. Treatment procedures
The majority of hippocampal granule neurons develops and
extends their axons between PND 1 and 21 (Amaral and Dent,
1981), We have initiated the treatment in puberty, after the full
development of hippocampal circuitry, period when interventions,
either drugs or stimulation, are more effective in the hippocampus
(El-Khoury et al., 2006)
Rats were left undisturbed from PND 15–42. On postnatal day 43,
half of the rats from each group (MS and CTR) were assigned to
dietary treatments with the antidepressant escitalopram (0.34 g/kg/
day chow for the first 2 weeks; 0.41 g/kg/day chow during the rest
of the experiment) (CTRþAD; MSþAD), or were given placebo,
admixed to food pellets (CTR; MS). The escitalopram doses were
increased sequentially, according to the method developed by
H. Lundbeck A/S (Copenhagen, Denmark) and tested by A. Mørk
(El-Khoury et al., 2006), resembling the clinical situation where a
range of escitalopram (or other antidepressants) is used to treat
depressed patients. These doses have been shown effective in revert-
ing depressive-like behaviors in the forced swimming test (FST) in the
MSmodel of depression (El-Khoury et al., 2006). Lactamin AB, Sweden,
prepared Denmark dietary escitalopram according to instructions
from H. Lundbeck A/S, Denmark. The escitalopram intake was
controlled by weighing the animals and monitoring the food intake
per animal (weekly intake in Table 1). The pellets made available were
weighed prior and post intake and dose estimated according to the
weight of each animal. The administered escitalopram dose was
approximately 25mg/kg/day. Animals were kept on their respective
diet until the end of the experiment on PND 73.
All animals have been handled for 5 days prior to behavioral
testing.
2.4. Forced swimming test
Forced swimming test (FST) was used as a behavior equivalent of
learned helplessness to test AD action (Porsolt et al., 1977; Castagne´
et al., 2011). It was carried out on PND 64 and 65 (note that the
escitalopram or vehicle diets were continued until PND 73). On the
first of the two test days, all animals were gently placed individually
in a vertical Plexiglas cylinder (height: 45 cm, diameter: 19 cm)
filled with 26 1C water at a depth that makes it impossible to reach
the bottom with hind paws (28–30 cm). The animals were removed
from the water after 10 min, and dried before being returned to
their home cages. The water was changed after each session. On the
second day, the animals were placed in the same cylinders for 5 min.
This session was video-recorded and an observer blinded to the
animals group subsequently scored the behavior of the animals.
According to the criteria of Porsolt et al. (1977), the rat was judged
to be immobile when it floated passively, making only small move-
ments to keep its nose above the surface. This test measures the
latency to immobility (or to despair, LTD) and the time spent
swimming versus the time spent floating, i.e. the percentage of
time spent immobile or immobility time (IT).
2.5. Morris water maze
The protocol used was the classical Morris water maze test, which
is sensitive to hippocampal-dependent spatial learning and memory
(Morris et al., 1982). The protocol was used as before (Dio´genes et al.,
(2011)). The maze consisted of a large circular tank (1.8 m in
diameter, 0.6 m in height) of water (temperature, 2571 1C) made
opaque with the addition of a small amount of non-toxic water-based
black paint. An escape platform (10 cm in diameter) was submerged,
non-visible, 1 cm below the water. Several visual cues for spatial
reference were placed on the walls of the testing room. The
performances were continuously monitored using an automated
tracking system (Smart 2.5, PanLab, Barcelona). From PND 80 to 84,
rats were given spatial acquisition training consisting of four
trials/day for four consecutive days, in which the platformwas placed
at a fixed position in the center of one of the four quadrants of the
tank (platform Q, left, right and across). On each day the subjects
were randomly placed in four different positions facing the wall, and
never in the platform quadrant. The inter-trial interval was of at least
15 min, during which animals were towel-dried and placed under an
infrared light to prevent hypothermia. The maximum trial duration
was 60 s, after which animals were manually guided to the platform
if they failed to locate it, and they were allowed to remain there for
20 s. At the fifth day a probe test was given in which the platformwas
removed and animals were allowed to swim freely for 60 s while
recording the percentage of time spent on each quadrant. The latency
to find the platform during acquisition and the percentage of time in
the platform quadrant in probe test were used to evaluate hippo-
campal dependent memory.
Table 1
Amount of ingested escitalopram pellets and dose equivalent.
Week Animal weight
(g)
Food ingested/day
(g)
Dose equivalent
(mg/kg/day)
1 180.42 19.19 24.7
2 230.98 25.84 25.3
3 218.8 21.60 27.6
4 231.2 19.80 23.9
5 209.25 19.87 26.5
6 210.79 19.87 26.3
Average 25.4 mg/kg/day.
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2.6. Statistics
Statistical Package for Social Sciences v19 (SPSS) was used for the
statistical treatment of data. After establishing homogeneity of
variances, a two-way ANOVA was carried out for analyzing FST
(LTD and IT) and time spent on quadrant after platform withdrawal
(using MS (n) and AD (#) treatment as factors). Simple main effect
analyses were performed, following significant interactions. Two-
way ANOVA repeated measures was used for the learning curve of
MWM. Statistical significance was accepted for Po0.05. Results are
expressed as mean7standard error of mean (SEM).
3. Results
3.1. Forced swimming test
As observed in Fig. 1, latency-to-despair (LTD) was found to be
decreased by MS (F(1,21)¼8.373; nP¼0.010). LTD decreased from
71.877.71 in CTR to 38.876.25 s in MS animals. The treatment
with escitalopram significantly improved LTD in MSþAD animals
to 65.677.35 s (F(1,20)¼5.015; #P¼0.038).
Escitalopram also affected the immobility time (IT) in all groups
of rats (F(1,23)¼4.658; P¼0.043) but no differences were found
when comparing MS and CTR animals (F(1,23)¼0.413; P¼0.528).
3.2. Morris water maze
3.2.1. Learning curve
A significant learning effect throughout the 4 days was present, for
all groups. The latency to reach the platform significantly improved
from 49.472.16 s on day 1, to 18.372.87 s on day 4 (F(3,66)¼
77.542; Po0.001). However, no significant changes between different
groups were found (F(3,22)¼0.575; P¼0.456; Fig. 2a).
3.2.2. Probe trial
The ability to recall spatial memory is tested following the
learning period, by withdrawing the platform. MS animals displayed
less time (23.577.98%) in the quadrant as compared to the CTR
group (38.879.18%; Fig. 2b). However, escitalopram reverted this,
improving the performance of MS animals (F(1.23)¼10.764;
nP¼0.004). The time spent on the platform quadrant increased to
34.377.04% in MS AD group (Fig. 2b). Escitalopram alone seems to
induce a slight decrease in time spent on platform for CTR animals,
but this difference is not statistically significant.
The average speed and total swimming distance on probe trial
were similar among groups (data not shown).
4. Discussion and conclusions
Maternal separation is known to induce deficits in memory
related tasks that persist throughout adulthood. We hypothesized
that treatment with an anti-depressant, escitalopram, would be
beneficial in reverting these deficits. We now report that chronic
treatment with escitalopram for one-month given to adult
animals can improve hippocampal-dependent memory and
latency to despair deficits induced by maternal separation (MS).
We found a significant effect of MS for acquisition, but not for
learning. Due to the heterogeneity of MS protocols, animal strains
(Huot et al., 2002; Hui et al., 2011) or both (Anisman et al., 1998;
Oitzl et al., 2000; Frisone et al., 2002; Zhu et al., 2011) it is difficult
to find a pattern of the cognitive deficits induced by MS. In
experimental conditions similar to ours, results are consistent,
showing a difference in acquisition and not in learning, as if an
Fig. 2. Escitalopram reverts MS-induced impairment in the probe trial. Hippocampal dependent memory performance was assessed by the Morris water maze test, in
which acquisition (a) and retention (b) were evaluated. Results are the mean7SEM of 5–7 animals; (n) Po0.01 for MS effect and (#) P¼0.004 for AD effect, calculated
using two-way ANOVA, followed by simple main affect analysis.
Fig. 1. Escitalopram reverts MS-induced increase in latency-to-despair. Learned
helplessness was assessed by the Porsolt forced swim test, in which latency to
despair (LTD) and immobility time (IT) were evaluated. Results are the mean7SEM
of 5–7 animals; (n) P¼0.010 for MS effect and (#) P¼0.038 for AD effect, calculated
using two-way ANOVA, followed by simple main affect analysis.
F.S.d. Couto et al. / European Journal of Pharmacology 695 (2012) 71–75 73
effect in learning was more resistant to MS action than the
acquisition (Aisa et al., 2007, 2009; Mello et al., 2009). The
mechanism for this MS induced cognitive deficits has been mostly
related to the induction of HPA axis disruption, shown by elevated
corticosteroids and corticosterone levels (Aisa et al., 2007; Batalha
et al., 2012), similar to what has been observed in depressed
patients (Sachar, 1971; Carroll, 1981). This state of hypercortiso-
lism promotes the shrinkage and the degeneration of hippocam-
pal neurons, both in humans (reviewed by Brown et al., 1999) and
animals (Batalha et al., 2012; Lupien and McEwen, 1997).
The main goal of the present study was to evaluate if an
antidepressant could decrease these deficits. Antidepressants
have several neuroprotective effects in the hippocampus of rats
displaying depressive-like behaviors, either neurogenic (Malberg
et al., 2000) or neuroremodeling (Bessa et al., 2009). However, the
impact of these putatively benefic changes is not known, as a
direct effect of escitalopram has never been shown before on a
memory task in this model of depression.
All groups showed a significant learning effect in the MWM
over the days, but no differences have been found upon treat-
ment. However, escitalopram treatment significantly improved
the time spent on the platform quadrant in the probe trial in the
MS group. The mechanisms underlying the antidepressant-related
cognitive effects, reside either on a direct action on hippocampus,
by stimulation of the neuronal remodeling (Bessa et al., 2009)
or through restoring the normal physiology of the HPA axis
(Mantheya et al., 2011).
MS is an appealing model of depression because it mimics the
mother–infant interaction, which is a key factor for developing
psychiatric disorders in the future (Freud, 1895; Heim and Nemeroff,
1999). MS does not induce very strong depressive-like behavior,
when compared to some genetically selected strains, such as the
‘‘depressed’’ flinders sensitive line (El-Khoury et al., 2006). However,
it is a more pertinent model when studying susceptibility to early-
life events and more related to human conditions. We now report
that, in assessing depression, statistical significance was only
reached when measuring the effect of escitalopram in latency-to-
despair (LTD), but not in immobility time (IT). IT use has been
criticized for its low sensitivity in detecting antidepressant actions of
SSRI and for having a positive response to psychostimulants (Borsini
and Meli, 1988; Rupniak, 2003). Adding the LTD parameter can
improve the sensibility to detect AD actions, especially for tricyclic
antidepressants (TCA), and LTD is not affected by psychostimulants
(Castagne´ et al., 2009), excluding changes due to general motor
stimulation. Current results reinforce the advantage of assessing LTD
to improve sensibility to SSRI antidepressant activity in rats.
Escitalopram alone seemed to induce a slight decrease in the
probe test time in the MWM, for CTR rats. This did not reach
statistical significance and we do not attribute it to any motor
effect since we have used the same dose range as previous
studies that found no impact in specific motor parameters (Xi
et al., 2011). An explanation for the findings is difficult, because
its use in healthy subjects is not ethically allowed. However,
escitalopram has some, although moderate, anticholinergic prop-
erties, and a tendency to cause ‘‘cognitive’’ flattening (Stahl,
2009). This could indicate that its beneficial action is limited to
animals with underlying deficits. On the other hand, it reinforces
the idea that care must be taken and confirms the need to use
healthy controls treated with antidepressants in such paradigms.
The use of p.o. antidepressant could strengthen the findings, as
these methodological approaches can be considered closer to
human reality. However, other variables such as genetics and
individual susceptibility to dosage must be accounted for. The
present data focused on a specific class of antidepressant, the
SSRIs. Whether the observed effects are due to a general anti-
depressant effect or instead to a specific mechanism of action of
this class would be interesting to evaluate, testing distinct classes
of drugs.
The present results may support a potential effective role of
antidepressants, atleast of the SSRI class, in the prevention of
dementia associated to depression, in patients.
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